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ABSTRACT 
 
The epidermal growth factor receptor (EGFR) is a transmembrane receptor 
tyrosine kinase integral in regulating cell growth, survival, and migration.  EGFR 
signaling, which is dependent on localization of the receptor within lipid rafts, is often 
hijacked during colon tumorigenesis.  Previous work has found that docosahexaenoic 
acid (DHA) is protective against colon cancer.  This fatty acid is proposed to function in 
part by perturbing lipid rafts and thereby altering cell signaling.  The overall objective of 
this work was to determine whether DHA alters EGFR function and signaling.   
 We assessed EGFR localization and ligand-induced phosphorylation in YAMC 
cells treated with fatty acids.  We found that DHA reduced the localization of EGFR to 
lipid rafts.  Concomitant with altering receptor localization, DHA was found to increase 
EGFR phosphorylation.  However, DHA paradoxically suppressed EGFR signal 
transduction.  We found that DHA uniquely altered EGFR activity, and other long chain 
polyunsaturated fatty acid did not exert the same effect.  We additionally observed 
similar effects on EGFR activation and signaling by feeding mice a diet enriched in fish 
oil (high in DHA), and this was attendant with reduced colon tumorigenesis.   
 We next probed the mechanism by which DHA enhances EGFR 
phosphorylation.  We found that DHA facilitates receptor dimerization to increase 
phosphorylation.  We additionally identified Ras activation as the site of perturbation of 
signal transduction.  DHA suppressed signal transduction by both changing the 
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localization of EGFR within the plasma membrane and increasing receptor endocytosis 
and degradation. 
 Lastly, we extended our observations into a wounding model.  Although DHA 
uniquely altered ligand-stimulated EGFR activity, both DHA and EPA altered EGFR 
transactivation and signaling upon injury.  This culminated in reduced wound healing in 
DHA and EPA treated cells.  In an animal model, we found that diets enriched in either 
DHA or EPA altered EGFR signaling in the colonocytes of wounded animals. 
 Overall, we found that DHA modifies EGFR signaling, which can be beneficial 
or detrimental for health depending on the disease state of an individual.  These data 
help elucidate a mechanism by which DHA protects against colon cancer, as well as 
indicating a potential downside of n-3 PUFA therapy.   
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1. INTRODUCTION* 
 
1.1 Colon cancer  
Colon cancer is a major public health concern due to the high prevalence of the 
disease both globally and in the United States (Jemal et al., 2011).  Colon cancer is third 
in cancer incidence in both men and women and the second leading overall cause of 
cancer mortality (Siegel et al., 2012), with incidence and death rates of colon cancer 
being higher in men than in women (Siegel et al., 2012).  In the United States alone, 
approximately 140,000 new cases occur each year, with colon cancer causing the death 
of approximately 50,000 people every year (Jemal et al., 2010).   Therefore, developing 
strategies for prevention and treatment of this pernicious disease is of the utmost 
importance. Both genetic and environmental factors have been indicated as mediators of 
colon cancer risk (Fernandez et al., 2004).  Additionally, many modifiable factors, 
including diet, exercise, and smoking are suggested to play a role in more than 50% of 
colon cancer cases (Emmons et al., 2005; Lieberman et al., 2003).  
1.1.1 Histological progression of colon cancer 
Formation of colon cancer is hypothesized to be a multi-step process that results 
from a systematic accumulation of both genetic and epigenetic perturbations that cause 
normal colonic epithelial cells to transform and progress into cancer.  Colonic 
transformation develops through multiple distinct histologically abnormal stages.  
 
__________________________ 
*Part of this chapter is reprinted with permission from “Membrane lipid raft organization is uniquely modified by n-3 
polyunsaturated fatty acids” by Harmony F. Turk and Robert S. Chapkin, 2012. Prostaglandins Leukotrienes and Essential Fatty 
Acids,doi: 10.1016/j.plefa.2012.03.008, Copyright 2012 by Elsevier Ltd. 
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Aberrant crypts foci:  Aberrant crypts foci (ACF), indicated as putative 
biomarkers of colonic carcinogenesis, are very early, microscopic lesions composed of 
hyperplastic epithelium(Takayama et al., 1998).  It currently remains unclear whether 
ACF are precursors for colon cancer, but many studies have shown that ACF incidence 
increases with increased risk factors for colon cancer (Rudolph et al., 2005).   
Polyps:  Polyps are macroscopic growths of hyperplastic or dysplastic cells that 
can be observed in the colon (Kinzler and Vogelstein, 2002).  Some polyps are 
innocuous, whereas others can develop into cancer.  Polyps are classified as either 
hyperplastic, adenomatous, or serrated (Noffsinger, 2009).   Hyperplastic polyps are 
traditionally classified as benign lesions.  However, it has been clearly demonstrated that 
adenomatous polyps, or adenomas, can develop into carcinomas subsequent to a well-
established accumulation of molecular alterations (Vogelstein et al., 1988; Vogelstein et 
al., 1989).  Recently, it has been shown that serrated polyps can also serve as precursors 
to colon cancer.  The molecular alterations that contribute to this pathway of 
tumorigenesis, termed the serrated neoplasia pathway, are distinct from those affiliated 
with the adenoma-to-carcinoma conversion (Noffsinger, 2009).  Although some polyps 
serve as precursor for cancer, polyps are considered benign growths because they have 
not yet broken through the basement membrane.   
Carcinoma:  Once one of these abnormal growths breaches the basement 
membrane and begins innfiltrating the surrounding tissue, it is classified as a carcinoma 
and is considered malignant.  The transformation from adenoma to carcinoma takes an 
average of eight to twelve years, but most adenomas are thought to never develop into 
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cancer (Saif and Chu, 2010).  Colon carcinomas can penetrate into underlying stromal 
layers and smooth muscle and eventually metastasize to distal locales.  The major site of 
colon cancer metastasis is the liver (Chambers et al., 2002). 
1.1.2 Molecular basis of colon cancer  
The multi-step process of carcinogenesis is hypothesized to include 3 major 
steps: initiation, promotion, and progression.  Each of these stages arises due to specific 
molecular and genetic changes that occur.  The molecular basis of colon cancer has been 
extensively researched.  Three major molecular contributors to colon cancer are 
chromosomal instability, inactivation of tumor suppressor genes, and activation of 
oncogenes. 
Genomic instability:  Genomic instability has been found to be a major 
contributor to colon cancer.  Genetic instability in colon cancer is often divided by 
researchers into two classes: microsatellite instability or chromosomal instability 
(Cancer Genome Atlas, 2012; Sugai et al., 2006).  Chromosomal instability is most often 
the source of genomic instability in colon cancer (Lengauer et al., 1997).  These two 
classes of genomic instability induce distinct perturbations to the genome.  Microsatellite 
instability displays a high rate of alterations in short, tandemly repeated nucleotide 
sequences, whereas chromosomal instability manifests as major abnormalities in 
chromosome structure and number (Georgiades et al., 1999).  Numerous genes which 
function to maintain genetic stability become inactivated in colonic epithelium to result 
in instability that leads to cancer (Barber et al., 2008).  Specifically, many colon cancer 
patients have inactivated mismatch repair genes, including MLH1 and MSH2 
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(Markowitz and Bertagnolli, 2009), and mismatch repair deficiency contributes to 
microsatellite instability (Lengauer et al., 1997).  In contrast, chromosomal instability is 
often linked to loss of genes that function as critical mitotic checkpoints (Georgiades et 
al., 1999).  Gene mutation and aberrant DNA methylation commonly drive the of 
inactivation of mismatch repair genes and mitotic checkpoint genes (Kondo and Issa, 
2004).  In fact, aberrant methylation has been clearly demonstrated to be a major 
mechanism of inactivation of MLH1 (Young et al., 2001).  Additionally, recent work 
assessing the colon cancer epigenome has shown that virtually all colon cancers have 
hundreds to thousands of abnormally methylated genes (Lao and Grady, 2011).  
Hypermethylation of promoter-associated CpG islands of genes leads to transcriptional 
silencing of genes.  Widespread CpG island promoter methylation, known as the CpG 
island methylator phenotype (CIMP), is frequently present in colon cancer (Toyota et al., 
1999).  CIMP is most commonly observed in colon cancers with microsatellite 
instability (Hawkins et al., 2002; Toyota et al., 1999).   
Inactivation of tumor suppressor genes:  Genes that restrict the growth of cells 
are referred to as tumor suppressor genes.  Inactivation of tumor suppressor genes 
unfetters cells from the constraints implemented by these genes, allowing for 
uncontrolled cell growth.  Similarly to mismatch repair genes, many tumor suppressor 
genes are inactivated in colon cancer through genetic mutation or aberrant methylation.  
Major tumor suppressor genes known to be inactivated in colon cancer include APC, 
TP53, and TGFBR2.  APC inhibits the nuclear localization of the oncoprotein β-catenin 
and targets it for proteolysis.  A deficiency in APC results in constitutive activation of 
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the Wnt signaling cascade, which is an initiating event in colon cancer (Markowitz and 
Bertagnolli, 2009).  Germ-line APC mutations lead to a predisposition for colon cancer, 
and somatic mutations and deletions of APC have been found to occur in most sporadic 
colon cancers (Goss and Groden, 2000).  Mutation of TP53 is also key in colon cancer.  
TP53 encodes p53, which is central in controlling the cell cycle (Vazquez et al., 2008).  
TP53 inactivation most often occurs at an intermediate stage in cancer development 
during the transition from adenoma to carcinoma (Markowitz and Bertagnolli, 2009).  
Moreover, approximately one in three colon cancers develops a mutation in TGFBR2, 
which encodes the receptor for TGF-β (Grady et al., 1999; Markowitz et al., 1995; 
Markowitz and Bertagnolli, 2009).  TGF-β signaling is involved in regulation of 
multiple cellular processes, including cell cycle progression and apoptosis.  In addition 
to mutations in TGFBR2, other components of the TGF-β pathway, including SMADs, 
are often mutated in colon cancer (Eppert et al., 1996; Wood et al., 2007).  Similar to the 
p53 pathway, inactivation of the TGF-β pathway correlates with the transition from 
adenoma to carcinoma (Grady et al., 1998).  However, TGF-β signaling plays a 
dichotomous role in human cancers.  It can serve as a tumor promoter in the latter stages 
of colon cancer by inducing the epithelial-to-mesenchymal transition and enhancing 
tumor invasion and metastasis(Gatza et al., 2011).  Overall, inactivation of tumor 
suppressor genes expedites tumorigenesis by enabling tumor cells to grow unchecked.   
Activation and overexpression of oncogenes:  In addition to inactivation of tumor 
suppressor genes, activation and/or overexpression of oncogenes plays a central role in 
colon tumorigenesis.  In contrast to tumor suppressor genes, oncogenes potentiate cell 
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growth.  Key oncogenes known to be mutated in colon cancer include RAS, PIK3CA, 
BRAF, and EGFR.  Activating mutations of RAS have been found to occur in 
approximately 40% of colorectal cancers (Bos et al., 1987; Markowitz and Bertagnolli, 
2009).  KRAS is the Ras isoform that most often has been found to be mutated in colon 
cancer (Samowitz et al., 2000).  BRAF, which encodes B-Raf, has also been found to be 
highly mutated in colon cancer (Davies et al., 2002).  B-Raf is a downstream signaling 
partner of Ras, and the Ras-Raf signaling cascade is integral in activating cell 
proliferation.  Another important signaling mediator, phosphatidylinositol 3-kinase 
(PI3K), is often hyperactivated in colon cancer.  In fact, approximately one-third of 
colon cancers possess an activating mutation in PIK3CA, the catalytic subunit of PI3K 
(Samuels et al., 2004).  PI3K leads to activation of Akt, which is important for inhibition 
of apoptosis.  Additionally, the epidermal growth factor receptor (EGFR), which 
regulates signaling through both Ras and PI3K, is often overexpressed in colon cancer 
(Galizia et al., 2006; Jorissen et al., 2003; McKay et al., 2002; Quesnelle et al., 2007; 
Shia et al., 2005).  Activating mutations of EGFR have been detected in some studies, 
but the rates of EGFR mutation have been found to be extremely low (Barber et al., 
2004; Ogino et al., 2005).  Higher rates of EGFR mutation were observed in a Japanese 
study (Nagahara et al., 2005), suggesting potential ethnic disparities in acquisition of 
EGFR mutations.   However, the promotive role of EGFR in colon cancer is well-
established.  Consistent with the inactivation of tumor suppressor genes, overexpression 
and/or hyperactivation of these oncogenes are central for the hyperproliferative and anti-
apoptotic phenotype of colon cancer.  
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1.1.3 Location of colon cancer 
Colon cancer can arise in either the right side (proximal) or left side (distal) of 
the colon.  Interestingly, research findings have implicated differing genetic alterations 
as the cause of colonic transformation in left-sided compared to right-sided colorectal 
cancers (Iacopetta, 2002; Meza et al., 2010; Sugai et al., 2006).  Microsatellite instability 
has been shown to be primarily located in right-sided cancers (Cancer Genome Atlas, 
2012), whereas chromosomal instability is more common in left-sided colon cancer 
(Lindblom, 2001).  CIMP incidence most often occurs in right-sided colon cancers 
(Hawkins et al., 2002).  Furthermore, mutations in TP53 and KRAS genes occur 
predominantly in left-sided carcinomas (Bleeker et al., 2000; Sugai et al., 2006).  The 
differences between left- and right-sided colon cancers provide evidence of different 
mechanisms contributing to colonic transformation.   
 
1.2 Epidermal growth factor receptor 
1.2.1 EGFR background 
In the 1960s, a peptide that could stimulate proliferation of epithelial cells was 
discovered and termed the epidermal growth factor (EGF) (Cohen, 1962; Cohen, 1965).  
A decade later, the EGF receptor was identified (Carpenter et al., 1978; Carpenter et al., 
1975).  EGFR was subsequently reported to be a receptor tyrosine kinase (Ullrich et al., 
1984).  Since its discovery, numerous studies have been conducted on EGFR, and it is 
one of the most well understood receptor tyrosine kinases.  EGFR is a member of the 
ErbB family of receptors, which is composed of EGFR/ErbB1, ErbB2/Neu/HER2, 
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ErbB3/HER3, and ErbB4/HER4 (Ferguson et al., 2003; Normanno et al., 2006; Yarden, 
2001). 
1.2.2 EGFR structure 
EGFR is a transmembrane glycoprotein comprised of 1186 amino acids (Ullrich 
et al., 1984).  EGFR consists of an extracellular ligand-binding domain, a single 
hydrophobic transmembrane region, and an intracellular domain (Olayioye et al., 2000).  
The 662 amino acid extracellular domain of EGFR is composed of four subdomains (I-
IV) (Bajaj et al., 1987).  Subdomains I and III are leucine rich regions that have been 
found to be integral in ligand binding.  Subdomains II and IV are cysteine rich regions, 
and subdomain II possesses the dimerization loop to support direct receptor-receptor 
interactions.  Prior to ligand binding, the extracellular domain of EGFR exists in a 
tethered conformation due to intramolecular interactions between subdomains II and IV.  
Following ligand binding, the receptor undergoes conformational changes allowing the 
dimerization loop to project from EGFR and facilitate interaction with another ligand 
bound EGFR.  Additionally, EGFR can heterodimerize with other members of the ErbB 
family.  When heterodimerizing, EGFR displays the highest affinity for ErbB2.  Unlike 
EGFR, the extracellular domain of ErbB2 precludes the receptor from binding ligand, 
and therefore, ErbB2 always functions in heterodimers with other members of the ErbB 
family.  ErbB3 also only functions in heterodimers because ErbB3 lacks an intracellular 
kinase domain.  The alpha-helical transmembrane domain of EGFR forms a single pass 
through the plasma membrane (Wells, 1999).  The final 542 amino acids of EGFR 
constitute the intracellular domain, which can be subdivided into three regions. The 
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juxtamembrane region (∼50 amino acids) is a site for feedback attenuation by protein 
kinase C and mitogen-activated protein kinases (MAPKs), including extracellular signal-
regulated kinases 1 and 2 (ERK1/2).  There is evidence that this region may also 
associate with heterotrimeric G proteins (Sun et al., 1997).  The next region, composed 
of ~250 amino acids, includes the tyrosine kinase domain (Wells, 1999).  Lastly, the 
final 229 amino acids constitute the C-terminal tail.  This region includes motifs for both 
autophosphorylation and transphosphorylation.  The tail is also involved in receptor 
regulation due to its three internalization motifs, sites for proteolytic activation and 
degradation, and autoinhibitory function (Wells, 1999).   
Classically, the inactive EGFR was thought to reside in the plasma membrane as 
a monomer prior to activation, which results in dimerization.  However, recent evidence 
has suggested the existence of preformed, inactive EGFR oligomers (Clayton et al., 
2005; Gadella and Jovin, 1995; Martin-Fernandez et al., 2002; Saffarian et al., 2007), 
although the majority of receptors are suggested to exist as monomers (Saffarian et al., 
2007).   The role that preformed oligomers play in EGFR function and signaling remains 
unclear. 
1.2.3 EGFR ligands 
EGFR has multiple ligands which can active EGFR in either an autocrine or 
paracrine manner.  Binding specificity of EGFR ligands is conferred by an EGF-like 
domain which consists of three disulfide-bonded intramolecular groups (Yarden, 2001).  
These ligands also contain variable structural motifs, including glycosylation sites, 
immunoglobulin-like domains, and heparin-binding sites. Some of the ligands for EGFR, 
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including EGF, TGF-α, and amphiregulin bind specifically to EGFR, whereas others, 
including betacellulin, heparin-binding growth factor, and epiregulin, have dual 
specificity for EGFR and ErbB4.  These ligands are translated with a plasma membrane 
tethering domain, and in response to certain stimuli, the ligands will undergo ectodomain 
cleavage, allowing them to activate EGFR.  The multiple ligands for EGFR impart high 
specificity and an expanded repertoire of potential signaling responses. 
1.2.4 EGFR activation 
Following ligand binding and receptor dimerization, the conformational changes 
allow the EGFR intracellular kinase domain to become activated.  It has been clearly 
shown that EGFR activation requires the formation of an asymmetric dimer of the kinase 
domains of an EGFR dimer (Zhang et al., 2006).  Thus, the C-lobe of the kinase domain 
of one EGFR docks to the N-lobe of the kinase domain of the other EGFR to induce the 
active conformation of a key regulatory helix (Jura et al., 2009; Zhang et al., 2006).  
Activation of the EGFR kinase domain additionally requires repositioning of functional 
regions in the kinase domain, such as inducing the active conformation of the activation 
loop (Wood et al., 2004).  These conformational changes culminate in activation of the 
kinase domain of one EGFR molecule within the dimer, which will phosphorylate 
tyrosine residues on the cytoplasmic C-terminal tail of the dimerization partner.  The 
residues that are phosphorylated in response to ligand-induced activation of EGFR 
include Y992, Y1045, Y1068, Y1086, S1142, Y1148, and Y1173 (Guo et al., 2003).   
Multiple signaling cascades can also lead to transactivation of EGFR.  Some 
cytokines can activate Janus tyrosine kinase 2 (Jak2), which can phosphorylate EGFR on 
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specific tyrosine residues (Yamauchi et al., 1997).  Additionally, many signaling 
cascades activate the tyrosine kinase Src, which can phosphorylate EGFR tyrosine 
residues to perpetuate EGFR signaling (Biscardi et al., 1999).  Furthermore, stimulation 
of G-protein coupled receptors (GPCR) leads to activation of matrix metalloproteinases 
(MMPs), which cleave EGF ligands tethered to the plasma membrane, allowing these 
ligands to activate EGFR (Higashiyama and Nanba, 2005; Sahin et al., 2004).   
1.2.5 EGFR function 
Following receptor activation, the phosphorylated tyrosine residues on the C-
terminal tail of EGFR serve as docking sites for downstream mediator and signaling 
proteins that contain Src homology 2 (SH2) domains and phosphotyrosine-binding 
(PTB) domains, such as Grb2, Shc, Crk, Nck, phospholipase C-γ1 (PLC-γ1), Src, PI3K, 
phosphatases (SHP1 and SHP2), and Cbl E3 ubiquitin ligase (Marmor and Yarden, 
2004; Yaffe, 2002).   EGFR mediates signaling through multiple canonical oncogenic 
signaling cascades, including the Ras/MAPK pathway, the PI3K/Akt pathway, and the 
signal transducer and activator of transcription (STAT) 3 pathway.  These signaling 
cascades result in modulation of transcription and translation, which ultimately lead to 
cell proliferation, migration, angiogenesis, and inhibition of apoptosis.  In addition to 
these kinase-dependent functions of EGFR, the receptor has been shown to have roles 
that are independent of its kinase activity.  EGFR can mediate some cellular processes 
through its ability to interact with other proteins.  One study has illustrated that EGFR 
stabilizes the sodium/glucose cotransporter 1 in the plasma membrane to facilitate 
uptake of glucose to sustain cell function and survival  (Weihua et al., 2008).  
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Additionally, many mutagenesis experiments have shown that expression of a kinase-
deficient EGFR mutant does not have nearly the detrimental effects on viability as 
knock-out of EGFR (Luetteke et al., 1994; Miettinen et al., 1995).  It has been clearly 
demonstrated that kinase-dead EGFR retains the ability to activate DNA synthesis and 
promote survival (Coker et al., 1994; Deb et al., 2001; Ewald et al., 2003; Zhu et al., 
2010).  Central to both kinase-dependent and kinase-independent EGFR function is the 
localization of the receptor.   
1.2.6 EGFR localization 
EGFR resides in the plasma membrane of epithelial, stromal, and select glial and 
smooth muscle cells (Wells, 1999).  Within the plasma membrane, EGFR is known to be 
localized to specific plasma membrane microdomains termed lipid rafts (described in 
further detail below).  Following receptor activation, EGFR can be internalized through 
clathrin-dependent and clathrin-independent forms of endocytosis (Sigismund et al., 
2008).  Following endocytosis, EGFR can be trafficked through endosomes to lysosomes 
for proteolysis or recycled back to the plasma membrane.  EGFR has been shown to 
retain the ability to activate some downstream signaling cascades from endosomes 
(Burke et al., 2001; Sadowski et al., 2009; Wiley and Burke, 2001).  Additionally, EGFR 
can be translocated to the nucleus or mitochondria (Boerner et al., 2004; Lin et al., 
2001).  In the nucleus, EGFR has been shown to directly alter gene expression by 
binding to promoters alone or through interactions with transcription factors, including 
STAT3, E2F1, and STAT5 (Hanada et al., 2006; Hung et al., 2008; Lin et al., 2001; Lo 
et al., 2010; Lo et al., 2005).  EGFR in the nucleus has been shown to regulate 
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expression of many important mediators of cell proliferation and survival, including 
cyclin D1 (Lin et al., 2001), inducible nitric oxide synthase (Lo et al., 2005), B-Myb 
(Hanada et al., 2006), cyclooxygenase-2 (Lo et al., 2010), aurora A (Hung et al., 2008), 
and c-Myc (Jaganathan et al., 2011).  In the mitochondria, EGFR has been shown to 
decrease cytochrome c oxidase activity and ATP production (Boerner et al., 2004; 
Demory et al., 2009).  This function of EGFR may aid cell survival by modulating 
cytochrome c oxidase dependent functions.  Mitochondrial targeting of EGFR has been 
indicated in drug resistance(Cao et al., 2011). 
1.2.7 EGFR in colon cancer 
As briefly mentioned above, EGFR is a master signal involved in colonic 
transformation (Matveev and Smart, 2002; Pike, 2005; Ringerike et al., 2002).  The 
EGFR signaling cascade is intimately linked with colon cancer.  EGFR has been 
implicated in all stages of colon tumorigenesis.  The early colonic abnormal lesions, 
ACF, have been shown to exhibit increased signaling through EGFR in humans (Cohen 
et al., 2006).  EGFR signaling is also required for the formation of colonic adenomas in 
mice treated with carcinogen (Fichera et al., 2007).  Furthermore, overexpression of 
EGFR has been reported in 30-85% of human colon cancer (Galizia et al., 2006; Jorissen 
et al., 2003; McKay et al., 2002; Quesnelle et al., 2007; Shia et al., 2005), and up to 
nearly 90% of cases of metastatic colon cancer overexpress EGFR (Arteaga, 2001).  In 
addition, EGFR is overexpressed in a wide range of tumors and is involved in their 
growth and proliferation through various mechanisms.  EGFR expression has recently 
found to vary based on colon tumor location (proximal versus distal; left- versus right-
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sided) and stage (Papagiorgis et al., 2012).  Expression of EGFR has been shown to 
correlate with a more aggressive disease (Coffey et al., 1992; Koretz et al., 1990; Yasui 
et al., 1988) resulting in poor prognosis (Lee et al., 2002; Mayer et al., 1993; Radinsky, 
1995).  In addition to EGFR expression, nuclear localization of EGFR has been linked to 
enhanced proliferation, inflammation, and drug resistance (Carpenter and Liao, 2009; 
Han and Lo, 2012; Lo, 2010; Wang et al., 2010).  Several small molecule kinase 
inhibitors and therapeutic antibodies that target EGFR are FDA-approved to treat cancer 
patients.  Cetuximab and Panitumumab are humanized monoclonal antibodies against 
EGFR that are currently being utilized in the treatment of metastatic colon cancer (Di 
Fiore et al., 2010; Han and Lo, 2012; Plesec and Hunt, 2009).  Interestingly, it has been 
shown that the localization of EGFR to lipid rafts can alter the response of breast cancer 
cells to EGFR-targeted therapy (Irwin et al., 2010), and changing the localization of 
EGFR from lipid rafts into the bulk membrane domain is suggested to improve the 
efficacy of anti-EGFR therapies.  Therefore, the following section will focus on the area 
of lipid raft research. 
 
1.3 Lipid rafts 
The lipid raft hypothesis was initially conceptualized to explain the aggregation 
of glycolipids at the apical membrane of epithelial cells (Simons and van Meer, 1988).  
This concept then developed further to encompass membrane subcompartmentalization.  
This hypothesis states that lateral heterogeneity, driven by affinity of membrane 
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components, functions in cellular signaling, endocytosis, membrane trafficking, and 
other membrane functions (Simons and Toomre, 2000).   
1.3.1 Composition 
Two types of membrane microdomains have been described: caveolae and lipid 
rafts.  Caveolae are more fully defined because they have a distinct morphology.  
Caveolae are 50-70 nm flask-shaped pits in the plasma membrane enriched in caveolin-1 
(Anderson, 1998; Parton, 1996).  Lipid rafts are much less distinct, and they are much 
more difficult to define due to their small size and heterogeneity.  The lipid raft 
hypothesis postulates that the size of lipid rafts can vary between 10 and 200 nm (Pike, 
2006).  Lipid rafts are further defined as dynamic plasma membrane domains enriched in 
cholesterol and sphingolipids (Pike, 2005).  They are also described as highly-ordered 
lipid assemblies due to the interaction between cholesterol and sphingolipids, as well as 
the enrichment of saturated and long hydrocarbon chains and hydroxylated ceramide 
backbones (Brown and London, 2000; Simons and Sampaio, 2011).  The composition of 
lipid rafts imparts upon them two distinct characteristics: detergent-resistance and low-
buoyant density (Jacobson et al., 2007).  These properties are highly exploited in studies 
on lipid rafts, which employ detergent extractions and gradient isolation of these 
domains.  To avoid the intrinsic problem of isolating lipid rafts, many researchers are 
focusing on microscopy techniques to study their composition, organization, and 
function (Ianoul and Johnston, 2007; Kusumi et al., 2011; Loura and Prieto, 2007; 
Marquer et al., 2012).  Lipid rafts are highly heterogeneous, and the structure of lipid 
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rafts is dynamic.  Lipid rafts are constantly altering their composition of both lipids and 
proteins.   
1.3.2 Proteins in lipid rafts 
Several studies have clearly demonstrated that certain proteins are dynamically 
associated with lipid domains.  Proteins can be targeted to lipid rafts through multiple 
mechanisms.  The protein-targeting theory hypothesizes that proteins collect in 
membrane domains based on specific molecular addresses encoded in the protein that 
direct them to these locations (Anderson and Jacobson, 2002).  It has also been shown 
that certain lipid modifications on proteins can target them to lipid rafts.  Cysteine 
palmitoylation is one lipid modification that can target proteins to rafts, particularly 
intracellular proteins (Levental et al., 2010).  It has been found that inhibition of protein 
palmitoylation can reduce the lipid raft localization of certain proteins (Webb et al., 
2000).  Additional raft-targeting lipid modifications include N-terminal myristic acid 
tails, isoprenylation, and the addition of C-terminal sterol moieties (Levental et al., 
2010).  In addition to lipid modifications, some proteins are hypothesized to be encased 
in a shell of cholesterol and sphingolipids which targets them to lipid rafts (Anderson 
and Jacobson, 2002).  Secretory vesicles containing sphingolipids and sterols carry raft 
protein cargo from the trans-Golgi network to the plasma membrane, indicating that 
lipids are directly involved in the sorting process (Klemm et al., 2009).  Furthermore, 
lipid rafts are enriched with specific proteins that contain cholesterol- or ganglioside-
binding domains (Coskun and Simons, 2010), which allows them to bind to lipid raft 
components.  Additionally, many glycosylphosphatidyl-inositol (GPI)-anchored proteins 
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localize to lipid rafts (Fiedler et al., 1993; van Zanten et al., 2009).  There are likely 
many additional modes of targeting proteins to lipid raft domains that remain to be 
elucidated.  The inclusion of proteins into lipid raft domains is contingent on raft lipid 
and protein composition (George and Wu, 2012). 
1.3.3 Role in signal transduction 
Membrane rafts play a fundamental role in mediating multiple cell functions, 
including signal transduction (Deans et al., 1998; Field et al., 1997; Simons and Toomre, 
2000; Smart et al., 1999b; Staubach and Hanisch, 2011).  Lipid rafts are thought to 
provide a platform in which signaling partners can accumulate to support highly efficient 
signal transduction.  Additionally, small rafts can coalesce upon activation of membrane 
signaling to form larger and more stable platforms for signaling (Hofman et al., 2008; 
Kono et al., 2002).  Extensive studies have been performed to elucidate the role of lipid 
rafts in the activation of T lymphocytes, which requires clustering of signaling 
components in a large, stable lipid raft domain at the immunological synapse (Alonso 
and Millan, 2001; Drbal et al., 2007).  Extrinsic induction of apoptosis relies on 
signaling through lipid rafts, and the composition of lipid rafts has been shown to affect 
apoptotic responses (Algeciras-Schimnich et al., 2002; Bang et al., 2005; George and 
Wu, 2012).   Many integral protein signaling components have been shown to localize to 
lipid rafts, including G-protein coupled receptors (GPCR), PDGF receptor, NGF 
receptor, VEGF receptor, and many more (Patel et al., 2008; Pike, 2005).  In many 
cases, the function of proteins depends greatly on their association with lipid rafts 
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(George and Wu, 2012).  The dynamics and heterogeneity of lipid rafts allow for a large 
number of signals to be transduced from the outer membrane to intracellular domains.   
1.3.4 Lipid rafts in cancer 
Recent evidence suggests that lipid rafts may modulate the malignant 
transformation process.  In fact, the levels of lipid rafts are increased in many types of 
cancer (Hazarika et al., 2004; Li et al., 2006; Patra, 2008).  Additionally, lipid rafts 
mediate cell signaling events that are often constitutively or hyper-activated in cancer 
(Fedida-Metula et al., 2012; Lasserre et al., 2008; Roy et al., 2008).    There is also some 
evidence suggesting that disruption of lipid rafts in cancer can lead to increased 
responsiveness to anti-cancer therapies (Irwin et al., 2010).  Additionally, some anti-
cancer drugs have beneficial effects through alteration of the protein content of lipid 
rafts (George and Wu, 2012).  In colon cancer, lipid rafts have been shown to function in 
cell death-mediated signaling (Lacour et al., 2004; Rebillard et al., 2007), entry of 
bioactive compounds (Adachi et al., 2007), and localization of key proteins involved in 
immune response (Bacso et al., 2002). 
1.3.5 EGFR in lipid rafts 
As mentioned above, the important signaling mediator EGFR is localized to lipid 
rafts.  Localization of EGFR to lipid rafts has been associated with both N-glycosylation 
and the second cysteine rich region of the EGFR (Cummings et al., 1985; Yamabhai and 
Anderson, 2002).  Extensive evidence suggests that the ability of EGFR to signal is 
dependent on its localization to lipid raft domains in the plasma membrane (Matveev and 
Smart, 2002; Pike, 2005; Ringerike et al., 2002; Roepstorff et al., 2002).  Lipid rafts 
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have
 
the ability to assemble the molecular machineries necessary
 
for intracellular 
propagation of EGFR signals and receptor internalization (Mineo et al., 1996; Pike and 
Casey, 1996; Puri et al., 2005).  Specifically, EGFR has been shown to colocalize with 
downstream signaling partners, including PI3K, Ras and c-Src in lipid rafts (Eisenberg 
and Henis, 2008; Irwin et al., 2010).   Due to the importance of lipid rafts as signaling 
platforms, perturbation of these domains is predicted to significantly affect cell 
signaling.  In fact, disruption of lipid rafts has been found to have significant effects on 
EGFR phosphorylation and downstream signaling.  Raft disruption through cholesterol 
depletion increases EGFR clustering prior to simulation (Saffarian et al., 2007).  
Cholesterol depletion also increases ligand binding, dimerization, and phosphorylation 
but decreases EGF-stimulated signaling (Chen and Resh, 2002; Pike, 2005; Pike and 
Casey, 1996; Pike and Casey, 2002; Pike and Miller, 1998; Ringerike et al., 2002; 
Roepstorff et al., 2002).  Furthermore, localization of EGFR to lipid rafts has been 
shown to affect the efficacy of EGFR-targeted chemotherapeutic agents.  Cells with 
higher amounts of EGFR within lipid rafts were found to be less responsive to tyrosine 
kinase inhibitors used in the treatment of cancer (Irwin et al., 2010).  Therefore, 
alteration of EGFR localization in lipid rafts is likely to result in modified EGFR 
signaling.   
 
1.4 Docosahexaenoic acid 
 Docosahexaenoic acid (DHA) is a fatty acid composed of a 22-carbon chain with 
6 cis double bonds.  The first double bond from the methyl end of the fatty acid is 
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located at the third carbon, thereby classifying DHA as an omega-3, or n-3, 
polyunsaturated fatty acid (PUFA).  DHA is found highly enriched in select tissues, 
including the brain (Breckenridge et al., 1972), sperm (Neill and Masters, 1973), and the 
retina (Stillwell and Wassall, 2003).  In fact, DHA can approach 50 mol% of the 
phospholipid acyl chains in the membranes of these tissues (Simopoulos et al., 1986), 
and di-DHA phospholipid species have been isolated from these tissues (Bell et al., 
1997).  In most other tissues, DHA is not highly concentrated and often composes less 
than 5 mol% of the total phospholipid acyl chains (Simopoulos et al., 1986).  DHA is 
primarily found in the sn-2 position of phospholipids in the membranes of these tissues 
(Anderson and Sperling, 1971).   However, DHA content of these “unenriched” tissues 
can be increased 2-10 fold through dietary measures (Robinson et al., 1993; Simopoulos 
et al., 1986; VanMeter et al., 1994).   Oily, cold water fish are the major dietary source 
of DHA.  DHA can rapidly incorporate into a variety of membranes, mainly into the 
mitochondria (Stillwell et al., 1997; Tahin et al., 1981) and the plasma membrane 
(Zerouga et al., 1996).  DHA is primarily incorporated into phosphatidylethanolamine 
and phosphatidylcholine (Robinson et al., 1993; Stubbs and Smith, 1984; Zerouga et al., 
1996), but DHA-accumulation in specific phospholipids can be tissue specific (Knapp et 
al., 1994; Salem et al., 1986).   
1.4.1 Effects of n-3 PUFA on colon cancer 
Risk of colon cancer is directly linked with modifiable factors, including diet 
(Martínez and Jacobs, 2004).   In fact, researchers have found over 180 dietary 
interventions and pharmacologic agents that reduce ACF in models of chemical-induced 
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colon carcinogenesis (Corpet and Tache, 2002).  One major dietary component that has 
been indicated in the prevention of colon cancer is fish oil.  Experimental, clinical, and 
epidemiological studies have strongly indicated a role for fish oil, and its most abundant 
bioactive dietary lipids eicosapentaenoic acid (EPA, 20:5 n-3) and DHA, in colon cancer 
prevention (Anti et al., 1994; Anti et al., 1992; Bartram et al., 1993; Caygill et al., 1996; 
Chang et al., 1998; Courtney et al., 2007; Geelen et al., 2007; Hall et al., 2008; Kim et 
al., 2010a; Pot et al., 2008) (Murff et al., 2012; Sasazuki et al., 2011).  However, 
knowledge of the mechanism(s) by which fish oil confers chemoprotection is 
rudimentary.  The current literature suggests multiple mechanisms to explain the anti-
neoplastic activity of DHA and EPA.  The suggested mechanisms include inhibition of 
cyclooxygenase (COX) activity (Calviello et al., 2004; Habbel et al., 2009; Swamy et al., 
2004), reduction of inflammation (Angeles Puertollano et al., 2001; Bannenberg et al., 
2007; Calviello et al., 2004; D'Ambola et al., 1991; Ibrahim et al., 2011; Rao et al., 
2001; Yaqoob et al., 1994), fatty acid signaling through G protein coupled receptors 
(Arita et al., 2005; Arita et al., 2007; Im, 2012; Krishnamoorthy et al., 2010; Oh et al., 
2010; Serhan et al., 2011), altered cellular oxidative stress (Benais-Pont et al., 2006; 
Chen and Istfan, 2000; Crnkovic et al., 2012; Dupertuis et al., 2007; Engel and Evens, 
2006; Ng et al., 2005; Nomura et al., 1999; Wang et al., 2000), and alteration of 
membrane dynamics (discussed in detail below).  Modification of cell membranes can 
have extensive effects on cellular function.  DHA has been shown to have substantial 
effects on plasma membrane properties, including membrane fluidity, phase behavior, 
permeability, fusion, and flip-flop (Stillwell and Wassall, 2003; Wassall et al., 2004).  
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Recent evidence further suggests that DHA can perturb lipid rafts (Chapkin et al., 2008a; 
Kim et al., 2008; Shaikh et al., 2009b).  DHA, due to its high degree of unsaturation, is 
sterically incompatible with cholesterol (Wassall et al., 2004), a major constituent of 
rafts.  Additionally, DHA displays non-ideal mixing with sphingomyelin, another major 
component of lipid rafts, in model membranes (Shaikh et al., 2009a). Conceivably, 
disruption of lipid rafts could be caused by the lack of affinity of DHA for lipid raft 
components.  As mentioned above, several important processes involve lipid rafts, 
including T-cell activation, signal transduction, and protein and lipid trafficking (Pike, 
2005).  Many of these lipid raft-mediated processes play an integral role in colon 
tumorigenesis.  Signaling pathways emanating from lipid rafts, frequently exacerbated in 
cancer, mediate a variety of tumor-promoting activities, including cell proliferation, 
migration, and invasion (Patra, 2008).  Additionally, chronic inflammation, central to the 
process of tumorigenesis (Ullman and Itzkowitz, 2011), involves excessive lipid raft-
mediated T-cell activation.  Numerous recent discoveries highlight the role of n-3 PUFA 
in the regulation of lipid rafts and lipid raft-mediated signaling.  
1.4.2 n-3 PUFA alter lipid raft size 
Lipid raft size is an important feature in lipid raft function that has been shown to 
be altered by n-3 PUFA (Nicolau et al., 2006).  Lipid raft size is integral for dynamic 
lateral segregation of signaling proteins into microdomains.  Partitioning of proteins into 
rafts can increase specific protein-protein collision rates to facilitate efficient signaling.  
However, to maximize this essential, biologically relevant function, rafts must be mobile 
and small, with a diameter up to 14 nm (Nicolau et al., 2006).  The size of lipid rafts in 
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splenic T-cells from wild type and fat-1 transgenic mice, which express n-3 fatty acid 
desaturase cloned from C. elegans, has been compared (Kang et al., 2004).  This enzyme 
can catalyze the production of endogenous n-3 PUFA by introducing a double bond into 
fatty acyl chains.   Fat-1 mice are a useful tool for the assessment of  the biological 
properties of n-3 PUFA without diet manipulation.  Fat-1 mice were shown to have T-
cells that exhibited enhanced clustering of lipid rafts to form large raft domains (Kim et 
al., 2008).  The poor affinity of cholesterol for n-3 PUFA likely causes a lipid-driven 
mechanism for lateral phase separation of cholesterol- and sphingolipid-rich lipid 
microdomains from n-3 PUFA.  By increasing the size of lipid rafts, n-3 PUFA impair 
efficient functioning of lipid rafts in T-cells.  This in turn suppresses T-cell activation 
(Kim et al., 2008), which is a potential mechanism by which n-3 PUFA function as anti-
inflammatory agents.  Similar results have been observed in HeLa cells, a human cancer 
cell line.  HeLa cells treated with DHA exhibited enhanced clustering of lipid raft 
domains compared to untreated cells (Chapkin et al., 2008c).  Consistent with these 
findings, work done by Rockett et al. in B cells illustrated that the effect of fish oil on 
lipid raft size is likely mediated specifically by DHA (Rockett et al., 2012).  In breast 
cancer cells, DHA has been shown to increase the height of lipid rafts, while reducing 
the overall number of lipid rafts (Corsetto et al., 2012).  Importantly, increasing lipid raft 
size has implications in the regulation of multiple signaling events associated with these 
microdomains.   
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1.4.3 n-3 PUFA alter lipid raft composition 
In addition to lipid raft size, the composition of lipid rafts is important for lipid 
raft function.  Lipid rafts provide a more ordered lipid environment than the bulk 
membrane due to interactions between cholesterol, sphingolipids, and phospholipids 
containing saturated fatty acyl chains (Brown and London, 2000).  Extraction of certain 
lipids from raft microdomains, including cholesterol, has been shown to perturb their 
function (Ilangumaran and Hoessli, 1998; Pike and Casey, 2002; Pike and Miller, 1998; 
Westover et al., 2003; Zhuang et al., 2002).  Therefore, the effect of n-3 PUFA on lipid 
composition of rafts in multiple cell types has been studied extensively.  Upon feeding 
mice a diet enriched in n-3 PUFA, the cholesterol content of lipid rafts in colonocytes 
was reduced by 46% compared to mice fed a diet enriched in n-6 PUFA (Ma et al., 
2004).  Dietary n-3 PUFA also reduced lipid raft sphingolipid content by ~45% in mouse 
splenic T-cells (Fan et al., 2003a).   Specifically, raft sphingomyelin content was 
decreased by 30% in T-cells from mice fed n-3 PUFA (Fan et al., 2004).  n-3 PUFA 
have been shown to have similar effects in multiple cell types.  Treatment of both 
endothelial and breast cancer cells with DHA was also found to reduce raft 
sphingomyelin and cholesterol content (Schley et al., 2007; Ye et al., 2010).  These n-3 
PUFA induced modifications of lipid raft composition are significant because 
cholesterol and sphingomyelin are major building blocks of lipid rafts that promote the 
formation of hydrophobic liquid-ordered molecular packing.  
Furthermore, various proteins are known to be enriched in lipid rafts.  
Specifically, eminent signaling proteins, including receptors and G proteins, require raft 
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localization for proper functioning (Pike, 2003; Smart et al., 1999a).  One such lipid raft 
sequestered protein is Ras.  Ras is an important signaling mediator, and one of its major 
isoforms, H-Ras, is well known to localize to lipid raft domains (Prior et al., 2003).  
Activation of H-Ras and downstream signal transduction has been shown to be 
dependent on lipid raft localization (Eisenberg et al., 2006; Mineo et al., 1996; Prior et 
al., 2001).  Feeding mice a diet enriched in n-3 PUFA and treating immortalized young 
adult mouse colonocytes (YAMC) with DHA decreased the localization of H-Ras to 
lipid raft domains in colonocytes (Ma et al., 2004).  Furthermore, DHA has been shown 
to inhibit the plasma membrane targeting of lipidated proteins, including H-Ras (Seo et 
al., 2006).  Src and Fyn are lipid raft localized signaling mediators, and DHA has been 
found to cause a redistribution of these proteins out of rafts in colon cancer cells 
(Duraisamy et al., 2007).  n-3 PUFA have also been shown to alter lipid raft partitioning 
of key proteins involved in T-cell activation, including PKCθ, PLC-γ1, and F-actin.  
Dietary fish oil significantly suppressed the recruitment of PKCθ to lipid rafts following 
stimulation (Fan et al., 2004).  In a complementary study, recruitment of PKCθ, PLC-γ1, 
and F-actin to lipid raft domains was suppressed in T-cells isolated from fat-1 transgenic 
mice compared to wild-type mice (Kim et al., 2008).  Treatment of T-cells with DHA 
has additionally been shown to displace IL-2R, JAK1, JAK3, and STAT5 from lipid raft 
domains (Li et al., 2005).  In B-cells, DHA has been shown to reduce the recruitment of 
TLR4 to lipid raft domains (Wong et al., 2009).  Overall, these data clearly demonstrate 
that n-3 PUFA modify the lipid raft microenvironment (Li et al., 2005).  A proposed 
model for the effect of n-3 PUFA on lipid rafts is presented in Fig. 1. 
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Figure 1.  Putative model for the effect of n-3 PUFA on lipid rafts.  Lipid rafts are nanoscale regions of the 
plasma membrane, enriched in cholesterol, sphingomyelin, and phospholipids containing saturated acyl chains.  
Both transmembrane and peripheral membrane proteins can be localized to lipid rafts.  Upon treatment with a 
combination of n-3 PUFA or DHA alone, these PUFA are incorporated into phospholipids which are inserted into 
both raft and non-raft regions of the plasma membrane.  This results in enhanced clustering of lipid raft regions, 
which are depleted of cholesterol and sphingomyelin.  Additionally, many lipid raft associated proteins 
“mislocalize” to the bulk membrane domain.  This results in a suppression of lipid raft mediated processes, 
including T-cell activation and downstream signal transduction. 
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1.4.4 n-3 PUFA perturb lipid raft regulated signaling 
Observations on the effect of n-3 PUFA on lipid raft size and composition 
indicate that n-3 PUFA likely suppress lipid raft mediated cell signaling.  Lipid rafts 
compartmentalize signal-transducing molecules to provide an environment conducive to 
signal transduction (Leitenberg et al., 2001).  Many studies have addressed the effect of 
n-3 PUFA on signaling events that originate in rafts.   n-3 PUFA feeding has been shown 
to suppress EGF-induced activation of H-Ras, but not K-Ras in colonocytes (Ma et al., 
2004).  Interestingly, H-Ras signaling has been shown to be sensitive to lipid raft 
perturbations, whereas K-Ras signaling is largely insensitive (Roy et al., 1999).  
Phosphorylation of PLC-γ1 is a lipid raft dependent process that occurs in the very early 
stages of T-cell activation (Zhang and Samelson, 2000).  Stimulation-induced PLC-γ1 
phosphorylation is inhibited in cells from fat-1 transgenic mice compared to wild-type 
mice (Kim et al., 2008).  Additionally, lipid rafts have been shown to both integrate and 
amplify signaling processes that lead to activation of transcription factors, including AP-
1 and NF-κB in T-cells.  Activation of NF-κB and AP-1 has been shown to be essential 
for induction of responses to immune and inflammatory challenges (Ben-Neriah and 
Karin, 2011; Hess et al., 2004).  Therefore, the effect of n-3 PUFA on receptor-induced 
activation of these important pathway modifiers has been studied.  Both fish oil and 
purified DHA suppress the binding activity of AP-1 and NF-κB (Fan et al., 2004).  
TLR4 activation in lipid rafts is important in B-cell mediated events, and TLR4 
activation has been shown suppressed by DHA (Wong et al., 2009).  Together, these 
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findings are consistent with the hypothesis that changes in membrane composition 
induced by n-3 PUFA have functional consequences with regard to cell signaling. 
1.4.5 n-3 PUFA suppress lipid raft-mediated cell function 
Lipid raft mediated cell signaling ultimately mediates numerous cell functions.  
T-cell activation requires lipid raft coalescence and translocation of key proteins, 
ultimately leading to the production of cytokines and cell cycle progression.  IL-2 
functions in both a paracrine and autocrine manner to induce T-cell proliferation.  
Feeding a diet enriched in n-3 PUFA has been shown to inhibit activation-induced 
production of IL-2 and thereby suppress T-cell proliferation (Fan et al., 2004).  
Additionally, T-cell proliferation in response to multiple stimuli is suppressed in fat-1 
mice (Kim et al., 2008).  Fish oil feeding also suppressed lipid-raft mediated B-cell 
stimulation of CD4+ T-cells (Rockett et al., 2012).  n-3 PUFA have additionally been 
found to reduce levels of the lipid raft localized lipid, phosphatidylinositol-4,5-
bisphosphate (PIP2), in T-cells, which results in suppression of actin-remodeling (Hou et 
al., 2012).  In epithelial cells, DHA-induced disruption of lipid rafts was found to reduce 
cell proliferation and increase apoptosis (Corsetto et al., 2012; Ravacci et al., 2012).  
DHA has additionally been shown to decrease oxidative-stress induced calcium influx, a 
lipid raft-mediated process, in endothelial cells (Ye et al., 2010).  These data signify the 
implicit role of n-3 PUFA in regulation of lipid raft mediated cell processes.   
1.4.6 Effects of DHA on EGFR 
Two initial studies have assessed the effects of n-3 PUFA on EGFR localization 
and signaling.  Initially, a combination of EPA and DHA was shown to alter the 
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localization of EGFR within the plasma membrane of a breast cancer cell line.  The 
altered localization was concurrent with increased ligand-induced EGFR 
phosphorylation and downstream activation of p38MAPK (Schley et al., 2007).  The 
second study utilized DHA alone, and similarly reported an alteration in EGFR 
localization in lung and breast cancer cell lines (Rogers et al., 2010).  Although EGFR 
phosphorylation and downstream signaling was only investigated under basal conditions, 
the increase in EGFR phosphorylation was associated with a suppression of Ras and 
ERK1/2 activation upon DHA treatment.  These initial observations, although intriguing, 
did not directly address how n-3 PUFA impact EGFR functionality since receptor 
activation was never examined within the context of a ligand specific for the EGFR.  
Therefore, the molecular mechanisms leading to the suppressive effects of DHA 
treatment on EGFR-dependent signaling remain undetermined.  Additionally, these 
studies only assessed a single downstream cascade emanating from EGFR.   
 
1.5 Current study 
The major objective of this research is to determine the effects of the long chain 
n-3 PUFA DHA on the activation and signaling axis of EGFR.  The evidence discussed 
here strongly suggests that DHA alters EGFR localization and thereby profoundly 
suppresses EGFR function.  Therefore, this study specifically addresses the effects of n-
3 PUFA on EGFR localization in the plasma membrane and downstream signaling.   In 
addition, we have assessed the effects of this class of dietary lipid on EGFR-mediated 
processes including cell proliferation and wound healing.  This study is intended to 
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elucidate the mechanism by which DHA functions in chemoprevention.  This work can 
bolster efforts aimed at determining ideal candidates for n-3 PUFA-mediated therapies 
targeting epithelial cells. 
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2. EFFECT OF DHA ON EGFR LOCALIZATION AND SIGNALING* 
 
2.1 Introduction 
 Colon cancer prevention is an open frontier for cancer research.  Many leaders in 
the field agree that significant efforts should be made to further research in 
chemoprevention.  Dietary manipulation can have a major impact on colon cancer risk.  
Sundry dietary agents have been found to either protect against or promote cancer.  One 
such dietary component is DHA.  Significant research suggests that DHA is protective 
against colon tumorigenesis.  However, in the United States, consumption of DHA is 
extremely low, with the average intake reported to be less than 0.2 g/day (Conquer and 
Holub, 1998; Kris-Etherton et al., 2000).  If conclusive data shows that DHA can protect 
against colon tumorigenesis, it would be manageable for at risk populations to increase 
their consumption of this fatty acid.  However, the exact mechanism(s) of action of DHA 
remains elusive.  It is imperative to understand the mechanism of action of a 
chemoprotective agent in order to determine optimal dosing and timing, as well as 
identifying people who are most likely to benefit from a particular intervention. 
 Research suggests that one potential mechanism of action of DHA is to perturb 
lipid rafts (Chapkin et al., 2008c).  This lipid raft disrupting effect of DHA has since 
been shown to occur in multiple cell types, including colonocytes.  Many critical 
signaling events involved in cell proliferation and migration originate in lipid rafts 
(Staubach and Hanisch, 2011).  Therefore, DHA is hypothesized to protect against colon 
__________________________ 
*Part of this chapter is reprinted with permission from “Alteration of EGFR spatiotemporal dynamics suppresses signal 
transduction” by Harmony F. Turk, Rola Barhoumi, and Robert S. Chapkin, 2012. PLoS ONE, 7,e39682, Copyright 2012 by 
Harmony F. Turk. 
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cancer by suppressing oncogenic cell signaling that emanates from lipid rafts.  However, 
it remains unclear which molecular mechanism are modulated by DHA. 
A major oncogenic protein known to localize to lipid rafts is EGFR.  As 
mentioned above, EGFR plays an important role in colon tumorigenesis.  Lipid rafts 
serve to facilitate EGFR signaling, as well as to partially constrain receptor activation 
(Ringerike et al., 2002).  EGFR signals through ERK1/2, STAT3, Akt, and mammalian 
target of rapamycin (mTOR) to stimulate cell proliferation and inhibit cell death.  
ERK1/2 (also known as p44/42 MAPK) are serine/threonine kinases.  ERK1/2 activation 
is rapidly stimulated by EGF, and ERK1/2 activation is integral for the G1- to S-phase 
transition of the cell cycle (Cargnello and Roux, 2011).  ERK1/2 regulate gene 
transcription by activating or stabilizing transcription factors, including Elk-1 and c-Fos.  
STAT3 is a transcription factor that homodimerizes upon activation, enters the nucleus, 
and activates genes required for cell survival (Bcl-X, survivin, caspases) and cell 
proliferation (c-Myc, p21, cyclin D1) (Klampfer, 2008).  Similar to ERK1/2, Akt is a 
serine/threonine protein kinase.  Akt phosphorylates numerous proteins involved in cell 
survival (BAD, CREB, Iκ-B kinase, Procaspase-9) and cell cycle progression (GSK-3, 
p21
WAF1
) (Nicholson and Anderson, 2002).  mTOR is also a serine/threonine kinase.  
EGF-induced stimulation of both Akt and ERK1/2 can lead to activation of a protein 
complex containing mTOR, i.e., mTORC1 (Laplante and Sabatini, 2012).  EGF can also 
induce activation of mTORC2, another mTOR-containing protein complex.  mTORC1 
regulates protein synthesis by activating ribosomal S6 kinase (S6K) and inhibiting 4E-
BP1 and Maf1 (Laplante and Sabatini, 2012).  mTORC2 is integral in regulating cell 
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survival by activating Akt and SGK1, and this complex is also important for activating 
cytoskeletal organization (Laplante and Sabatini, 2012).  EGFR also activates a 
multitude of other signaling mediators that regulate other cellular functions, including 
migration, adhesion, invasion, and angiogenesis (Yarden, 2001).  Precise signaling of 
EGFR has been intimately linked to its lipid raft localization (Chen and Resh, 2002; Pike 
and Casey, 1996; Roepstorff et al., 2002).  DHA has been shown to redistribute some 
lipid raft localized proteins into the bulk domain (Duraisamy et al., 2007; Kim et al., 
2008), which affects protein function.  Consequently, we propose that DHA could alter 
the lipid raft localization of EGFR and thereby modify receptor function.  
Our first aim was to assess the effect of DHA on EGFR localization and 
signaling in young adult mouse colonocytes (YAMC), a non-malignant transformed cell 
line.  Specifically, we evaluated the membrane distribution of EGFR in cells left 
untreated or treated with DHA or the control fatty acid linoleic acid, LA 18:2n-6.  We 
then analyzed the effect of the localization of EGFR on the ability of the receptor to 
autophosphorylate and activate downstream signaling through ERK1/2, STAT3, Akt, 
and mTOR.  We also compared the effects of DHA and EPA on EGFR phosphorylation.  
Lastly, we determined the effect of DHA on cell viability, including cell proliferation 
and overall cellular death. 
 
 34 
 
2.2 Materials and methods  
2.2.1 Cell culture 
Young adult mouse colonic (YAMC) cells, conditionally immortalized 
colonocytes, were originally obtained from R.H. Whitehead, Ludwig Cancer Institute 
(Melbourne, Australia).   Both wild-type and EGFR
-/-
 isotype YAMC cells were utilized.  
YAMC cells (passages 12–17) were cultured under permissive conditions, 33°C and 5% 
CO2 in RPMI 1640 media (Mediatech, Manassas, VA) supplemented with 5% fetal 
bovine serum (FBS; Hyclone, Logan, UT), 2 mM GlutaMax (Gibco, Grand Island, NY), 
5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenious acid (Collaborative Biomedical 
Products, Bedford, MA), and 5 IU/mL of murine interferon-γ (Roche, Mannheim, 
Germany).  Select cultures were treated for 72 h with 50 µM fatty acid [DHA, linoleic 
acid (LA, 18:2n-6), arachidonic acid (AA, 20:4n-6), or eicosapentaenoic acid (EPA, 
20:5n-3); NuChek, Elysian, MN] complexed with bovine serum albumin (BSA).  Where 
indicated, DHA treated cultures were washed three times with PBS followed by 
incubation with untreated media or LA for an additional 40 h.  In select cultures, for the 
final 16-18 h, complete media was replaced with low-serum (0.5% FBS) media.   Cells 
were then stimulated with 0-25 ng/mL recombinant mouse EGF (Sigma, St. Louis, MO) 
and harvested.    
2.2.2 Lipid raft isolation 
To determine the localization of EGFR within the plasma membrane, YAMC 
cells were treated with fatty acid and serum starved as above.  Detergent-free lipid raft-
enriched fractions were isolated as previously described (Ma et al., 2004; Smart et al., 
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1995).  All steps were performed at 4°C.  YAMC cells grown in 12 T-175 flasks per 
treatment were harvested with trypsin-EDTA (Gibco) and pelleted at 200 x g for 5 min.  
The pellets were resuspended in Buffer A (250 mM sucrose, 1 mM EDTA, 20 mM 
Tricine, 100 µM activated sodium orthovanadate, 40 µL/mL protease cocktail, pH 7.8) at 
1 x 10
7 
cell/mL.  Cells from each treatment were pooled and lysed by two rounds of 
rapid freeze (-80
o
C) and thaw (37
o
C).  Cell lysates were then centrifuged at 1000 x g for 
10 min, and the supernatants were retained.  Cell pellets were resuspended in Buffer A 
and homogenized as above, and the centrifugation step was repeated.  The resulting 
supernatants were pooled into a post-nuclear supernatant (PNS). The PNS was layered 
on top of 30% Percoll (Amersham, Pittsburg, PA) in Buffer A and centrifuged at 84,000 
x g for 30 min in a Beckman SW28 rotor.  The plasma membrane fraction was collected 
and sonicated 3 times (50-J bursts) with 2 rapid pulses each time.  The samples were 
then mixed with OptiPrep (Accurate Chemical and Scientific Corp, Westbury, NY) in 
Buffer A (final concentration 23%), overlaid with a 6 mL linear 20 to 10% OptiPrep 
gradient, and centrifuged in a Beckman SW41Ti rotor at 52,000 x g for 90 min.  The top 
5 mL of the gradient was collected and combined with 4 mL of 50% OptiPrep in Buffer 
A.  An aliquot of the denser membrane band was also collected.  The 9 mL fraction was 
overlaid with 1 mL of 15% Optiprep in Buffer A and 0.5 mL of 5% Optiprep in Buffer A 
and was centrifuged at 52,000g for 90 min in a Beckman SW41Ti rotor.  A lipid 
raft/caveolae-enriched membrane fraction was collected from the 5/15% interface, and a 
membrane fraction defined as the intermediate fraction was collected at the bottom of 
the 15% layer.  Slide-a-lyser cassettes (Pierce, Rockford, IL) were used to dialyze 
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samples overnight in dialysis buffer (1 mM EDTA, 20 mM tricine, pH 7.8).  Samples 
were placed into 1.5 mL Eppendorf tubes and centrifuged in a SpeedVac System to 1/3 
the original volume to concentrate.  Protein concentration was measured with Coomassie 
Plus Protein assay (Pierce), and fractions were subjected to SDS-PAGE and western 
blotting as described above. 
2.2.3 Colocalization 
The plasmid containing RFP conjugated with a truncated H-Ras composed of the 
C-terminal 9 amino acid targeting domain (RFP-tH) was a generous gift from Ian Prior, 
Univ. of Liverpool (Apolloni et al., 2000).  The plasmid containing full length human 
EGFR fused to GFP containing a point mutation of A206K in the GFP sequence to 
prevent GFP dimerization (EGFR-mGFP) was a kind gift from Hung-Jun Liao, 
Vanderbilt University (Liao and Carpenter, 2007).  Cells were seeded at a density of 1.0 
x 10
5 
cells per well into Lab-Tek II 2-well chambered coverglass slides (Nalge Nunc, 
Rochester, NY) 24 h prior to transfection and cultured in complete RPMI media 
containing 50 µM fatty acid.  Cells were cotransfected with 0.3 µg RFP-tH and 1.5 µg 
EGFR-mGFP using Effectene (Qiagen, Valencia, CA) in media without fatty acid 
according to the manufacturer’s instructions.  Transfection conditions were optimized to 
minimize the amount of DNA and lipofection reagent used to avoid nonspecific 
cytotoxicity.  Four h after transfection, cells were washed and the media was replaced 
and supplemented with 50 µM fatty acid for 48 h.  Cells were incubated in serum-
starvation media (0.5% FBS) with fatty acid for the final 16-18h prior to imaging.  Cells 
were imaged 48 h after transfection.  Prior to imaging, cultures were washed with 
 37 
 
Leibovitz’s L-15 medium (Gibco) followed by addition of 1 mL of Leibovitz’s media 
(without serum) per well.  Images were collected with a Zeiss 510 META NLO 
Multiphoton Microscope System consisting of an Axiovert 200 MOT microscope (Carl 
Zeiss Microimaging, Thornwood, NY) equipped with argon and helium-neo lasers, 
PMT, and LSM software. For EGFR-mGFP and RFP-tH, excitation wavelengths of 488 
nm and 543 nm were used, and fluorescence emission was monitored at 530 nm and 590 
nm, respectively.  Images were collected in confocal mode with the pinhole set at 1 AU 
using a 40X objective (1.3 NA oil immersion lens) at room temperature.  Identical 
acquisition parameters were used for all images within the experiment.  Colocalization at 
the plasma membrane was analyzed by quantifying Mander’s colocalization coefficient 
for green (EGFR-mGFP) with red (RFP-tH) using Nikon Elements AR 3.2.  Analysis 
was performed on background-subtracted 16-bit images.  
2.2.4 Western blotting 
For western blotting, cells were homogenized in ice-cold homogenization buffer 
(50 mM Tris-HCl, pH 7.2, 250 mM sucrose, 2 mM EDTA, 1 mM EGTA, 50 mM 
sodium fluoride, 100 mM sodium orthovanadate, 1%Triton X-100, 100 µM activated 
sodium orthovanadate, 10 mM β-mercaptoethanol, and protease inhibitor cocktail) as 
previously described (Davidson et al., 1999).  Following homogenization, lysates were 
sheared using a 29G needle, incubated on ice for 30 min, and centrifuged at 16,000 x g 
for 20 min.  The supernatant was collected and protein concentration was assessed using 
Coomassie Plus Protein assay (Pierce).  Lysates were treated with 1X pyronin sample 
buffer and subjected to SDS polyacrylamide gel electrophoresis (PAGE) in precast 4–
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20% Tris-glycine mini gels (Invitrogen).  After electrophoresis, proteins were 
electroblotted onto a polyvinylidene fluoride membrane with the use of a Hoefer Mighty 
Small Transphor unit at 400 mA for 90 min. Following transfer, the membrane was 
incubated in 5% BSA (Roche) and 0.1% Tween 20 in TBS (TBST) at room temperature 
for 1 h with shaking, followed by incubation with shaking overnight at 4
o
C with primary 
antibody diluted in 5% BSA in TBST.  Membranes were washed with TBST and 
incubated with peroxidase conjugated secondary antibody as per manufacturer’s 
instructions.  Bands were developed using Pierce SuperSignal West Femto
TM
 maximum 
sensitivity substrate.  Blots were scanned using a Fluor-S Max MultiImager system (Bio-
Rad, Hercules, CA).  Quantification of bands was performed using Quantity One 
software (Bio-Rad).  Monoclonal rabbit anti-EGFR, phospho-EGFR (Tyr1068), Akt, 
phospho-Akt (Ser473), ERK1/2, p-ERK1/2, STAT3, phospho-STAT3 (Tyr705), p70 
S6kinase, and phospho-p70 S6kinase (Thr389) and monoclonal mouse phospho-tyrosine 
were purchased from Cell Signaling (Danvers, MA).  Affinity purified mouse anti-
clathrin heavy chain and purified mouse anti-caveolin 1 were purchased from BD 
Transduction Laboratories (Bedford, MA).  Peroxidase conjugated goat anti-rabbit IgG 
was purchased from Kirkegaard and Perry Laboratories (Gaithersburg, MD), and 
peroxidase conjugated goat anti-mouse IgG was purchased from Jackson 
ImmunoResearch (West Grove, PA).  For detection of ganglioside GM-1, peroxidase 
conjugated cholera toxin B subunit was purchased from Sigma.   
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2.2.5 Immunoprecipitation 
Cell lysates were incubated with rotation purified polyclonal rabbit anti-EGFR 
antibody (Millipore, Billerica, MA) overnight.  The protein-antibody conjugates were 
then pulled down using protein-G conjugated Dynabeads (Invitrogen).  Protein was 
eluted from the Dynabeads using 2X pyronin buffer, and equal volumes of the samples 
were run on SDS-PAGE and western blotted for EGFR, phospho-tyrosine, or ubiquitin.  
Lysates analyzed for ubiquitination of EGFR were treated with 5 mM N-ethylmaleimide 
to prevent post lysis deubiquitination of EGFR (Gan et al., 2010). 
2.2.6 Cell proliferation and viability 
YAMC cells (both wild-type and EGFR
-/-
) were treated with fatty acids for 24 h 
prior to being seeded into a 96-well plate at a density of 1.0 x 10
5
 cells per well.  Cells 
were cultured in complete media supplemented with fatty acids for an additional 48 h.  
Cells were then washed with PBS and cell proliferation was measured using CyQuant 
cell proliferation assay (Molecular Probes, Grand Island, NY) according to the 
manufacturer’s instructions.  Cell viability was assessed using Trypan blue (Invitrogen).  
YAMC cells were grown in T-175 flasks and untreated or treated with fatty acids (DHA 
or LA) for 72 hours. Cells were then trypsinized and placed into a conical tube.  Trypsin 
activity was neutralized using complete RPMI-1640 media.  A 0.4% trypan blue solution 
in PBS was prepared, and a cell suspension to trypan blue solution was prepared at a 
ratio of 10:1.  This preparation was then loaded onto a hemocytometer, and the number 
of blue (dead) and total cells was counted.   
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2.2.7 Mice 
Female C57BL/6 wild-type mice were used. All procedures followed guidelines 
approved by the U.S. Public Health Service and the Institutional Animal Care and Use 
Committee at Texas A&M University.  This study and all animal protocols and 
procedures were approved by the Institutional Animal Care and Use Committee at Texas 
A&M University (Permit number: AUP2010-079).  All efforts were made to minimize 
suffering.  Mice were maintained under barrier conditions and initially consumed a 
Teklad commercial mouse non-purified diet (Harlan, Indianapolis, IN) ad libitum. Mice 
were maintained for 15 weeks on a semi-purified defined diet that was adequate in all 
nutrients, containing 320 (g/kg diet) sucrose, 200 casein, 220 corn starch, 3 DL-
methionine, 35 AIN 76 salt mix, 10 AIN 76 mineral mix, 2 choline chloride, 60 cellulose 
(Bio-Serv, Frenchtown, NJ), 150 corn oil (CO) (Dyets, Bethlehem, PA) or 115 vacuum-
deodorized Menhaden fish oil (FO) (Omega Protein, Houston, TX) plus 35 CO.  The 
animals were provided the defined diet 2 weeks prior to an injection of azoxymethane 
(AOM; 7.5 mg/kg body weight).  One week after the AOM injection, mice were exposed 
to 3 cycles of 1% dextran sulfate sodium (DSS) for 4 d followed by 17 d of recovery.  
Mice were sacrificed 6 weeks after the last DSS treatment (13 weeks post AOM 
injection) by CO2 asphyxiation.  Colon lesions were mapped and excised prior to colonic 
mucosa isolation by scraping, and the mucosa was snap frozen in liquid nitrogen and 
stored at -80°C until homogenization.  Lesions were fixed in 4% paraformaldehyde, 
embedded in paraffin, stained with hematoxylin-eosin, and evaluated in a blinded 
manner by a board-certified pathologist.  For immunoblotting, mucosa was homogenized 
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in ice-cold homogenization buffer as described above.  For immunoprecipitation, 
mucosa was homogenized using Pierce Classic
TM
 IP lysis buffer according to the 
manufacturer’s instructions.  Following homogenization, lysates were sheared using a 
29G needle, incubated on ice for 30 min, and then centrifuged at 16,000 x g for 20 min.  
The supernatant was collected.  Protein concentration was determined using Coomassie 
Protein Plus assay (Pierce). 
2.2.8 Statistics 
The effect of 2 independent variables (treatment effects) was assessed using 
Student’s t-test.  The effect of more than 2 independent variables (treatment effects) was 
assessed using the one-way analysis of variance test (ANOVA), and differences among 
means were evaluated using Tukey’s post-hoc test of contrast.  P values <0.05 were 
considered to be statistically significant. 
 
2.3 Results 
2.3.1 DHA reduces partitioning of EGFR into lipid raft domains 
Lateral organization of EGFR within the plasma membrane is directly linked to 
receptor function.  Previous reports have shown that n-3 PUFA can alter the localization 
of EGFR within the plasma membrane of lung and breast cancer cells (Rogers et al., 
2010; Schley et al., 2007).  Therefore, we first determined the effect of DHA on 
localization of EGFR within the plasma membrane of colonocytes.  Experiments were 
conducted using the YAMC cell line, originally described by Whitehead and colleagues 
(Whitehead et al., 1993).  We employed two complementary, established methods to 
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investigate the localization of EGFR.  First, a detergent-free method of plasma 
membrane fractionation to isolate lipid raft enriched domains was utilized (Ma et al., 
2004).  We chose to use a detergent-free method due to strong evidence suggesting that 
detergent-based methods of extraction can lead to artifacts (Smart et al., 1995).  Cells 
were either untreated (control; no fatty acid) or incubated with 50 µM DHA or LA 
(control fatty acid) for 72 h.  We utilized this dose of fatty acid because we have 
previously found that it can recapitulate similar results as feeding a fish-oil enriched diet 
to experimental animal models(Fan et al., 2003b).  Additionally, consumption of an n-3 
PUFA enriched diet can result in circulating levels of DHA in excess of 50 μM (Kim et 
al., 2010b).  Furthermore, we treat our cell cultures with BSA-complexed fatty acids, 
which resemble the non-esterified fatty acids that are bound to albumin in vivo.  For the 
final 16-18 h of fatty acid treatment, cells were serum starved (0.5% FBS) prior to 
harvesting because EGFR has been shown to be localized to lipid rafts prior to 
activation.  The bulk plasma membrane was isolated and fractionated on density 
gradients into three fractions, and each fraction was analyzed for EGFR using western 
blotting.  The lowest density fraction from each treatment was enriched with caveolin 
and GM-1, which served as lipid raft markers, and depleted of clathrin, which is 
excluded from lipid rafts, indicating that this fraction is enriched with lipid rafts.  In 
control and LA treated cells, EGFR was highly concentrated in the lipid raft enriched 
(LR) fraction of the plasma membrane (Fig. 2).  This fraction exhibited a more than 
three-fold enrichment in EGFR compared to the intermediate density membrane (IDM) 
and high density membrane (HDM) fractions. However, in DHA treated cells, EGFR  
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Figure 2.  DHA reduces the localization of EGFR to lipid rafts.  YAMC cells were treated with 50 μM BSA-
complexed fatty acids for 72 h (12 flasks per treatment).  For the final 16-18 h, cells were serum starved (0.5% FBS) 
with the same concentration of fatty acids.  Cells were harvested from each flask, pooled (n=12), and the plasma 
membrane (PM) was isolated. Following isolation, the plasma membrane was fractionated into 3 distinct fractions, 
high density membrane (HDM), intermediate density membrane (IDM), and lipid raft enriched membrane (LR) by 
gradient ultracentrifugation.  Fractions were collected and an equal amount of protein from each fraction was analyzed 
by western blotting using antibodies against EGFR, caveolin-1, and clathrin or using peroxidase conjugated cholera 
toxin B subunit (for GM-1).  Quantification of band intensity was performed, and data are presented as the relative 
amount of EGFR in each fraction, with the sum of each fraction equaling 100.  Western blots are representative of 2 
independent experiments. C, control; LA, linoleic acid; DHA, docosahexaenoic acid; PM, plasma membrane; HDM, 
high density membrane; IDM, intermediate density membrane; LR, lipid raft enriched membrane. 
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displayed a more even distribution across all plasma membrane fractions.  In fact, we 
observed equal enrichment of EGFR in the LR and IDM fractions in DHA treated cells.  
These results indicate a change in EGFR localization within the plasma membrane upon 
treatment with DHA.  
To corroborate our initial results, confocal fluorescence microscopy was also 
used to determine localization of EGFR.  Control and fatty acid treated cells were co-
transfected by means of lipofection with plasmids encoding monomeric GFP-tagged 
EGFR (EGFR-mGFP) and RFP-tagged truncated H-Ras (RFP-tH).  RFP-tH, which is 
targeted by a CAAX motif that is both palmitoylated and farnesylated, is a well-
established lipid raft marker that is localized exclusively to low density fractions on 
sucrose gradients (Prior et al., 2001).  It additionally has been clearly demonstrated to 
form cholesterol dependent nanoclusters on the inner leaflet of the plasma membrane 
(Plowman et al., 2005; Prior et al., 2003).  RFP and GFP are ideal for colocalization 
studies because they do not have overlapping excitation and emission peaks.  
Colocalization was quantified by calculating Mander’s colocalization coefficient at the 
plasma membrane.  In control and LA treated cells, plasma membrane EGFR-mGFP 
strongly colocalized with RFP-tH (Fig. 3).  This colocalization was significantly 
decreased by treatment with DHA.  These results are intriguing and indicate that DHA 
altered the localization of EGFR, RFP-tH, or both within the membrane.  However, 
interpretation of these results in regards to lipid rafts is limited due to the fact that rafts 
are below the limit of resolution (~200 nm) using confocal microscopy.  Interestingly, in 
many of the DHA treated cells, EGFR-GFP and RFP-tH formed patches in the 
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membrane that were localized in close proximity to each other, but not overlapping.  
Additionally, the overall localization of the lipid raft marker, RFP-tH, was altered by 
treatment with DHA, which is in agreement with a plethora of data suggesting that DHA 
alters lipid rafts (Chapkin et al., 2008c; Kim et al., 2008; Shaikh et al., 2009b).  Lastly, 
whereas EGFR was primarily localized to the plasma membrane in control and LA 
treated cells, a substantial proportion of EGFR in the DHA-treated cells was localized 
intracellularly.  This allows us to conclude that DHA altered the cellular localization of 
EGFR.  Overall, these complementary datasets strongly indicate that DHA treatment 
altered the plasma membrane organization of EGFR within colonocytes, which is 
consistent with previous observations in breast and lung cells (Rogers et al., 2010; 
Schley et al., 2007).   
2.3.2 DHA increases EGFR phosphorylation 
Due to the role that lipid rafts play in the regulation of EGFR activation and 
downstream signaling, we next investigated the effects of DHA on EGFR activation 
status and signaling in YAMC cells.  Untreated and fatty acid treated cells were serum-
starved (0.5% FBS) overnight in order to reduce signaling from growth factors within 
the serum.  Subsequently, cells were stimulated with 25 ng/mL EGF for 10 min followed 
by isolation of cell lysates.  To assess the effects of fatty acid treatment on EGF-induced 
EGFR phosphorylation, lysates were probed for EGFR phosphorylated on Tyr1068, one 
of the major sites of EGFR phosphorylation that is involved in activation of downstream 
signaling.  EGF stimulated EGFR phosphorylation in all treatment groups (Fig. 4).   
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Figure 3.  DHA reduces colocalization of EGFR with the lipid raft marker, tH.  YAMC cells were treated with 
50 μM BSA-complexed fatty acids for 72 h.  Twenty-four h after initiating fatty acid treatment, cells were co-
transfected with RFP-tH and EGFR-mGFP.  Approximately 32 h after transfection, cells were incubated in serum 
starvation media (0.5% FBS) overnight prior to imaging.  Images are representative of 4 independent experiments.  
Whole cell images of each individual channel and the merged images are shown on the left.  High magnification 
images of the plasma membrane are shown on the right.  Mander’s colocalization coefficient was calculated at the 
plasma membrane for the amount of EGFR-mGFP (green) colocalizing with tH-RFP (red) using Nikon Elements 
AR 3.2.  The coefficient is the mean of n=30-40 cells per treatment.  Statistical significance between treatments 
(*P<0.05) was determined using ANOVA and Tukey’s test of contrast. Bars,10 μm. 
      Mander’s 
 Colocalization 
    Coefficient 
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Figure 4.  DHA enhances ligand-induced phosphorylation of EGFR.  YAMC cells were treated with BSA-
complexed fatty acids for 72 h.  For the final 16-18 h, cells were incubated in serum starvation (0.5% FBS) with the 
same concentration of fatty acids.  Cells were either unstimulated or stimulated for 10 min with 25 ng/mL EGF and 
subsequently harvested. A) Equal amounts of protein from whole cell lysates were western blotted for total and 
phosphorylated (Tyr1068) EGFR.  Additionally, EGFR was immunoprecipitated from total cellular lysates prior to 
western blotting for EGFR and phosphorylated tyrosine resides. Quantification of band volume was performed and data 
are presented as mean ± SEM normalized to control (n=3-4 experiments per treatment).  Data are expressed as the ratio 
of the phosphorylated receptor to total receptor and normalized to control.  Statistical significance between treatments 
(*P<0.05) was determined using ANOVA and Tukey’s test of contrast.  C, control; LA, linoleic acid; DHA, 
docosahexaenoic acid 
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However, DHA treatment resulted in a greater than two-fold increase in EGFR 
phosphorylation compared to untreated control or LA treated cells.  EGFR was also 
immunoprecipitated from cell lysates followed by immunoblotting for total 
phosphorylated tyrosine residues.  Consistent with the results for Tyr1068, DHA 
enhanced total EGFR tyrosine phosphorylation by greater than two-fold (Fig. 4).  
We additionally determined if higher doses of DHA could further increase EGFR 
phosphorylation.  YAMC cells were treated with 50, 75, and 100 μM DHA for 72 h and 
stimulated with EGF.  We found that all doses lead to an increase in EGFR 
phosphorylation, but there was no further increase in EGFR phosphorylation at higher 
doses of DHA (Fig. 5).  Therefore, we continued using the physiologically relevant dose 
of 50 μM DHA for future experiments.   
Since DHA and EPA are both long chain omega-3 fatty acids that have been 
shown to reduce colon tumor development, we examined whether each of these fatty 
acids cause an increase in EGFR phosphorylation or if the effect is specific to DHA.  We 
also assessed the effects of arachidonic acid (AA; 20:4 n-6) on EGFR phosphorylation as 
a control, long-chain n-6 PUFA.  This allows us to compare the effects of fatty acids 
with 4, 5, and 6 double bonds.  Cells were treated with fatty acids, serum-starved, and 
stimulated with EGF as in previous experiments.  Cell lysates were probed for 
phosphorylated EGFR.  Neither AA nor EPA treatment resulted in an increase in EGFR 
phosphorylation compared to control (Fig. 6).  Only DHA treatment increased the 
phosphorylation status of EGFR, indicating a unique property of this fatty acid. 
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We postulated that if the DHA-induced phosphorylation of EGFR is a result of 
membrane enrichment causing disruption of lipid rafts, then the effect should be 
reversible by depleting the cells of DHA.  To test this hypothesis, cells were treated with 
DHA, followed by a washout period wherein the cells were either left untreated or 
treated with LA.  We have previously shown that this wash-out period is sufficient to 
reduce the amount of DHA in the plasma membrane (Seo et al., 2006).  Following the 
wash-out period in DHA treated cells, ligand-induced EGFR phosphorylation was 
normalized back to the same level as control (Fig. 7).  These data indicate that the 
Figure 5.  Low doses of DHA are effective for enhancing EGFR phosphorylation.  YAMC cells were treated with 
varying concentrations of BSA-complexed DHA (0, 50, 75, or 100 μM) for 72 h.  For the final 16-18 h, cells were 
incubated in low serum media (0.5% FBS) with the same concentration of fatty acid.  Cells were then stimulated for 10 
min with 25 ng/mL EGF and subsequently harvested. Equal amounts of protein from whole cell lysates were western 
blotted for phosphorylated (Tyr1068) EGFR.  Quantification of band volume was performed and data are presented as 
mean ± SEM normalized to control (n=3 experiments per treatment).  Data are expressed as the ratio of the 
phosphorylated receptor to total receptor and normalized to control.  Statistical significance between treatments 
(represented by different letters, P<0.05) was determined using ANOVA and Tukey’s test of contrast.  DHA, 
docosahexaenoic acid 
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inhibition of EGFR signaling by DHA is dependent on its presence in the plasma 
membrane. 
 
 
 
 
 
 
 
 
Figure 6.  DHA uniquely modifies EGFR phosphorylation.  YAMC cells were treated with BSA-
complexed fatty acids for 72 h.  For the final 16-18 h, cells were incubated in serum starvation (0.5% FBS) 
with the same concentration of fatty acids.  Cells were either unstimulated or stimulated for 10 min with 25 
ng/mL EGF and subsequently harvested.  Lysates were assessed by western blotting for phosphorylated EGFR 
(Tyr1068).  The blot is representative of 3 independent experiments.  Data are presented as mean ± SEM of 
phosphorylated EGFR, normalized to control. Statistical significance between treatments as indicated by 
different letters (P<0.05) was determined using ANOVA and Tukey’s test of contrast. C, control; AA, 
arachidonic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; LA, linoleic acid.   
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 2.3.3 DHA suppresses activation of downstream mediators of EGFR signaling 
Since EGFR phosphorylation is characteristically associated with activation of 
downstream signaling, we probed cell lysates for phosphorylation of downstream 
effector proteins, including ERK1/2, STAT3, and Akt.  In cells treated with DHA, there 
was a ~50% reduction in the EGF-stimulated activation of ERK1/2 and STAT3 
Figure 7.  Washout of DHA from the plasma membrane reverses the effect of DHA on EGFR 
phosphorylation.  YAMC cells were either untreated or treated with 50 µM DHA for 72 h.  Select DHA treated 
cultures were then washed and incubated for an additional 40 h with either untreated media or 50 µM LA.  For 
the final 16-18 h, cells were serum starved (0.5% FBS) followed by stimulation with 25 ng/mL EGF then 
harvested. Lysates were assessed by western blotting for phosphorylated EGFR (Tyr1068).  The blot is 
representative of 3 independent experiments.  Data are presented as mean ± SEM of phosphorylated EGFR, 
normalized to control. Statistical significance between treatments as indicated by different letters (P<0.05) was 
determined using ANOVA and Tukey’s test of contrast. C, control; DHA, docosahexaenoic acid; LA, linoleic 
acid. 
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compared to untreated control and LA treated cells (Fig. 8).  DHA had no effect on Akt 
phosphorylation at Ser473 (Fig. 8).  However, Akt phosphorylation at this site was not 
significantly induced by EGF stimulation in any of the treatment groups.  To assess 
mTORC1 activity, we measured phosphorylation of S6K, a kinase that is directly 
phosphorylated by mTOR at Thr389.  We found that DHA significantly suppressed 
EGF-induced phosphorylation of S6K, indicating reduced activation of mTOR (Fig. 8).  
Together, these data suggest that DHA disrupts the EGFR signaling cascade in 
colonocytes. 
We further investigated the effect of DHA on EGFR phosphorylation and 
signaling at multiple time points.  Untreated control and DHA treated cells were 
stimulated with 25 ng/mL EGF for 0-30 min.  Consistent with initial results, EGFR 
phosphorylation was significantly increased by DHA treatment at 2, 5, and 10 min 
following stimulation (Fig. 9 A).  EGFR phosphorylation peaked in DHA treated cells at 
5 min and started decreasing, whereas EGFR phosphorylation was highest at 10 min in 
control samples, suggesting a dynamic alteration in EGFR regulation.  Downstream 
signaling from EGFR through ERK1/2 and STAT3 was suppressed by DHA at each time 
point assessed (Fig. 9, B and C).  
2.3.4  Suppression of cell proliferation by DHA  
In order to document a functional endpoint of the DHA-induced decrease in 
EGFR signaling, we chose to measure cell proliferation, which is regulated in part by 
signaling through EGFR.  DHA treatment of wild-type YAMC cells resulted in an 
approximately 40% decrease in cell proliferation compared to control and LA treated 
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cells (Fig. 10).  Additionally, the effect of DHA on proliferation of an isogenic cell line 
that does not express EGFR (EGFR
-/-
) was assessed.  Interestingly, DHA treatment had 
no effect on cell proliferation in EGFR
-/-
 YAMC cells compared to control.  Together, 
these data demonstrate that DHA suppresses cell proliferation in an EGFR-dependent 
manner.  Additionally, LA was found to increase cell proliferation in both wild-type and 
EGFR
-/-
 cells, suggesting that this effect is EGFR-independent.   
To verify that the DHA-mediated reduction in cell number is a direct result of 
decreased cell proliferation and not caused by an increase in cell death, we additionally 
assessed cell viability in control, LA, and DHA treated YAMC cells.  Cell viability was  
assessed using the trypan blue assay.  DHA had no effect on cell viability compared to 
control and LA treated cells (Fig. 11).  This corroborates previously reported data that 
DHA does not increase apoptosis in the YAMC cell line (Kolar et al., 2007).  These 
results confirm that the reduction in cell number mediated by DHA is a result of 
suppressed cell proliferation and not an induction of cell death.    
 
  
 54 
 
                            
 
                                 
Figure 8.  DHA reduces the EGF-induced activation of ERK1/2, STAT3, and S6K.  Whole cell lysates were 
analyzed by western blotting for total and phosphorylated downstream mediators of EGFR signaling, including 
ERK1/2, STAT3, S6K, and Akt.  Each blot is representative of 3-4 independent experiments with 3 replicates per 
treatment.  Band quantification was performed, and data are presented as mean ± SEM normalized to control (n=3-4 
experiments per treatment).  Data are expressed as the ratio of the phosphorylated receptor to total receptor and 
normalized to control.  Statistical significance between treatments (*P<0.05) was determined using ANOVA and 
Tukey’s test of contrast.  C, control; LA, linoleic acid; DHA, docosahexaenoic acid. 
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B 
Figure 9.  DHA alters the kinetics of EGFR activation and signaling.  YAMC cells were treated with control or 
BSA-complexed DHA for 72 h.  For the final 16-18 h, cells were incubated in low serum media (0.5% FBS) with 
the same concentration of fatty acids.  Cells were stimulated for 0-30 min with 25 ng/mL EGF and subsequently 
harvested.  Equal concentrations of protein from the whole cell lysates were analyzed by western blotting for (A) 
phosphorylated EGFR, (B) phosphorylated ERK1/2, and (C) phosphorylated STAT3. Each immunoblot is 
representative of 3 independent experiments.  Quantification of band volume was performed and data are presented 
as mean ± SEM and normalized to time 0 (n=3).  Statistical significance between treatments (*P<0.05; **P<0.01) 
was determined using Student’s t-test.   
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Figure 10.  DHA reduces cell proliferation in an EGFR-dependent manner.  Wild-type and EGFR-/- YAMC 
cells were treated with 50 μM BSA-complexed fatty acid for 24 h.  Following the initial treatment, cells were 
seeded at an equal density into a 96-well plate, and cultured under the same treatment conditions for an additional 
48 h.  Cell proliferation was measured using CyQUANT cell proliferation assay.  Results are representative of 3 
independent experiments.  Data are expressed as mean ± SEM (n=6 samples per treatment).  Statistical significance 
between treatments as indicated by different letters (P<0.05) was determined using ANOVA and Tukey’s test of 
contrast.  No comparisons were made between proliferation of wild-type and EGFR-/- cells. 
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2.3.5 Effect of fish oil on EGFR phosphorylation 
The in vitro data clearly demonstrating the capacity of DHA to alter EGFR 
signaling prompted us to test the effect of feeding a fish oil diet to mice on EGFR 
signaling and tumor development in the colon.  We utilized an established model for 
colon cancer induction in mice.  This model consists of a single injection of the 
carcinogen azoxymethane (AOM) and multiple rounds of inflammation that are induced 
with dextran sodium sulfate (DSS).  AOM forms DNA adducts, and the repeated rounds 
of DSS and recovery mimic the active and inactive inflammation experienced by 
humans.  This combination of AOM and DSS results in both flat and polypoid lesions 
Figure 11.  DHA does not induce cell death.  YAMC cells were treated with control or BSA-complexed fatty 
acids (LA or DHA) for 72 h.  Cells were trypsinized and stained with Trypan blue.  The number of dead and total 
cells was counted using a hemocytometer.  Data are presented as the mean of the number of dead cells/total 
number of cells ± SEM.  No statistical significance between treatments (P<0.05) was observed as calculated using 
ANOVA and Tukey’s test of contrast.   
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similar to those seen in humans with the disease, as well as the nuclear translocation of 
β-catenin that is often observed in human colon cancer (Clapper et al., 2007).  We 
evaluated the status of total and phosphorylated EGFR in colonic mucosa from AOM-
injected, DSS-treated C57BL/6 mice fed diets enriched in fish oil (containing DHA) or 
corn oil (control, contains primarily LA and no n-3 polyunsaturated fatty acids).   Protein 
lysates from the uninvolved colonic mucosa were harvested and western blotted for total 
and phosphorylated EGFR (Tyr1068) or immunoprecipitated for EGFR followed by 
western blotting for phosphorylated tyrosine residues.  Consistent with the cell culture 
data, phosphorylation of EGFR increased approximately two-fold in mice fed a fish oil 
diet compared to mice fed a corn oil diet, while no difference in the total expression of 
EGFR was observed (Fig. 12).   
2.3.6 Effect of fish oil on EGFR signaling 
We further probed tissue lysates for phosphorylation of ERK1/2, STAT3, and 
Akt.  Similar to Fig. 8 data, phosphorylation of ERK1/2 and STAT3 decreased by 
approximately 40% and 50%, respectively, in fish oil fed mice compared to corn oil fed 
mice with no difference in phosphorylation of Akt between diets (Fig. 13).  Overall, 
these data indicate a role for dietary fish oil in regulation of EGFR signal transduction. 
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Figure 13.  Fish oil feeding inhibits activation of downstream mediators of EGFR signaling.  Carcinogen 
(AOM) and DSS-treated mice were fed a diet enriched in fish oil or corn oil (contains no DHA) for a total of 15 
weeks.  Whole cell lysates were isolated from scraped colonic mucosa and probed by western blotting for total and 
phosphorylated downstream mediators of EGFR signaling, including ERK1/2, STAT3, and Akt.  Each lane 
represents a protein sample from a different mouse (total n=12 mice per diet).  Quantification of band volume was 
performed and data are presented as mean ± SEM of the ratio of phosphorylated protein to total protein and 
normalized to CO.  Statistical significance between diets was determined using Student’s t-test.  CO, corn oil; FO, 
fish oil. 
Figure 12.  Fish oil feeding increases EGFR phosphorylation.  Carcinogen (AOM) and DSS-treated mice were 
fed a diet enriched in fish oil or corn oil (contains no DHA) for a total of 15 weeks.  Whole cell lysates were 
isolated from scraped colonic mucosa.  Equal concentrations of protein were assessed by western blotting for total 
and phosphorylated EGFR (Tyr1068).  Additionally, EGFR was immunoprecipitated from mucosal lysates and 
western blotted for phosphorylated tyrosine residues and EGFR.  Each lane represents a different mouse (total 
n=12 mice per diet).  Statistical significance between diets was determined using Student’s t-test.  CO, corn oil; 
FO, fish oil. 
CO FO 
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2.3.7 Effect of fish oil on tumor formation  
Ultimately, for a chemoprotective agent to be considered effective, it must be 
shown to prevent or reduce the formation of tumors in the tissue of interest.  Therefore, 
we assessed the effect of fish oil feeding on tumor formation in the colon.  At the time of 
sacrifice, colonic tumors from the animals were removed, followed by staining and 
typing.  We found tumor formation in animals on both diets.  Interestingly, fish oil fed 
animals developed fewer tumors compared to animals fed a corn oil diet (Fig. 14).  
Additionally, more fish oil fed animals (13 of 25) did not develop any tumors compared 
to corn oil fed animals (4 of 22).  This indicates that fish oil contains chemoprotective 
properties. 
 
 
 
Figure 14.  Fish oil reduces colon tumor multiplicity.  Carcinogen (AOM) and DSS-treated mice were fed a diet 
enriched in fish oil or corn oil (contains no DHA) for a total of 15 weeks.  Colon lesions were removed and fixed in 
4% paraformaldehyde, embedded in paraffin, sectioned and stained with hematoxylin-eosin, and then evaluated.  The 
mean colon tumor entity number, including adenomas and adenocarcinomas, per mouse in each diet treatment is 
presented, n=22-25 mice per diet.  Statistical significance between diets was determined using Student’s t-test.  CO, 
corn oil; FO, fish oil. 
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2.4 Discussion 
 EGFR is a transmembrane receptor tyrosine kinase involved in transmitting 
external cues to the intestinal epithelium, thereby modulating cell proliferation, 
migration, and survival.   Recent evidence suggests that the membrane lipid 
microenvironment can significantly modulate EGFR localization and function (Coskun 
et al., 2011).   Here, we report that membrane incorporation of DHA alters the lateral 
organization of EGFR (Figs. 2 and 3).  The lateral organization of the receptor has been 
shown to directly regulate ligand binding and receptor phosphorylation (Chen and Resh, 
2002; Ringerike et al., 2002; Roepstorff et al., 2002).  Consistent with these 
observations, we demonstrated that DHA treatment resulted in increased ligand-
stimulated EGFR phosphorylation (Fig. 4).  Therefore, the DHA-induced shift of EGFR 
localization within the plasma membrane alters the ability of the receptor to 
transphosphorylate.  These findings favor a model in which receptor modulation by fatty 
acids is mediated by effects on the plasma membrane.   
The differential effects of DHA and EPA, the two n-3 PUFAs enriched in fish 
oil, are often overlooked and underappreciated.  Therefore, we assessed whether EPA 
had the same effect as DHA on EGFR phosphorylation.  Interestingly, in contrast to 
DHA, neither EPA nor AA, another long-chain PUFA, exerted an effect on EGFR 
phosphorylation (Fig. 6).  This is consistent with a previous study showing that DHA, 
but not EPA, suppressed EGF-stimulated activation of AP-1 (Liu et al., 2001).  
Collectively, these results highlight the uniqueness of DHA, which has been shown to 
significantly alter numerous membrane properties (Stillwell and Wassall, 2003; Wassall 
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and Stillwell, 2008).  The effects of DHA on EGFR signaling are reversible when 
supplementation with DHA is discontinued and the fatty acid is washed out of the 
plasma membrane (Fig. 7).  This is consistent with our hypothesis that DHA enrichment 
in the plasma membrane directly modulates EGFR signaling.  DHA is a structurally 
unique fatty acid.  It is slightly polar due to its six double bonds, and it rapidly reorients 
through multiple conformational states (Wassall and Stillwell, 2008).  This flexible 
structure renders DHA incompatible with ordered saturated acyl chains and cholesterol, 
two major constituents of lipid rafts.  Multiple biophysical studies utilizing model 
membranes and molecular dynamic simulations have shown that DHA acyl chains do 
not pack efficiently with cholesterol and saturated acyl chains (Rosetti and Pastorino, 
2011; Soni et al., 2008).   Although, the exact effect that DHA has on lipid rafts remains 
to be fully elucidated, an abundance of data clearly demonstrate that DHA can impede 
lipid raft mediated processes and alter lipid raft composition (Fan et al., 2004; Schley et 
al., 2007). 
Lipid rafts are involved in sundry cellular processes, which require diversity in 
the composition of membrane domains (Pike, 2004).  Both lipid-protein and lipid-lipid 
associations have the potential to organize features of the membrane, resulting in a 
heterogeneous population of lipid rafts.  This heterogeneity is likely to result in 
differential effects of n-3 PUFA on lipid rafts.  Therefore, the role of n-3 PUFA in the 
regulation of processes emanating from different types of lipid rafts is poorly understood 
and requires further investigation.  Functional raft-based membrane heterogeneity is 
dependent upon both lipid and protein physical parameters (Lingwood et al., 2009), and 
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we have observed that n-3 PUFA can alter lipid raft composition of both lipids and 
proteins.  Based on the interactions within certain raft domains, n-3 PUFA could be 
expected to perturb the function of some lipid raft domains while leaving others 
unaffected.  Future research should be directed toward discerning the effects of n-3 
PUFA on different types of lipid rafts.   
According to the canonical process of signal transduction, the observed increase 
in EGFR phosphorylation upon treatment with DHA is expected to be correlated with 
enhanced downstream signaling.  Two previous studies have observed that DHA 
increases EGFR phosphorylation, but they reported conflicting results regarding 
downstream signaling (Rogers et al., 2010; Schley et al., 2007).  However, one of these 
studies did not directly stimulate cells with a ligand specific for EGFR, which renders 
the results difficult to interpret.  Therefore, in our study, we evaluated the effect of DHA 
on EGF-stimulated activation of multiple signaling cascades in the colonic epithelium.  
Although DHA was found to increase EGFR phosphorylation, we noted that this fatty 
acid uniquely inhibited EGF-stimulated activation of downstream signaling from EGFR 
through ERK1/2, STAT3, and mTOR/S6K (Fig. 8).  A substantial body of work has 
documented the central role of lateral membrane organization in mediating EGFR signal 
transduction (Lingwood and Simons, 2010).  Integral to EGFR signaling is its 
localization to lipid raft domains due to the ability of these specialized membrane 
domains to assemble the molecular machineries necessary for intracellular propagation 
of EGFR signaling.  Stimulation with EGF induces coalescence of lipid raft domains, 
promoting the formation of these signaling platforms, which suggests a central role for 
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these domains in EGFR signal propagation (Hofman et al., 2008).  Our data suggest that 
by altering the plasma membrane localization of EGFR, DHA causes a paradoxical 
increase in EGFR phosphorylation and suppression of EGFR signal transduction.  
Studies have indicated that within the lipid raft, EGFR is slightly confined which 
partially restricts receptor activation (Ringerike et al., 2002).  We hypothesize that the 
reduced partitioning of EGFR to lipid rafts upon DHA treatment is what facilitates the 
enhanced receptor phosphorylation.  However, localization of EGFR within lipid rafts 
expedites interactions between EGFR and its downstream signaling partners.  We 
therefore extrapolate that the altered localization of EGFR in DHA treated cells 
diminishes signal transduction by reducing the interactions of EGFR and its signaling 
partners.  This attenuation of EGFR signaling then results in a diminution of cell 
proliferation (Fig. 10).  Due to the reliance of cancer cells on overwhelming cell 
proliferation, this action of DHA likely contributes to its chemoprotective properties.  
Phosphorylation of EGFR has previously been considered a marker for activation 
of downstream signaling.  In contrast, our data describe a mechanism whereby DHA 
unfetters EGFR from the constraints of lipid rafts to increase phosphorylation, but this 
altered plasma membrane localization reduced colocalization of EGFR and its 
downstream signaling partners to suppress signal transduction.  Further understanding of 
the relationship between plasma membrane composition and receptor organization is 
required to fully elucidate the regulation of cell signaling.   
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3. MECHANISMS OF ACTION OF DHA ON EGFR FUNCTION* 
 
3.1 Introduction 
The initial observations of the paradoxical effect of DHA on EGFR laid the 
groundwork for further investigation.  Canonically, stimulation of EGFR with its ligand 
results in conformational changes that facilitate receptor dimerization.  Receptor 
dimerization elicits activation of the tyrosine kinase domain, which then phosphorylates 
tyrosine residues on the C-terminal tail of dimerization partner.  These phosphorylated 
tyrosine residues function as docking sites for downstream signaling mediators, and 
these mediators then activate multiple signaling cascades.  Our data demonstrate that 
DHA increases the phosphorylation of EGFR while decreasing the activation of 
downstream signaling pathways.  However, the molecular mechanisms underlying the 
enigmatic effects of DHA on EGFR function remain undetermined.   
First, we wanted to clarify the mechanism by which DHA induces an increase in 
EGFR phosphorylation.  Previous studies have suggested a number of possible 
contributing mechanisms.  One potential mechanism is that by perturbing signal 
transduction DHA reduces feedback inhibition of EGFR phosphorylation.  The 
activation status of EGFR is partially regulated by a feedback loop from downstream 
signaling events (Avraham and Yarden, 2011).  Specifically, ERK1/2 activation 
modulates EGFR phosphorylation, and inhibition of ERK1/2 activation has been shown 
to result in increased EGFR phosphorylation (Gan et al., 2010).  We have shown that  
__________________________ 
*Part of this chapter is reprinted with permission from “Alteration of EGFR spatiotemporal dynamics suppresses signal 
transduction” by Harmony F. Turk, Rola Barhoumi, and Robert S. Chapkin, 2012. PLoS ONE, 7, e39682, Copyright 2012 by 
Harmony F. Turk.  
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treatment with DHA reduces activation of ERK1/2, which could reduce feedback 
inhibition and lead to receptor hyperphosphorylation.  Additionally, EGFR activation 
can also be significantly impacted by the environment in which the receptor resides.  As 
detailed previously, the plasma membrane localization of EGFR considerably affects 
receptor activity.  Redistribution of EGFR from lipid rafts to the bulk domain results in 
an increase in ligand-dependent and ligand-independent receptor phosphorylation (Chen 
and Resh, 2002; Lambert et al., 2006; Pike and Casey, 2002).  EGFR localization to lipid 
raft domains restricts the receptor to some extent (Matveev and Smart, 2002), but the 
underlying cause of this remains unknown.   One potential mechanism was presented by 
Coskun et al., who demonstrated that the lipid environment can directly influence EGFR 
dimerization, resulting in altered EGFR phosphorylation (Coskun et al., 2011).  
Therefore, by shifting EGFR from lipid rafts and altering the lipid environment of the 
receptor, DHA could potentiate EGFR dimerization and in so doing enhance receptor 
phosphorylation.   
In addition to teasing out the mechanism of DHA-mediated increased EGFR 
phosphorylation, we also aimed to elucidate the process by which DHA reduces EGFR 
signal transduction.  This required the identification of the specific step of signal 
transduction that is interrupted.  We determined that EGF-induced activation of ERK1/2, 
STAT3, and mTOR is inhibited by DHA.  Of these pathways, activation of ERK1/2 
downstream of EGFR is the most direct and straightforward.  The immediate proximal 
event in signal transduction following EGFR phosphorylation is recruitment of a 
cytosolic complex of Grb2 and son of sevenless (SOS) to the plasma membrane (Holt et 
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al., 1996).  Grb2 is a 23-kDa adapter protein consisting of a single SH2 domain flanked 
by two SH3 domains (Lowenstein et al., 1992).  Following EGFR phosphorylation, Grb2 
traffics to EGFR and directly binds to the receptor at Tyr1068 and to a lesser extent 
Tyr1086 via its SH2 domain (Batzer et al., 1994).  Grb2 can also indirectly link to EGFR 
through interaction with Shc, another SH2 domain containing adapter protein that can 
bind to phosphorylated EGFR at Tyr1173 and Tyr992 (Batzer et al., 1994).  Binding of 
the Grb2-Sos complex to EGFR brings SOS into close proximity with its substrate, Ras.  
SOS is a guanylnucleotide exchange factor that activates the exchange of GDP for GTP 
on Ras, resulting in Ras activation (Chardin et al., 1993).  GTP-bound Ras then recruits 
Raf to the membrane where it is activated.  Raf activation results from phosphorylation 
that is dependent on both Ras and Src-family tyrosine kinase (Marais et al., 1995; Marais 
et al., 1997; Mason et al., 1999).  Raf is a serine/threonine kinase that phosphorylates 
MEK1 and MEK2.  MEK1/2 are dual-specificity protein kinases that facilitate the 
activation of ERK1/2 by phosphorylating them on tyrosine then threonine residues 
(Roskoski, 2012).  Activation of each step in this signaling cascade is simple to assess, 
which will allow us to pinpoint the site of disruption in signal transduction.  
The extent and duration of receptor signaling is regulated by receptor endocytosis 
and degradation.  Many signaling mediators also function to facilitate receptor 
endocytosis.  For example, in addition to leading to the activation of the Ras, Grb2 
recruitment to EGFR is required for receptor endocytosis and degradation as well as 
(Jiang et al., 2003).  EGFR endocytosis can also be affected by the plasma membrane 
localization of the receptor.  EGFR endocytosis can occur through lipid raft-dependent 
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or –independent processes (Puri et al., 2005; Sigismund et al., 2008).  The principal two 
endpoints of receptor endocytosis are receptor recycling back to the plasma membrane 
or targeting of the receptor for degradation.  Receptor ubiquitination, which is mediated 
by Grb2-dependent recruitment of c-Cbl, ensures sorting of EGFR to lysosomes 
(Umebayashi et al., 2008).  Receptor internalization and ubiquitination are major 
mechanisms of signal attenuation, although it is well-established that EGFR is able to 
continue signaling from early endosomes (Sadowski et al., 2009; Sorkin et al., 2000; 
Wiley and Burke, 2001).  Therefore, it is necessary to assess the effects of DHA on 
EGFR endocytosis and degradation to fully understand the role of DHA in modulating 
EGFR function. 
The aim of this research was to thoroughly probe the mechanism by which DHA 
regulates EGFR signaling.  We tested two hypotheses to determine how DHA increases 
EGFR phosphorylation.  Then, we sequentially evaluated each step in the EGFR-Ras-
ERK1/2 signaling cascade in order to pinpoint the exact break point in signal 
transduction.  By locating the site of signal perturbation, we have been able to further 
understand the mechanism by which DHA suppresses signal transduction.   
 
3.2 Materials and methods 
3.2.1 Cell culture 
Young adult mouse colonic (YAMC) cells, conditionally immortalized 
colonocytes, were originally obtained from R.H. Whitehead, Ludwig Cancer Institute 
(Melbourne, Australia).   YAMC cells (passages 12–17) were cultured under permissive 
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conditions, 33°C and 5% CO2 in RPMI 1640 media (Mediatech, Manassas, VA) 
supplemented with 5% fetal bovine serum (FBS; Hyclone, Logan, UT), 2 mM GlutaMax 
(Gibco, Grand Island, NY), 5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenious 
acid (Collaborative Biomedical Products, Bedford, MA), and 5 IU/mL of murine 
interferon-γ (Roche, Mannheim, Germany).  Select cultures were treated for 72 h with 
50 µM fatty acid [DHA, linoleic acid (LA, 18:2n-6), arachidonic acid (AA, 20:4n-6), or 
eicosapentaenoic acid (EPA, 20:5n-3); NuChek, Elysian, MN] complexed with bovine 
serum albumin (BSA).  In select cultures, for the final 16-18 h, complete media was 
replaced with low-serum (0.5% FBS) media.   Cells were then stimulated with 0-25 
ng/mL recombinant mouse EGF (Sigma, St. Louis, MO) and harvested.  In select 
cultures, cells were incubated with the ERK1/2 inhibitor U0126 (Invitrogen, Grand 
Island, NY) at 10 µM for 2 h prior to stimulation with EGF.   
3.2.2 Receptor dimerization 
To assess EGFR dimerization, cells were treated as above.  Following serum-
starvation, cells were washed with ice-cold PBS prior to incubation with 0 or 25 ng/mL 
EGF on ice for 1 h.  Cells were then washed with ice-cold PBS followed by incubation 
on ice
 
for 20 min with 3 mM bis(sulfosuccinimidyl)
 
suberate (BS
3
, Pierce), a non-
permeable crosslinking reagent.  In all
 
experiments, a freshly prepared solution of BS
3
 
was used.  The
 
crosslinking reaction was quenched by adding 250 mM glycine in PBS 
and further incubation on
 
ice for 5 min.  Cells were washed with PBS and homogenized 
as above.  Protein concentration was measured and lysates were assessed by western 
blotting for EGFR as described above.  
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3.2.3 Western blotting 
For western blotting, cells were homogenized in ice-cold homogenization buffer 
(50 mM Tris-HCl, pH 7.2, 250 mM sucrose, 2 mM EDTA, 1 mM EGTA, 50 mM 
sodium fluoride, 100 mM sodium orthovanadate, 1% Triton X-100, 100 µM activated 
sodium orthovanadate, 10 mM β-mercaptoethanol, and protease inhibitor cocktail) as 
previously described (Davidson et al., 1999).  Following homogenization, lysates were 
sheared using a 29G needle, incubated on ice for 30 min, and centrifuged at 16,000 x g 
for 20 min.  The supernatant was collected and protein concentration was assessed using 
Coomassie Plus Protein assay (Pierce).  Lysates were treated with 1X pyronin sample 
buffer and subjected to SDS polyacrylamide gel electrophoresis (PAGE) in precast 4–
20% Tris-glycine mini gels (Invitrogen).  After electrophoresis, proteins were 
electroblotted onto a polyvinylidene fluoride membrane with the use of a Hoefer Mighty 
Small Transphor unit at 400 mA for 90 min. Following transfer, the membrane was 
incubated in 5% BSA (Roche) and 0.1% Tween 20 in TBS (TBST) at room temperature 
for 1 h with shaking, followed by incubation with shaking overnight at 4
o
C with primary 
antibody diluted in 5% BSA in TBST.  Membranes were washed with TBST and 
incubated with peroxidase conjugated secondary antibody as per manufacturer’s 
instructions.  Bands were developed using Pierce SuperSignal West Femto
TM
 maximum 
sensitivity substrate.  Blots were scanned using a Fluor-S Max MultiImager system (Bio-
Rad, Hercules, CA).  Quantification of bands was performed using Quantity One 
software (Bio-Rad).  Monoclonal rabbit anti-EGFR was purchased from Cell Signaling 
(Danvers, MA).  Monoclonal mouse anti-ubiquitin and polyclonal rabbit anti-K, H, and 
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N-Ras were purchased from Santa Cruz (Santa Cruz, CA).  Peroxidase conjugated goat 
anti-rabbit IgG was purchased from Kirkegaard and Perry Laboratories (Gaithersburg, 
MD), and peroxidase conjugated goat anti-mouse IgG was purchased from Jackson 
ImmunoResearch (West Grove, PA).   
3.2.4 Total internal reflection fluorescence (TIRF) microscopy 
A plasmid containing the SH2 domain of Grb2 conjugated to YFP (Grb2-YFP) 
was generously provided by Alexander Sorkin, University of Colorado (Sorkin et al., 
2000).  For TIRF experiments, cells were treated with fatty acids for 24 h prior to 
transfection.  Cells were transfected using Amaxa nucleofection kit L (Amaxa, Basel, 
Switzerland) with 2.0 µg Grb2-YFP.   Following transfection, cells were seeded at a 
density of 25,000 cells/well into MatTek (Ashland, MA) glass bottom 35 mm dishes in 
the presence of fatty acid.  Approximately 32 h after transfection, cells were incubated in 
serum starvation media (0.5% FBS) containing fatty acid for 16-18 h prior to imaging.  
Images were acquired on a Zeiss TIRF3 Microscope system consisting of a Zeiss 
AxioObserver Z1 microscope (Carl Zeiss) equipped with a high resolution AxioCam 
MRm camera, argon laser, and AxioVision 4 software.  An excitation wavelength of 514 
nm was used, and emission was monitored at 537 nm.  All images were collected using a 
100X objective (1.4 NA oil immersion) at 37°C and 5% CO2.  To observe the 
translocation of Grb2-YFP to the plasma membrane, cells were stimulated with 100 
ng/mL EGF, and images were collected every 5 sec.  Images were collected using 
identical image acquisition parameters for all images within the experiment.  Whole cell 
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fluorescence intensity was performed on background-subtracted 16-bit images using 
Nikon Elements AR 3.2. 
3.2.5 Ras activation assay 
To assess the activation status of Ras, YAMC cells were treated for 72 h with 
fatty acid and serum starved for the final 16-18 h.  Cells were stimulated with 25 ng/mL 
EGF for 2 min, then harvested using Pierce cell lysis buffer.  Activated (GTP-bound) 
Ras was subsequently isolated and assessed by western blotting using the Pierce Active 
Ras Pull-Down and Detection
TM
 kit according to the manufacturer’s instructions.  
Additionally, Ras isoforms were detected by western blotting the isolated GTP-bound 
Ras using isoform specific antibodies as described above. 
3.2.6 Cell proliferation assay 
YAMC cells were treated with fatty acids for 24 h, followed by transfection 
using nucleofection (Amaxa kit L) with a constitutively active form of H-Ras (H-
RasG12V-GTP), provided by Dr. Ian Prior (Rotblat et al., 2004), prior to being seeded 
into a 96 well plate at a density of 1.0 x 10
5
 cells per well and cultured for 48 h.  Cells 
were cultured in complete media supplemented with fatty acids for an additional 48 h. 
Cells were then washed with PBS and cell proliferation was measured using CyQuant 
cell proliferation assay (Molecular Probes, Grand Island, NY) according to the 
manufacturer’s instructions. 
3.2.7 Biotinylation 
To assess cell surface EGFR and receptor internalization, cells were treated with 
fatty acids, serum starved and surface biotinylated using thiol-cleavable EZ-Link Sulfo-
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NHS-SS-Biotin (Pierce), 0.5 mg/mL, dissolved in PBS for 30 min on ice.  Labeled cells 
were then rinsed two times with ice-cold PBS, and excess biotin was quenched with 60 
mM iodoacetamide in PBS buffer for 5 min at 4°C.  Select cultures were harvested at 
this step in order to quantify cell surface expression of EGFR.  Cells were then washed 
three times with ice-cold PBS, followed by incubation at 33°C in prewarmed serum-free 
RPMI media for 5 min followed by stimulation with 25 ng/mL EGF for 0-30 min.   
Biotin groups remaining on the cell surface were then cleaved off by three 20 min 
washes with buffer containing reducing agent [100 mM MESNA (sodium-2-
mercaptoethane sulfonate), 50 mM Tris (pH 8.6), 100 mM NaCl, 1 mM EDTA, and 
0.2% BSA] at 4°C. Cells were then washed three times in ice-cold PBS and lysed in 
RIPA buffer (20 mM Tris, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 1% sodium 
deoxycholate, 1% SDS, and 1% Triton X-100) containing protease and phosphatase 
inhibitors. The lysates were clarified by centrifugation at 16,000 x g for 20 min.  Protein 
concentration was assessed using BCA protein assay (Pierce).  Biotinylated EGFR was 
captured on streptavidin ELISA plates (Nunc Immobilizer Streptavidin C8) from the cell 
lysates diluted to 5 µg/mL total protein in PBS containing 0.5% Tween 20, pH 7.3 
(PBST), during a 2 h incubation at room temperature on a shaker. Plates were then 
washed three times with PBST, incubated with anti-EGFR antibody (Santa Cruz) (2 
µg/mL) for 2 h at room temperature, washed, and incubated with horseradish 
peroxidase-conjugated secondary antibody for 1 h at room temperature.  The plates were 
subsequently washed three times in PBST before adding color substrate (R&D Systems, 
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Minneapolis, MN) for 5-10 min. Color development was stopped by addition of an equal 
amount of 4 M H2SO4 and analyzed at 450 nm. 
3.2.8 Statistics 
The effect of 2 independent variables (treatment effects) was assessed using 
Student’s t-test.  The effect of more than 2 independent variables (treatment effects) was 
assessed using the one-way analysis of variance test (ANOVA), and differences among 
means were evaluated using Tukey’s post-hoc test of contrast.  P values <0.05 were 
considered to be statistically significant. 
 
3.3 Results 
3.3.1 Mechanism of DHA-induced increase in EGFR phosphorylation 
EGFR phosphorylation is controlled by a variety of factors.  Therefore, we next 
determined the mechanism by which DHA increases EGFR phosphorylation.  Since we 
demonstrated that DHA both alters the membrane environment of EGFR and suppresses 
ERK1/2 phosphorylation, we assessed whether either of these two mechanisms 
contributed to the observed DHA-induced increase in EGFR phosphorylation.  First, we 
utilized a specific inhibitor of ERK1/2, U0126, to recapitulate the suppressive effect of 
DHA on ERK1/2 activation.  We then assessed the effect of this inhibitor on EGFR 
activation status.  We found that treatment of cells with 10 µM U0126 for 2 h prior to 
stimulation completely inhibited EGF-induced activation of ERK1/2 (Fig. 15 A).  
However, this inhibition had no effect on overall EGFR phosphorylation, suggesting that 
a downstream feedback-mediated increase in EGFR phosphorylation induced by 
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ERK1/2 suppression is not a mechanism by which DHA enhances EGFR 
phosphorylation. 
We subsequently measured the effect of DHA on EGFR dimerization.  Following 
stimulation with EGF, EGFR dimers were linked using bis(sulfosuccinimidyl) suberate 
(BS
3
),
 
a non-permeable crosslinking reagent.  DHA treated cells exhibited a greater than 
three-fold increase in dimerization compared to control and LA treated cells (Fig. 15 B).  
This is consistent with previous studies indicating that the lipid environment affects 
EGFR dimerization (Coskun et al., 2011), suggesting that the effect of DHA on EGFR is 
due to the alteration in the lipid environment of the receptor, resulting in increased 
EGFR dimerization and, therefore, phosphorylation.   
3.3.2 DHA inhibits EGF-stimulated Ras GTP-binding 
Due to the fact that DHA treatment increased EGFR phosphorylation while 
concurrently suppressing activation of downstream mediators, we attempted to pinpoint 
the site of perturbation in the signaling cascade.  Since the EGFR-Ras-ERK1/2 pathway 
is well documented, we examined the components of this pathway downstream of the 
receptor.  Following EGF stimulation, growth receptor-bound protein 2 (Grb2) is 
recruited to the plasma membrane and binds to phosphorylated tyrosine residues of 
EGFR (Y1068 and Y1086).  To assess recruitment of this immediate proximal signal 
downstream of EGFR phosphorylation, cells were transfected with fluorescently-tagged 
SH2 domain of Grb2 (Grb2-YFP), capable of binding to the phosphorylated tyrosine 
residues of EGFR.  Cells were subsequently imaged using TIRF microscopy to assess 
Grb2-YFP translocation to the plasma membrane in response to EGFR activation.  
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Figure 15.  DHA facilitates EGFR dimerization to enhance receptor phosphorylation.  (A) Control treated 
YAMC cells were incubated with low serum media overnight.   Select cultures were then treated with 10 µM 
U0126 for 2 h followed by stimulation with 25 ng/mL EGF.  Cell lysates were assessed by western blotting for 
phosphorylated ERK1/2 and EGFR.  (B) Following stimulation with EGF, cells were subjected to chemical 
crosslinking prior to harvesting cell lysates.  Cell lysate was assessed by western blotting for EGFR.  EGFR 
dimers were identified as bands with twice the molecular weight of EGFR monomers.  Data are presented as 
mean ± SEM of dimerized EGFR, normalized to control. Statistical significance between treatments (*P<0.05) 
was determined using ANOVA and Tukey’s test of contrast. C, control; DHA, docosahexaenoic acid; LA, 
linoleic acid.   
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Following stimulation with EGF, Grb2-YFP was rapidly recruited to the plasma 
membrane (Fig. 16).  We observed a significant increase in EGF-stimulated Grb2-YFP 
plasma membrane translocation in DHA treated cells compared to control and LA 
treated cells.   
Grb2 recruits Sos, a guanine nucleotide exchange factor (GEF), to activate Ras.  
Therefore, we assessed Ras activation status by pulling-down GTP-bound Ras followed 
by western blotting for Ras.  DHA-treated cells had significantly lower levels of GTP-
bound Ras compared to control and LA-treated cells (Fig. 17).  This observation 
indicates that the DHA-induced perturbation in the EGFR-Ras-ERK1/2 pathway occurs 
at the site of Ras activation. Ras is comprised of three distinct isoforms, including H-
Ras, K-Ras, and N-Ras.  Isoform-specific signaling is regulated by differential 
compartmentalization within cell surface microdomains and intracellular compartments 
(Prior et al., 2003).  H-Ras is enriched in lipid rafts, both caveolar and noncaveolar, 
whereas K-Ras is exclusively located in the bulk membrane (Prior et al., 2001; Prior et 
al., 2003).  Additionally, N-Ras is mainly segregated into noncaveolar lipid rafts 
(Matallanas et al., 2003).  Furthermore, Ras proteins have been shown to signal from the 
Golgi complex, the endoplasmic reticulum, and endomembranes, e.g., endosomes (9, 26, 
32). The effect of this distinctive segregation on the signals generated by Ras remains to 
be determined.  Therefore, we assessed the effect of DHA on activation of each Ras 
isoform to provide further clarity into the mechanism by which DHA suppressed EGF-
induced Ras activation.  We found that DHA suppressed activation of all three isoforms 
of Ras (Fig. 17), indicating a common mechanism by which DHA suppresses EGF- 
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Figure 16.  DHA increases EGF-stimulated recruitment of Grb2 to the plasma membrane.  YAMC cells were 
treated with 50 µM BSA-complexed fatty acids for 72 h.  Twenty-four h after initiating fatty acid treatment, cells 
were transfected with Grb2-YFP.  For the final 16-18 h, cells were incubated with low serum (0.5% FBS) with the 
same concentration of fatty acids and imaged using TIRF microscopy.  Cells were stimulated with 100 ng/mL EGF 
and imaged every 5 sec.  Images are representative of 4 independent experiments (n=22-25 cells/treatment).  
Changes in total surface intensity were quantified using Nikon Elements AR 3.2.  Fluorescence images and the 
respective surface intensity plots are shown.  Surface intensity plots were generated in Nikon Elements AR 3.2; the 
scale is from blue (lowest intensity) to red/pink (highest intensity).  Data are presented as mean ± SEM normalized 
to control. Bars, 10 µM. Statistical significance between treatments (P<0.05) as indicated by different letters was 
determined using ANOVA and Tukey’s test of contrast.  C, control; LA, linoleic acid; DHA, docosahexaenoic acid. 
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Figure 17.  DHA inhibits EGF-stimulated activation of all Ras isoforms.  YAMC cells were treated with 50 μM 
BSA-complexed fatty acids for 72 h.  For the final 16-18 h, cells were incubated with low serum media (0.5% FBS) 
with the same concentration of fatty acids.  Cells were stimulated with 25 ng/mL EGF for 2 min and harvested.  GTP-
bound Ras was isolated using a GST pull-down assay.  Isolated GTP-bound Ras was then analyzed by western 
blotting for pan Ras.  Isolated GTP-bound Ras was additionally analyzed by western blotting for H, K, and N-Ras.  
Blots are representative of 3 independent experiments.  Quantification of band volume was performed.  Data are 
expressed as mean ± SEM (n=3), normalized to control.  Statistical significance between treatments (P<0.05) as 
indicated by different letters was determined using ANOVA and Tukey’s test of contrast.  C, control; LA, linoleic 
acid; DHA, docosahexaenoic acid. 
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Figure 18.  Expression of constitutively active H-Ras partially rescues cells from DHA-mediated reduction of 
cell proliferation.  Wild-type YAMC cells were treated with 50 μM BSA-complexed fatty acid for 24 h.  Cells were 
then transfected using nucleofection with GFP-H-RasG12V and seeded at an equal density into a 96-well plate, and 
cultured under the same treatment conditions for an additional 48 h.  Cell proliferation was measured using 
CyQUANT cell proliferation assay. Data are expressed as mean ± SEM (n=9 samples per treatment).  Statistical 
significance between treatments as indicated by different letters (P<0.05) was determined using ANOVA and 
Tukey’s test of contrast.   
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induced activation of Ras.  Furthermore, activation of H-Ras was almost entirely 
inhibited by DHA, suggesting a distinct mechanism of regulation for this specific 
isoform.    
We additionally assessed whether expression of a constitutively active form of 
H-Ras (GFP-H-RasG12V) could rescue the DHA-induced suppression of cell 
proliferation.  We found that DHA-treated cells expressing constitutively activated H-
Ras recovered partially from the DHA-induced suppression of cell proliferation but still 
exhibited approximately a 15% decrease in cell proliferation compared to control cells 
expressing GFP-H-RasG12V (Fig. 18). 
3.3.3 DHA induces increased EGFR internalization and degradation 
Since DHA suppressed activation of each of the isoforms of Ras, this suggested a 
potential lipid raft-independent mechanism of action.  Endocytosis is a major mechanism 
of EGFR signal attenuation by targeting the activated receptor for lysosomal proteolysis 
(Polo and Di Fiore, 2006).  Recent evidence suggests that lipid rafts may play a role in 
mediating EGFR endocytosis (Puri et al., 2005; Sigismund et al., 2008).  Additionally, 
EGFR phosphorylation and Grb2 recruitment to EGFR are intimately linked to EGFR 
internalization (Burke et al., 2001; Goh et al., 2010; Jiang et al., 2003; Yamazaki et al., 
2002).  Therefore, we next assessed the effect of DHA on EGFR endocytosis using a 
surface biotinylation assay.   Interestingly, internalization of EGFR occurred more 
rapidly in DHA treated cells compared to untreated (control) cells (Fig. 19 A).  In 
addition, consistent with data in Figs. 2 and 3, DHA reduced the steady-state plasma 
membrane localization of EGFR in unstimulated cells (Fig. 19 B).   
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Figure 19.  DHA increases EGF-stimulated EGFR internalization and reduces resting state levels of EGFR at 
the plasma membrane.  YAMC cells were incubated with untreated media or media supplemented with 50 µM 
BSA-complexed DHA for a total of 72 h.  For the final 16-18 h, cells were incubated in low serum (0.5% FBS).  (A) 
Cell surface proteins were labeled with EZ-Link Sulfo-NHS-SS-Biotin followed by stimulation with 25 ng/mL EGF 
for 0-30 min.  After stimulation, cells were washed and biotin remaining on the cell surface was cleaved.  Cell 
lysates were harvested, and biotinylated EGFR was quantified by ELISA using streptavidin coated plates and anti-
EGFR antibody.  (B) Cell surface EGFR was assessed by treating cells the same as in A, and harvesting without 
stimulating with EGF or cleaving cell surface biotin. .  Data represent mean ± SEM.  In (A), data are normalized to 
time 0.  In (B), data are normalized to control (no fatty acid).  Statistical significance between treatments (*P<0.05) 
was determined using Student’s t-test. C, control; DHA, docosahexaenoic acid. 
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Following internalization, EGFR can either be recycled back to the cell surface 
or be targeted to the lysosome for degradation.  Ubiquitin acts as a sorting signal to 
down-regulate the functions of plasma membrane proteins.  EGFR internalization and 
degradation are facilitated by ubiquitin (Eden et al., 2011).  Receptor endocytosis 
stimulated by ubiquitination is considered to be crucial to prevent oncogenesis because it 
sorts the receptor to the lumen of multivesicular bodies and terminates growth factor 
signaling (Umebayashi et al., 2008).  This is especially crucial for EGFR since it has 
been shown to continue to signal from endosomes after it is internalized (Burke et al., 
2001).  Therefore, we assessed ubiquitination of the receptor in order to determine 
whether the DHA-induced increase in EGFR internalization was associated with 
increased receptor ubiquitination and degradation.   Immunoprecipitation of EGFR 
followed by western blotting for ubiquitin to assess EGFR ubiquitination was utilized.  
We found that EGFR ubiquitination was significantly increased by DHA treatment (Fig. 
20).  Additionally, EGFR expression was reduced in DHA treated cells 30 min after 
stimulation.   Together, these data suggest that DHA further regulates EGFR signaling 
capacity by increasing EGFR internalization and degradation. 
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Figure 20.  DHA increases EGFR ubiquitination.  Cells were stimulated with 25 ng/mL EGF for 0-30 min and 
harvested.  EGFR was immunoprecipitated from the total cell lysate, assessed by western blotting for ubiquitin, 
and quantification of band intensity was performed.  All results are representative of at least 3 independent 
experiments.  Data represent mean ± SEM.  Data are normalized to time 0.  Statistical significance between 
treatments (**P<0.01) was determined using Student’s t-test. C, control; DHA, docosahexaenoic acid. 
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3.4  Discussion 
Our initial observations regarding the role of DHA in regulating EGFR signaling 
opened numerous avenues for continued research.  Here, we further probed the 
mechanism by which DHA alters EGFR function.  We found that DHA enhances EGFR 
phosphorylation by increasing receptor dimerization.  This is consistent with previous 
observations on the effect of altered EGFR plasma membrane localization on EGFR 
activation (Chen and Resh, 2002; Ringerike et al., 2002; Roepstorff et al., 2002).  Many 
of these studies showed that cholesterol altered both receptor dimerization and ligand 
binding.  Therefore, research on the effect of DHA on ligand binding is required for full 
understanding of the role of DHA in control of EGFR function. 
To further understand the mechanism by which DHA suppresses EGFR signal 
transduction, we attempted to identify the exact locus of the DHA-induced perturbation 
in EGFR signal transduction.  Therefore, we assessed the individual components of the 
EGFR-Ras-ERK1/2 signaling axis.  Grb2 is an immediate proximal downstream 
mediator of EGFR signaling and directly binds to phosphorylated tyrosine residues of 
EGFR, including Tyr1068, which we showed here to be increased by DHA treatment.  
Grb2 mediates multiple responses to EGFR phosphorylation, including propagation of 
intracellular signaling and receptor endocytosis.  We observed that DHA treatment 
increased the EGF-stimulated recruitment of Grb2 to the plasma membrane (Fig. 16), 
indicating that DHA does not affect the ability of phosphorylated EGFR to recruit 
intracellular signaling mediators.  We subsequently demonstrated that the “breakpoint” 
in the DHA-mediated suppression of EGFR signaling was at the level of Ras activation 
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(Fig. 17).  Our laboratory has previously shown that DHA suppresses the levels of 
activated GTP-bound Ras under basal conditions (Collett et al., 2001).  We have 
extended these observations by demonstrating that EGF-stimulated activation of all three 
isoforms of Ras was suppressed by DHA.  In addition, DHA had the strongest inhibitory 
effect on activation of H-Ras.  This is intriguing due to the fact that both H-Ras and 
EGFR are localized to lipid rafts (Prior et al., 2001), and that EGF-stimulated 
interactions between Ras and its downstream partner Raf-1 have been shown to occur in 
lipid rafts (Mineo et al., 1996).    A potential explanation for the observed DHA-induced 
suppression of activation of Ras, specifically H-Ras, is based on the altered localization 
of EGFR within the plasma membrane.   Convincing evidence illustrates the importance 
of lateral segregation of signaling cascades on the plasma membrane.  Indeed, for signal 
transduction to occur, phosphorylated EGFR must form a transient complex with Grb2, 
Sos, and Ras (Buday and Downward, 1993).  Due to the altered plasma membrane 
localization of EGFR upon treatment with DHA, this could result in a spatial abrogation 
of signal transduction by reducing the formation of these transient complexes.   
In addition to our previous observations that DHA regulated the localization of 
EGFR within the plasma membrane, we illustrated here that DHA also altered the 
subcellular distribution of EGFR.  Under unstimulated conditions, DHA treated cells 
contained significantly less EGFR at the plasma membrane (Fig. 19 B).  Additionally, 
concomitant with increased EGFR phosphorylation, DHA treated cells exhibited 
enhanced EGFR endocytosis following receptor stimulation (Fig. 19 A).  Because a 
majority of signaling cascades are activated by EGFR at the plasma membrane, receptor 
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endocytosis and degradation play an important role in terminating EGFR signaling.  
Therefore, the DHA-induced enhancement of EGFR internalization is an additional 
mechanism by which DHA can suppress the ability of EGFR to activate downstream 
signaling.  Once internalized, EGFR can continue signaling from endosomes, recycle 
back to the plasma membrane, or traffic for degradation.  This is noteworthy because 
DHA increased EGFR ubiquitination and degradation (Fig. 20).  Interestingly, although 
DHA treatment did not affect the steady-state levels of EGFR, following ligand-induced 
activation, it significantly increased EGFR ubiquitination and degradation.  Since 
receptor endocytosis and degradation can function to mitigate signal transduction, we 
propose that this is an additional mode by which DHA modulates the signaling capacity 
of EGFR.   
Since DHA antagonizes the activation of all Ras isoforms regardless of their 
plasma membrane localization, it is likely that an additional mechanism mediates the 
suppression of EGFR signal transduction by DHA.  Therefore, we hypothesize that the 
observed increased endocytosis of the receptor contributes to the suppressive phenotype.  
The majority of activation of Ras by EGFR has been shown to occur at the plasma 
membrane (Augsten et al., 2006).  Therefore, the observed DHA-induced increase in 
EGFR internalization likely contributes to the reduced activation of all Ras isoforms.  
We are currently determining whether the altered plasma membrane localization of 
EGFR and/or enhanced EGFR endocytosis is responsible for the suppression of 
downstream signaling.  Additionally, further work is required to determine how the 
altered plasma membrane localization of EGFR contributes to enhanced receptor 
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internalization and degradation.  Previous work by Sigismund et al. indicates that high 
levels of EGFR phosphorylation can lead to activation of additional forms of EGFR 
endocytosis which sort EGFR for degradation instead of recycling (Sigismund et al., 
2008).  Therefore, it is possible that DHA could function by altering EGFR plasma 
membrane localization, resulting in higher levels of EGFR phosphorylation and 
activation of a non-canonical form of receptor endocytosis that sorts the receptor for 
degradation as opposed to recycling.  Current studies in our lab are focused on testing 
this hypothesis.  
These results have substantial biological relevance because Ras plays a central 
role in the development of human colon cancer and is commonly hyperactivated by 
somatic mutation or signaling through growth factor receptors (Lievre et al., 2010).  
Hence, by suppressing EGF-stimulated activation of Ras, DHA can provide protection 
against colonic transformation.  In addition to suppressing activation of the Ras-ERK1/2 
pathway, DHA suppressed EGF-induced activation of STAT3.  STAT3 can be activated 
downstream of EGFR by several pathways, and Ras signaling has been shown to be 
intimately linked to STAT3 activation (Corcoran et al., 2011; Plaza-Menacho et al., 
2007; Yeh et al., 2009).  Therefore, the reduction in STAT3 activation could be a direct 
result of reduced activation of Ras.  Additionally, lipid rafts have been shown to play a 
central role in the activation of STAT3 (Sehgal et al., 2002), which may explain the 
DHA-induced suppression of EGF-induced STAT3 activation.  Clearly, further studies 
are required to determine the exact mechanism of action.  Additionally, expression of a 
constitutively active form of H-Ras partially rescued the DHA-induced suppression of 
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cell proliferation.  The limited ability of GFP-H-RasG12V was likely due to the effect 
that DHA has on other downstream pathways from EGFR that are independent of Ras 
signaling. 
Overall, these results further clarify the mechanism of action by which DHA 
perturbs EGFR function.  Based on our findings, we have created a putative model 
depicting the effect of DHA on EGFR (Fig. 21).  This model illustrates that DHA alters 
EGFR localization, which contributes to the increase in EGFR dimerization and 
phosphorylation.  However, the altered localization of EGFR causes a lateral break in 
signal transduction that is dependent on lipid rafts.  Additionally, the increased EGFR 
phosphorylation, and potentially other unknown processes, stimulates increased receptor 
endocytosis, which impedes signaling events that emanate from the plasma membrane.  
The enhanced receptor degradation subsequently subdues endosomal signaling.  All of 
this culminates in an abrogation of signal transduction to hamper cell proliferation.
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Figure 21.  Proposed model for the effect of DHA on EGFR localization and signaling.  Under control conditions, EGFR is enriched in liquid ordered lipid raft 
domains of the cell.  Upon stimulation, ligand bound receptors dimerize and transphosphorylate.  Signaling events are initiated from the phosphorylated tyrosine 
residues, and signaling is efficient due to the lateral organization of EGFR and downstream signaling partners. Upon fatty acid treatment, the cell incorporates DHA 
into plasma membrane phospholipids, which redistributes EGFR in the membrane.  Ligand-induced receptor dimerization and phosphorylation is increased, along 
with receptor ubiquitination, internalization, and degradation.  The altered lateral and subcellular organization of EGFR results in inefficient cell signaling..  This 
results in altered cellular function, including a reduction of cell proliferation.   
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4. EFFECT OF DHA ON COLONIC WOUND HEALING 
 
4.1 Introduction 
Intestinal wound healing requires a delicate balance of migration, proliferation, 
and differentiation of epithelial cells (Moyer et al., 2007).  The first step of wound 
healing is epithelial restitution, in which epithelial cells adjacent to the wound rapidly 
migrate into the wounded area (Dignass and Podolsky, 1993; Dise et al., 2008; Sturm 
and Dignass, 2008).  Restitution begins quickly following injury, within minutes to 
hours, and this process has been shown to be independent of cell proliferation (Dignass 
and Podolsky, 1993; Sturm and Dignass, 2008).  The next step of wound healing, which 
begins hours to days after injury, requires proliferation of the mucosal epithelium to 
increase the number of enterocytes available to repopulate the injured area (Dignass and 
Podolsky, 1993; Iizuka and Konno, 2011).  The final stage of wound healing requires 
maturation and differentiation of epithelial cells to restore and maintain intestinal 
function (Sturm and Dignass, 2008). 
Many pathways that are hijacked by cancer cells are integral in the process of 
wound healing.  Central amongst these pathways is the EGFR pathway.  EGFR signaling 
is involved in all of the stages of intestinal wound healing, including restitution, 
proliferation, and differentiation.  It has been clearly demonstrated that treatment with 
EGFR ligands, including EGF, HB-EGF, and TGF-α, promotes intestinal wound healing 
(El-Assal and Besner, 2005; Goke et al., 1998).  In response to a wounding event, EGFR 
becomes activated.    This activation is regulated in part by G-protein coupled receptors, 
 92 
 
which signal to activate matrix metalloproteinases (Yin and Yu, 2009).  These serve to 
cleave EGFR ligands from the plasma membrane so they can bind to their receptor.  Src 
family tyrosine kinases have also been shown to play a central role in wound-induced 
transactivation of EGFR (Xu et al., 2006).  In addition, ERK1/2 can mediate ligand 
shedding in response to wounds (Yin and Yu, 2009).   
Multiple downstream signaling pathways from EGFR are central in regulating 
distinct stages of wound healing.  Restitution requires extensive reorganization of the 
actin cytoskeleton through activation of Rho family small GTPases, including Rac1 and 
Cdc42 (Hall, 1998; Hopkins et al., 2007).  Rho-GTPases alternate between an active 
GTP-bound form and an inactive GDP-bound form.  Activation of Rho-GTPases 
promotes their translocation to the plasma membrane where they amplify signaling 
pathways involved in modification of the actin cytoskeleton.  Activation of Rac1 and 
Cdc42 facilitates actin polymerization by inducing activation of WAVE and WASP/N-
WASP nucleation factors, which then serve to activate the actin Arp2/3 complex (Eden 
et al., 2002; Rohatgi et al., 1999).  Activation of different Rho GTPases correlates with 
formation of different cytoskeletal projections.  Specifically, Rac1 activation is 
classically associated with the formation of lamellipodia, whereas Cdc42 is correlated 
with filopodia formation (Nobes and Hall, 1995a; Nobes and Hall, 1995b).  It has been 
clearly demonstrated that EGFR activates Rac1 and Cdc42 through multiple downstream 
signaling cascades, including PI3K and Src (Dise et al., 2008; El-Sibai et al., 2007), and 
EGFR-mediated activation of these mediators is imperative for wound healing.  PLC-γ1 
is another downstream signaling partner of EGFR that mediates intestinal epithelial cell 
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migration (Li et al., 2009; Polk, 1998).  PLC-γ1 contains an SH2 domain that allows it to 
directly bind to EGFR (Anderson et al., 1990; Meisenhelder et al., 1989).  Binding to 
EGFR results in phosphorylation of tyrosine residues on PLC-γ1, which increases its 
enzymatic activity (Kamat and Carpenter, 1997).  PLC-γ1 also contains two pleckstrin 
homology (PH) domains, which allow it to bind to phosphatidylinositol lipids in the 
plasma membrane.  PLC-γ1 catalyzes the hydrolysis of phosphatidylinositol-4,5-bis-
phosphate (PIP2) into two second messengers, inositol 1,4,5-trisphophate and 
diacylglycerol (DAG).  It has been shown that PLC-γ1 and Rac1 directly interact to co-
regulate cytoskeletal remodeling and cell migration in response to EGF (Li et al., 2009).  
In addition to these early processes that enhance restitution, EGFR is integral in 
mediating the cell proliferation stage of wound healing by activating multiple 
downstream signaling cascades, including Ras-ERK1/2 and STAT3.   
We have previously demonstrated that the n-3 PUFA, DHA, inhibits ligand-
induced signaling through EGFR in colonocytes, which ultimately results in a 
suppression of cell proliferation.  Based on the ability of DHA to suppress aspects of 
EGFR signaling and the central role of EGFR-mediated signaling in wound healing, we 
hypothesize that DHA is inimical with respect to intestinal wound healing.  Furthermore, 
DHA affects multiple lipid raft mediated events, and lipid rafts have been shown to play 
a central role in EGFR-mediated cell migration (Murai, 2012).  The postulate that DHA 
is detrimental for intestinal wound healing is supported by recent data generated by our 
laboratory, e.g., mice fed a diet enriched in fish oil, high in DHA, exhibited reduced 
overall survival and increased wounding following treatment with dextran sodium 
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sulfate (DSS)(Jia et al., 2008).  An additional study conducted in humans demonstrated 
that wound healing of the skin is delayed in patients dosed with a combination EPA and 
DHA (McDaniel et al., 2008).  Conversely, some studies have demonstrated a beneficial 
effect of n-3 PUFA in response to injury (Gravaghi et al., 2011; Hudert et al., 2006).  
These conflicting data are interesting and warrant further probing of the mechanisms by 
which n-3 PUFA affect wound healing.  Since DHA, but not EPA, alters EGFR 
signaling (Fig. 6), we hypothesized that the differential effects of these two dietary lipids 
could explain the discrepancy in the n-3 PUFA and wound healing literature.  Therefore, 
we probed the effects of fatty acids on EGFR signaling and wound healing.  
 
4.2 Materials and methods 
4.2.1 Cell culture 
Young adult mouse colonic (YAMC) cells, conditionally immortalized 
colonocytes, were originally obtained from R.H. Whitehead, Ludwig Cancer Institute 
(Melbourne, Australia).   YAMC cells (passages 12–17) were cultured under permissive 
conditions, 33°C and 5% CO2 in RPMI 1640 media (Mediatech, Manassas, VA) 
supplemented with 5% fetal bovine serum (FBS; Hyclone, Logan, UT), 2 mM GlutaMax 
(Gibco, Grand Island, NY), 5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenious 
acid (Collaborative Biomedical Products, Bedford, MA), and 5 IU/mL of murine 
interferon-γ (Roche, Mannheim, Germany).  Select cultures were treated for 72 h with 
50 µM fatty acid [DHA, LA, or EPA; NuChek, Elysian, MN] complexed with bovine 
serum albumin (BSA).  In select cultures, for the final 16-18 h, complete media was 
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replaced with low-serum (0.5% FBS) media.   Cells were then stimulated with 0-25 
ng/mL recombinant mouse EGF (Sigma, St. Louis, MO) and harvested.  To prepare 
whole cell extracts of wounded cells, cells were grown to confluence in 150-mm dishes.  
The monolayer was cross-scraped 25 times in all directions (100 scrapes total) with a 1-
mL pipette tip as previously described (Egan et al., 2003).  The monolayer was then 
gently washed with ice-cold PBS three times and harvested. 
4.2.2 Western blotting 
For western blotting, cells were homogenized in ice-cold homogenization buffer 
(50 mM Tris-HCl, pH 7.2, 250 mM sucrose, 2 mM EDTA, 1 mM EGTA, 50 mM 
sodium fluoride, 100 mM sodium orthovanadate, 1%Triton X-100, 100 µM activated 
sodium orthovanadate, 10 mM β-mercaptoethanol, and protease inhibitor cocktail) as 
previously described (Davidson et al., 1999).  Following homogenization, lysates were 
sheared using a 29G needle, incubated on ice for 30 min, and centrifuged at 16,000 x g 
for 20 min.  The supernatant was collected and protein concentration was assessed using 
Coomassie Plus Protein assay (Pierce).  Lysates were treated with 1X pyronin sample 
buffer and subjected to SDS polyacrylamide gel electrophoresis (PAGE) in precast 4–
20% Tris-glycine mini gels (Invitrogen).  After electrophoresis, proteins were 
electroblotted onto a polyvinylidene fluoride membrane with the use of a Hoefer Mighty 
Small Transphor unit at 400 mA for 90 min. Following transfer, the membrane was 
incubated in 5% BSA (Roche) and 0.1% Tween 20 in TBS (TBST) at room temperature 
for 1 h with shaking, followed by incubation with shaking overnight at 4
o
C with primary 
antibody diluted in 5% BSA in TBST.  Membranes were washed with TBST and 
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incubated with peroxidase conjugated secondary antibody as per manufacturer’s 
instructions.  Bands were developed using Pierce SuperSignal West Femto
TM
 maximum 
sensitivity substrate.  Blots were scanned using a Fluor-S Max MultiImager system (Bio-
Rad, Hercules, CA).  Quantification of bands was performed using Quantity One 
software (Bio-Rad).  Monoclonal rabbit anti-EGFR, anti-phosphorylated (Tyr1068) 
EGFR, anti-PLC-γ1, and anti-phosphorylated (Tyr783) PLC-γ1 were purchased from 
Cell Signaling (Danvers, MA).  Peroxidase conjugated goat anti-rabbit IgG was 
purchased from Kirkegaard and Perry Laboratories (Gaithersburg, MD). 
4.2.3 Small Rho-GTPase activity assay 
 Activation of Cdc42 and Rac1 was assessed using kits from Cytoskeleton 
(Denver, CO).  Samples for these assays were harvested as detailed above using the lysis 
buffer provided with the kits and supplemented with protease and phosphatase inhibitors 
(Sigma).  Activation of Cdc42 was analyzed using the G-LISA Cdc42 Activation Assay 
Biochem Kit in the colorimetric format.  Activation of Rac1 was assessed using the Rac1 
G-LISA Activation Assay in the colorimetric format.  The assays were performed using 
25 μg of protein according to the manufacturer’s instructions.  Absorbance was 
measured on a SpectraMax 190 Microplate Reader (Molecular Devices, Sunnyvale, CA). 
4.2.4 Scratch assay 
 YAMC cells in T-75 flasks were either untreated or treated with 50 μM fatty acid 
(LA, DHA, or EPA) for 24 hours.  Cells were then trypsinized and seeded at a density of 
100,000 cells/mL into 35-mm glass bottom dishes.  Cells were cultured for another 48 h 
in the presence of fatty acid and serum starved (0.5% FBS) for the final 16-18 h.  
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Following serum starvation, cells were washed once with PBS and scratched using a 
sterile P-200 pipette tip.  Cells were then washed twice with PBS and incubated with 
serum-free media supplemented with 25 ng/mL EGF.  Cells were then imaged with a 
10X Plan Fluor phase objective on a Nikon TiE inverted microscope equipped with 
perfect focus system to maintain focus over time and an incubation chamber at 33°C 
with 5% CO2.  Images were taken with a Photometrics CoolSNAP HQ
2
, 14 Bit, 20 MHz, 
monochrome cooled CCD camera.  The software used in image acquisition and analysis 
was NIS Elements AR.  Images were taken every 15 min for 24 h to observe wound 
healing.  Wound healing was quantified by counting the number of cells that infiltrated 
the wounded area at 12 and 24 h following the wounding event. 
4.2.5 Migration assay 
 Cell migration was assessed using the QCM 24-well colorimetric cell migration 
assay (Millipore).  YAMC cells were seeded into T-75 flasks and untreated or treated 
with fatty acids (LA, DHA, EPA) for 72 h.  For the final 16-18 h of treatment, cells were 
serum-starved (0.5% FBS).  Cells were then trypsinized and seeded into inserts at a 
density of 0.5 x 10
6
 cells/mL in serum free media.  The inserts are composed of 
membranes with 8 μm pores through which the cells can migrate.  The inserts were set 
into wells containing media supplemented with 25 ng/mL EGF, and the membrane of the 
insert was placed into contact with the media.  The cells were incubated for 12 h at 33°C 
and 5% CO2 and allowed to migrate through the membrane.  Following incubation, the 
cells on the top side of the insert were thoroughly removed, and the migration insert was 
stained using the kit provided cell stain.  Subsequently, the stain was eluted using the 
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provided extraction buffer, and 100 μL of the dye mixture was added to a 96-well plate.  
The optical density was measured at 560 nm on a SpectraMax 190 Microplate Reader 
(Molecular Devices).   
4.2.6 Animals 
Male C57BL/6 wild-type mice aged 12-15 weeks were purchased from Jackson 
Laboratories. All procedures followed guidelines approved by the U.S. Public Health 
Service and the Institutional Animal Care and Use Committee at Texas A&M 
University.  This study and all animal protocols and procedures were approved by the 
Institutional Animal Care and Use Committee at Texas A&M University. Mice were 
maintained under barrier conditions and initially consumed a Teklad commercial mouse 
non-purified diet (Harlan, Indianapolis, IN) ad libitum. Mice were maintained for 15-21 
days on a semi-purified defined diet that was adequate in all nutrients, containing 440 
(g/kg diet) sucrose, 200 casein, 220 corn starch, 3 DL-methionine, 35 AIN 76 salt mix, 
10 AIN 76 mineral mix, 2 choline chloride, 60 cellulose (Bio-Serv, Frenchtown, NJ), 30 
corn oil (CO) (Dyets, Bethlehem, PA) or 10 DHA (Incromega DHA700E SR; Bioriginal 
Food & Science Corp, Saskatchewan, Canada) plus 20 CO or 10 EPA (SLA Pharma, 
Watford, UK).  The DHA utilized is highly purified (>70%) DHA ethyl ester, and the 
EPA is highly purified (>95%) EPA free fatty acid.  The mice received the diet for 10 
days prior to treatment with 2.5% DSS in the drinking water for 5 days.  Following DSS 
treatment, mice were allowed to recover for 0, 3, or 6 days.  Mice were terminated using 
CO2 asphyxiation.  The colon was then removed and cut into a longitudinal half.  One 
half of the colon was rolled into a Swiss roll, fixed in paraformaldehyde, embedded in 
 99 
 
paraffin, and sectioned.  The sections were then analyzed in a blinded manner by a board 
certified pathologist.  From the other half of the colon, colonic mucosa was isolated by 
scraping and combining with lysis buffer from the Rac1 activation assay buffer.  Lysates 
were sheared by passage through a 27G needle, incubated on ice for 30 min, and then 
centrifuged at 16,000 x g for 20 min.  The supernatant was collected.  Protein 
concentration was determined using Coomassie Protein Plus assay (Pierce). 
4.2.7 Statistics 
 The effect of independent variables (treatment effects) was assessed using the 
one-way analysis of variance test (ANOVA), and differences among means were 
evaluated using Tukey’s post-hoc test of contrast.  P values <0.05 were considered to be 
statistically significant. 
 
4.3 Results 
4.3.1  EGFR transactivation by wounding. 
We have previously shown that EGFR phosphorylation in response to direct 
stimulation with ligand is increased by DHA (Fig. 4).  However, other long chain 
polyunsaturated fatty acids, including LA, AA, and EPA do not exert the same effect 
(Figs. 4 and 6).  Therefore, we wanted to expand upon these observations by determining 
if fatty acids can alter EGFR transactivation in response to injury.  Since in response to 
wounding, EGFR becomes transactivated (Egan et al., 2003), we wounded a monolayer 
of colonic epithelial cells by scratching the monolayer extensively.  We found that 
phosphorylation of EGFR was strongly induced in untreated control cells and LA treated 
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cells (Fig. 22).  Treatment of cells with DHA or EPA, however, reduced the injury-
induced transactivation of EGFR. 
 
 
 
 
Figure  22.  DHA and EPA reduce wound-induced EGFR phosphorylation.  YAMC cells were either untreated 
(control) or treated with 50 μM fatty acid (LA, DHA, or EPA) for 72 h.  For the final 16-18 h, cells were serum 
starved (0.5% FBS) followed by extensive wounding.  Following wounding, cells were incubated for 2 min.  Cells 
were then harvested and the cell lysates were collected.  Total cell lysates were analyzed by western blotting for 
phosphorylated and total EGFR.  Two independent experiments were conducted.  Band volumes were quantified 
using QuantityOne software.  Representative immunoblot and data are presented; mean ± SEM (n=4).  Statistical 
difference as indicated by different numbers (P<0.05) was measured using one-way ANOVA and Tukey’s test of 
contrast. C, control; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LA, linoleic acid. 
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4.3.2 Activation of Rho-GTPases in response to EGF or injury 
 EGFR activates many important mediators in order to stimulate cellular events 
that are required for wound healing.  For example, EGFR-mediated activation of PLC-
γ1, Rac1, and Cdc42 has been shown to be integral in wound healing (Dise et al., 2008; 
El-Sibai et al., 2007; Li et al., 2009).  Therefore, we assessed activation of each of these 
signaling mediators in response to direct stimulation with an EGFR specific ligand, 
EGF, or in response to injury.  We assessed activation of Rac1 and Cdc42 with an assay 
that specifically recognizes the activated, GTP-bound forms of these molecules.  We 
found that EGF stimulated activation of Rac1 to a similar extent in control, LA, and EPA 
treated cells (Fig. 23 A).  Treatment with DHA significantly reduced EGF-stimulated 
activation of Rac1.  Furthermore, whereas Cdc42 activation was equally induced in 
control, LA, and EPA treated cells, DHA significantly reduced activation of Cdc42 in 
response to EGF (Fig. 24 A).  We additionally assessed activation of Rac1 and Cdc42 in 
response to injury.  The same degree of Rac1 activation upon injury was observed in 
control and LA treated cells (Fig. 23 A).  DHA and EPA, however, significantly reduced 
activation of Rac1 by injury.  Similarly, compared to control treated cells, DHA and 
EPA decreased injury-mediated activation of Cdc42 (Fig. 24 B).  Additionally, DHA 
suppressed Cdc42 activation to a greater extent than EPA.  
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Figure 23.  DHA and EPA alter EGFR-mediated Rac1 activation.  YAMC cells were either untreated (control) or 
treated with 50 μM fatty acid (LA, DHA, or EPA) for 72 h.  For the final 16-18 h, cells were serum starved (0.5% 
FBS).  Cells were then stimulated either with (A) 25 ng/mL EGF or (B) by extensive wounding.  Following 
stimulation, cells were incubated for 2 min, harvested, and the cell lysates were collected.  Total cell lysates were 
analyzed by G-LISA for active, GTP-bound Rac1.  Two independent assays were conducted.  Representative data are 
presented as mean ± SEM (n=6).  Statistical difference as indicated by different numbers (P<0.05) and was measured 
using one-way ANOVA and Tukey’s test of contrast. C, control; DHA, docosahexaenoic acid; EPA, eicosapentaenoic 
acid; LA, linoleic acid. 
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Figure 24.  DHA and EPA alter EGFR-mediated activation of Cdc42.  YAMC cells were either untreated 
(control) or treated with 50 μM fatty acid (LA, DHA, or EPA) for 72 h.  For the final 16-18 h, cells were serum 
starved (0.5% FBS).  Cells were then stimulated either with (A) 25 ng/mL EGF or (B) by extensive wounding.  
Following stimulation, cells were incubated for 2 min, harvested, and the cell lysates were collected.  Total cell 
lysates were analyzed by G-LISA for active, GTP-bound Cdc42.  Two independent assays were conducted.  
Representative data are presented as mean ± SEM (n=6).  Statistical difference as indicated by different numbers 
(P<0.05) was measured using one-way ANOVA and Tukey’s test of contrast. C, control; DHA, docosahexaenoic 
acid; EPA, eicosapentaenoic acid; LA, linoleic acid. 
 
 104 
 
4.3.3 Effect of EGF or injury on PLC-γ1 signaling  
We additionally assessed activation of PLC-γ1 by EGF stimulation or wounding 
by western blotting for phosphorylated and total PLC-γ1.  We probed for Tyr783 
phosphorylated PLC-γ1 because phosphorylation at this residue is directly mediated by 
its binding to EGFR (Kim et al., 1990).  EGF stimulated phosphorylation of PLC-γ1 in 
all treatment groups, but stimulation in DHA treated cells was significantly lower than 
all other treatment groups (Fig. 25 A).  Similar to Rac1 and Cdc42, treatment with either 
EPA or DHA inhibited injury-induced activation of PLC-γ1 (Fig. 25 B).   
4.3.4 Scratch and migration assays 
 Based on our initial observation that DHA impedes important processes required 
for wound healing, we next wanted to perform a functional assay to observe wound 
healing.  Cells were scrape-wounded and treated with or without EGF.  The wound was 
imaged every 15 min for 24 h.  Wound healing was measured by counting the number of 
cells that had infiltrated the wounded area at 12 and 24 h after the wounding event.  
Unstimulated cells exhibited slow and ineffective wound healing (Fig. 26).  In contrast, 
EGF strongly stimulated wound healing in control and LA treated cells.  However, EGF-
mediated wound healing of both DHA and EPA treated cells was significantly delayed 
(Fig. 26).  
Cell migration was assessed using a transwell migration assay.  We utilized EGF 
to stimulate cell migration through a membrane with 8 μm pores and allowed the cells to  
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Figure 25.  DHA and EPA alter EGFR-mediated activation of PLC-γ1.  YAMC cells were either untreated 
(control) or treated with 50 μM fatty acid (LA, DHA, or EPA) for 72 h.  For the final 16-18 h, cells were serum 
starved (0.5% FBS).  Cells were then stimulated with (A) 25 ng/mL EGF or (B) by extensive wounding.  Following 
stimulation, cells were incubated for 2 min, harvested, and the cell lysates were collected.  Total cell lysates were 
analyzed by western blotting for phosphorylated and total PLC-γ1.  Band volume was quantified using QuantityOne 
software.  Two independent experiments were conducted.  Representative immunoblots and data are presented; 
mean ± SEM (n=4).  Statistical difference as indicated by different numbers (P<0.05) was measured using one-way 
ANOVA and Tukey’s test of contrast. C, control; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LA, 
linoleic acid. 
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Figure 26.  DHA and EPA impede EGF-stimulated wound healing.  YAMC cells were either untreated (control) or treated with 50 μM fatty acid (LA, DHA, 
or EPA) for 72 h.  For the final 16-18 h, cells were serum starved (0.5% FBS).  Cells were then scratched with a  p-200 pipette tip and stimulated with 25 ng/mL 
EGF.  Cell migration into the wounded area was imaged every 15 min on a Nikon TiE inverted microscope for 24 h.  Cell migration was quantified by counting 
the number of cells that had migrated into the wounded area at 12 and 24 h after the initial wound.  Four independent experiments were conducted.  
Representative images and data are presented; mean ± SEM (n=10).  Statistical difference as indicated by different numbers (P<0.05) was measured using one-
way ANOVA and Tukey’s test of contrast. C, control; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LA, linoleic acid.  Bar=50 um. 
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migrate for 12 h. Cells migrated to a similar extent in control and LA treated cells (Fig. 
27).  However, treatment with either DHA or EPA significantly reduced cell migration.     
4.3.6  Survival rates in vivo 
 Based on these observations, we wanted to determine whether consuming dietary 
lipids can alter acute wound healing in an animal model.  Therefore, we fed mice a diet 
enriched in either corn oil (CO), purified EPA, or purified DHA for 10 days.   Next, the 
animals were exposed for 5 days to 2.5% DSS in the drinking water.  DSS is a wounding 
agent that is often utilized to induce a form of mouse colitis that presents similar clinical 
and histological features of human inflammatory bowel diseases (Yan et al., 2009).  DSS 
causes colonic wounding by interfering with intestinal barrier function and stimulating 
local inflammation (Laroui et al., 2012).  In this study following DSS treatment, mice 
received either no recovery period or were allowed to recover for a period of 3 or 6 days.  
The mice were maintained on the diets throughout the entire study period.  We assessed 
changes in body weight over the entire period.  Interestingly, mice fed a DHA-enriched 
or EPA-enriched diet lost significantly more weight than mice on the CO-enriched diet 
(Fig. 28).  Furthermore, mice on the DHA diet began to gain back weight between 3 and 
6 days of recovery, whereas mice on the other diets did not.  We additionally analyzed 
survival in mice allowed to recover for 6 days.  We found that survival of mice fed the 
EPA diet was reduced compared to the CO diet (Fig. 29).  The DHA diet, however, did 
not reduce overall survival compared to the CO diet.  We are additionally currently 
assessing inflammation and injury, as well as colonocytes proliferation and apoptosis, in 
these mice.  
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Figure 27.  DHA and EPA hinder EGF-stimulated cell migration.  YAMC cells were either untreated (control) or 
treated with 50 μM fatty acid (LA, DHA, or EPA) for 72 h.  For the final 16-18 h, cells were serum starved (0.5% 
FBS).  Following serum starvation, cells were trypsinized, counted, and an equal number of cells were seeded into the 
top chamber of a 2-chamber well in serum free media.  The bottom chamber was filled with media supplemented with 
25 ng/mL EGF.  Cells were incubated for 12 h and allowed to migrate through the membrane between the chambers.  
Cells were then stained, and the cells remaining in the top chamber were removed.  The dye was then eluted from the 
stained cells that had migrated through the membrane.  The optical density of the dye/elution mixture was then 
measured on a spectrophotometer.  Two independent experiments were conducted.  Data are presented as mean ± 
SEM (n=6).  Statistical difference as indicated by different numbers (P<0.05) was measured using a one-way 
ANOVA and Tukey’s test of contrast. C, control; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LA, 
linoleic acid. 
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Figure 28.  Diets enriched in different fatty acids have varying effects on mouse weights.  Mice were fed a diet 
with CO as the sole lipid source or a diet enriched with purified DHA or EPA for 10 days.  Mice were then continued 
on the diet and exposed to 2.5% DSS for 5 days.  Mice were then allowed to recover from DSS for 0, 3 or 6 days.  The 
body weights of mice were measured before beginning diet (day -10), at the beginning of DSS treatment (day 0), at the 
end of DSS treatment (day 5), and following recovery (days 8 and 11).  The average body weight was calculated and 
graphed over time for each diet group (n=25-75). 
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Figure 29.  EPA reduces survival of mice treated with DSS.  Mice were fed a diet with CO as the sole lipid 
source or a diet enriched with purified DHA or EPA for 10 days.  Mice were then continued on the diet and exposed 
to 2.5% DSS for 5 days.  Mice were then allowed to recover from DSS for 0, 3 or 6 days.  (A) Overall mortality of 
mice at all time points was quantified (n=65-75 mice per diet).  (B) The survival of animals that were allowed to 
recover for 6 days was assessed using a Kaplan-Meier Survival Curve (n=20 mice per diet).   
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Figure 30.  The pattern of EGFR phosphorylation differs in mice fed different lipids.   Mice were fed a diet 
with CO as the sole lipid source or a diet enriched with purified DHA or EPA for 10 days.  Mice were then 
continued on the diet and exposed to 2.5% DSS for 5 days.  Mice were then allowed to recover from DSS for 0, 3 or 
6 days. Whole cell lysates were isolated from scraped colonic mucosa and probed by western blotting for total and 
phosphorylated EGFR.  Quantification of band volume was performed, and data are presented as mean ± SEM 
normalized to 0 day recovery (n=4). Statistical significance between diets was determined using a one-way ANOVA 
and Tukey’s test of contrast.  At day 3, CO fed animals had significantly higher levels of p-EGFR than DHA or EPA 
fed animals (**P≤0.001).  CO, corn oil; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid. 
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4.3.6 EGFR activation in mice 
 Next, we wanted to assess EGFR activation status over the recovery period. 
EGFR phosphorylation was determined in the scraped colonic mucosa of the mice to 
observe changes in EGFR activation.  We compared EGFR phosphorylation after 0, 3, or 
6 days of recovery from DSS.  EGFR phosphorylation peaked at day 3 of recovery in  
mice fed the CO diet and then decreased by day 6 (Fig. 30).  In the DHA and EPA 
treated animals, we found that peak EGFR phosphorylation did not occur until day 6 of 
recovery, with EGFR phosphorylation constantly increasing from day 0 to day 6 (Fig. 
30). 
4.3.7 Mucosa cytoskeletal-remodeling signaling in mice 
 After observing diet-induced differences in EGFR phosphorylation, we next 
wanted to compare downstream activation of Rac1 and Cdc42.  Consistent with EGFR 
phosphorylation, Cdc42 activation peaked at day 3 of recovery in CO fed mice, and 
activation then decreased by day 6 of recovery (Fig. 31).  In contrast, Cdc42 activation 
continued to increase in DHA or EPA fed mice throughout the entire observed recovery 
period.   Activation of Cdc42 in CO fed mice was significantly higher than in DHA or 
EPA fed mice at day 3 of recovery but significantly lower at day 6.  A similar overall 
pattern was additionally observed in activation of Rac1 (Fig. 32).  Rac1 activation in CO 
fed mice at day 3 of recovery was significantly higher than DHA or EPA fed mice, but 
no significant difference was observed at day 6 of recovery.   
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Figure 31.  The pattern of Cdc42 activation differs in mice fed different lipids.  Mice were fed a diet with CO 
as the sole lipid source or a diet enriched with purified DHA or EPA for 10 days.  Mice were then continued on the 
diet and exposed to 2.5% DSS for 5 days.  Mice were then allowed to recover from DSS for 0, 3 or 6 days. Whole 
cell lysates were isolated from scraped colonic mucosa and probed by G-LISA for GTP-bound Cdc42.  Two 
independent assays were conducted.  Data are presented as mean ± SEM (n=6-8).  Statistical significance between 
groups was quantified using a one-way ANOVA and Tukey’s test of contrast.  At day 3, CO fed mice had 
significantly higher levels of GTP-bound Cdc42 than DHA or EPA fed mice (*P≤0.05).  At day 6, CO fed mice had 
significantly lower levels of GTP-bound Cdc42 than DHA or EPA fed mice (**P≤0.001). 
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Figure 32. The pattern of Rac1 activation differs in mice fed different lipids.  Mice were fed a diet with CO as 
the sole lipid source or a diet enriched with purified DHA or EPA for 10 days.  Mice were then continued on the diet 
and exposed to 2.5% DSS for 5 days.  Mice were then allowed to recover from DSS for 0, 3 or 6 days. Whole cell 
lysates were isolated from scraped colonic mucosa and probed by G-LISA for GTP-bound Rac1.  Two independent 
assays were conducted.  Data are presented as mean ± SEM (n=6-8).  Statistical significance between groups was 
quantified using a one-way ANOVA and Tukey’s test of contrast.  At day 3, CO fed mice had significantly higher 
levels of GTP-bound Rac1 than DHA or EPA fed mice (*P≤0.05).  At day 6, CO fed mice had significantly lower 
levels of GTP-bound Rac1 than DHA or EPA fed mice (**P≤0.001). 
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4.4 Discussion 
 To our knowledge, this is the first time that the differential effects of DHA and 
EPA on EGFR signaling in the context of wound healing have been assessed.  There is 
an abundance of interest in this field, especially since many Americans currently take 
fish oil supplements due to their well-established health benefits (Wu et al., 2011).  
Interestingly, our data indicate that n-3 PUFA may not always promote optimal health, 
which may help clarify some of the inconsistencies in the literature.   
 We found that both DHA and EPA reduce wound-induced transactivation of 
EGFR.  Multiple signaling pathways have been found to be involved in the 
transactivation of EGFR.  Interestingly, prostaglandin E2 (PGE2) mediates activation of 
MMPs, which cleave EGFR-ligands from the plasma membrane (Al-Salihi et al., 2007; 
Oshima et al., 2011; Pai et al., 2002).  It is well-established that DHA and EPA reduce 
production of PGE2 (Calder, 2005; Trebble et al., 2003), which could in turn prevent 
transactivation of EGFR.  Additionally, Src has been shown to mediate activation of 
MMPs to induce EGFR activation (Pai et al., 2002; Xu et al., 2006).  Interestingly, Src 
signaling has been shown to be facilitated by lipid rafts (Holzer et al., 2011), and n-3 
PUFA have profound effects on lipid rafts and signaling events that emanate from these 
heterogeneous domains (Chapkin et al., 2008b; Siddiqui et al., 2007).  The observed 
effect of DHA and EPA on activation of EGFR could be caused by inhibition of one of 
these mechanisms, but further work is required to pinpoint the mechanism by which n-3 
PUFA inhibit transactivation of EGFR in response to injury.   
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 We next observed that in response to ligand, DHA, but not EPA, inhibited EGFR 
signaling through PLC-γ1, Rac1, and Cdc42.  This is consistent with our previous 
observations that DHA suppresses EGFR signal transduction (Fig. 8).  In response to 
wounding, both EPA and DHA reduced activation of PLC-γ1, Rac1 and Cdc42, which is 
consistent with the data indicating that EPA and DHA inhibit transactivation of EGFR 
(Fig. 22).  In addition to these mediators, we have previously shown that DHA inhibits 
EGFR-mediated activation of ERK1/2 and STAT3 (Fig. 8).  All of these factors are 
integral in mediating wound healing, which further suggests that n-3 PUFA could be 
unfavorable for recovery from injury. 
 With respect to the analysis of wound healing and cell migration in vitro, EGF 
enhanced wound healing in control and LA treated cells (Fig. 26).  However, wound 
healing was strongly impeded by treatment with DHA or EPA.  Similar results were 
observed for cell migration.  It is intriguing that although EPA did not impair ligand-
induced EGFR signaling, it did impair EGF-induced biological responses.  This suggests 
that the effects of EPA in regard to wound healing and migration may be independent of 
EGFR.  This hypothesis could be tested by utilizing an EGFR-null cell line.  
Additionally, EGF-induced cytoskeleton remodeling has been shown to be mediated by 
the products of 5-lipoxygenase and cyclooxygenase (Peppelenbosch et al., 1993).  DHA 
and EPA compete with arachidonic acid as substrates for these enzymes, which could 
affect cytoskeleton remodeling and cell migration in a manner independent of activation 
of the EGFR signaling mediators we analyzed.   
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The in vivo results further demonstrate that DHA and EPA alter wound healing in 
part by modifying EGFR-mediated signaling events.  DHA and EPA fed animals 
exhibited greater losses in body weight in response to DSS treatment.  Additionally, 
consistent with the in vitro effect of EPA on wound healing, EPA fed animals displayed 
the lowest survival levels.  These data together suggest that early wound healing events 
are being inhibited by DHA and EPA.  Upon assessment of downstream signaling, we 
found that peak activation of EGFR and downstream signaling mediators are delayed in 
animals fed EPA or DHA.  This suggests that the CO fed mice are recovering more 
quickly than the n-3 PUFA fed mice.  Although we cannot specify that the changes in 
downstream signaling are only due to changes in EGFR regulation and not other parallel 
pathways, the data clearly demonstrate differential regulation of important wound 
healing signaling events in n-3 PUFA fed mice compared to CO fed mice.  It is 
important to keep in mind the multitude of pathways that can be altered by dietary 
components.  Here, we focused specifically on signaling through EGFR, but future 
studies will assess diet effects on the regulation of other essential regulators of wound 
healing. 
Although it still remains unclear how DHA and EPA alter EGFR activation in 
colonic wound healing, it is patently obvious that these bioactive lipids present a barrier 
to wound healing due to altered cell signaling.  However, the process of wound healing 
is complex and complicated, and this study only focused on the EGFR-mediated 
signaling events that contribute to wound healing.  DHA and EPA are known to have 
many beneficial effects, and research on both DHA and EPA clearly detail a role for 
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these fatty acids in reducing inflammation (Calder, 2005).  Although early immune-
mediated events are required for wound healing, prolonged inflammation can be 
detrimental to this process.  DHA and EPA can be metabolized into a number of 
different lipid mediators, including resolvins, protectins, and maresins, which facilitate 
resolution of inflammation (Bannenberg, 2010).  These lipid mediators have varying 
biological activities, which contributes to differential effects of EPA and DHA.  In this 
study, we observed that DHA fed animals started gaining weight between days 3 and 6 
of recovery, whereas other diet groups did not.  This suggests that DHA could be 
facilitating events that expedite later stages of wound healing, perhaps by resolving 
inflammation. 
This work is particularly important for people who experience colonic wounding, 
e.g., IBD.  IBD patients undergo multiple sequences of active disease and recovery.  
These individuals have low expression of EGFR ligands (Oikonomou et al., 2010), and 
current work suggests that supplementation with EGF elicits a positive response in IBD 
patients (Sinha et al., 2003).  Some data suggest a beneficial role for n-3 PUFA in IBD 
(Gravaghi et al., 2011; Hudert et al., 2006), but other data indicate no effect or even a 
detrimental role (Hawthorne et al., 1992; Hou et al., 2011; Lorenz et al., 1989).  A 
systematic review and meta-analysis of human studies indicated no clear beneficial role 
for n-3 PUFA in IBD patients (Turner et al., 2011).  The data presented here suggests 
that the inhibition of EGFR signaling by n-3 PUFA could delay wound healing in these 
individuals.  However, the anti-inflammatory effects of n-3 PUFA could be beneficial 
during some disease stages, e.g., resolution of chronic inflammation.  Future work 
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should focus on determining optimal timing and dosing of n-3 PUFA to elicit the 
beneficial effects of these dietary lipids while avoiding the detrimental effects.   
Overall, the focus of this study was to determine whether the effects of n-3 
PUFA on EGFR signaling affects colonic wound healing.  This study for the first time 
demonstrates a potential mechanism to explain why n-3 PUFA do not facilitate recovery 
and remission of IBD patients.  This research illustrates that the inhibitory effects of 
DHA and EPA on injury-induced transactivation of EGFR likely contribute to delayed 
wound healing.   
 120 
 
5. SUMMARY AND CONCLUSIONS* 
 
5.1 Summary 
  DHA, an n-3 PUFA highly enriched in fish oil, was found to uniquely disrupt 
canonical functioning of EGFR, a transmembrane receptor tyrosine kinase.  DHA altered 
the plasma membrane localization of EGFR, which resulted in increased receptor 
dimerization and phosphorylation.  DHA also enhanced receptor internalization and 
degradation.  The modified localization and endocytosis of the receptor contributed to a 
suppression of downstream signal transduction, which ultimately impeded biological 
processes, e.g., cell proliferation and wound healing.  Additionally, we found that both 
DHA and another n-3 PUFA, EPA, prevented transactivation of EGFR in response to 
injury.   These observations have been summarized in Fig. 33 to detail the effect of n-3 
PUFA on cellular functions that directly impact mucosal physiology.  
 
5.2 Conclusions 
Because of the broad-acting effects of n-3 PUFA on mammalian physiology, it 
has been postulated that these dietary fatty acids act at a fundamental level common to 
all cells, i.e., by altering the physical properties of biological membranes (Chapkin et al., 
2008a; Shaikh et al., 2009b; Wassall et al., 2004; Wassall and Stillwell, 2008).  A wealth 
of published literature supports the hypothesis that n-3 PUFA play an important role in 
mediating lipid raft composition.   
__________________________ 
*Part of this chapter is reprinted with permission from “Membrane lipid raft organization is uniquely modified by n-3 
polyunsaturated fatty acids” by Harmony F. Turk and Robert S. Chapkin, 2012. Prostaglandins Leukotrienes and Essential Fatty 
Acids, doi: 10.1016/j.plefa.2012.03.008, Copyright 2012 by Elsevier Ltd.    
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Figure 33.  Proposed model for the differential effects of DHA and EPA on EGFR signaling.  Transient EGFR 
signaling is important for cellular functions that promote wound healing.  However, constitutive activation of EGFR 
signaling can facilitate malignant transformation of the colon.  We have demonstrated that n-3 PUFA suppress EGFR 
signaling, but DHA and EPA function through different mechanisms.  DHA, but not EPA, increases ligand-induced 
activation of EGFR but inhibits signal transduction. Additionally, both DHA and EPA impede transactivation of 
EGFR stimulated by injury.  The disease state dictates the overall effect of n-3 PUFA on health.  
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Previous data from our lab (Chapkin et al., 2008c; Kim et al., 2008), along with 
the data presented herein, clearly demonstrate that n-3 PUFA modify lipid raft 
organization and composition, leading to altered cell signaling and function.  EGFR, a 
lipid raft resident and important signaling mediator, is significantly affected by DHA.  
DHA shifts the lateral distribution of EGFR from lipid rafts into the bulk domain, which 
directly impacts EGFR function.  EGFR phosphorylation is increased, but signal 
transduction is impaired.  These observations are important because they are contrary to 
the traditional dogma of receptor tyrosine kinase signaling.  DHA alters EGFR 
trafficking, as evidenced by altered EGFR localization within the plasma membrane, 
reduction in the receptor at the plasma membrane, and increased receptor endocytosis 
and degradation following activation.  Our lab has previously documented effects of 
DHA on trafficking of other lipid-raft localized proteins, including H- and N-Ras (Seo et 
al., 2006).  Therefore, the effect of DHA on protein trafficking is likely pervasive.   
The role for n-3 PUFA in prevention and treatment of colon cancer is well 
documented, but the efficacy of n-3 PUFA is still a source of contention.  Many current 
prevention and treatment options are aimed at suppression of aberrant cell growth.  We 
have demonstrated a role for DHA in the regulation of this process by modifying the 
organization of lipid rafts and reducing oncogenic signaling that radiates from these 
domains.  Lipid rafts play a central role in multiple cellular processes involved in colonic 
tumorigenesis.  A number of studies have indicated that cholesterol, a major component 
of lipid rafts, accumulates in various tumors, and it has been proposed that progressive 
increases in membrane cholesterol contribute to the expansion of lipid rafts to potentiate 
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oncogenic cell signaling pathways (Freeman and Solomon, 2004; Li et al., 2006).  
Additionally, studies have clearly illustrated that lipid rafts play a functional role during 
tumorigenesis of multiple types of cancer (Staubach and Hanisch, 2011).  Therefore, the 
disruption of rafts by n-3 PUFA indicates a potentially protective and therapeutic role for 
these dietary lipids in cancer.  This mechanism of action could also impact other 
complex disease states that rely on lipid raft-mediated processes for potentiation of the 
disease pathology, including Alzheimer’s disease, Parkinson’s disease, cardiovascular 
diseases, HIV, and many others (Michel and Bakovic, 2007).  Overall, the basic 
knowledge obtained from our studies provides a solid mechanistic underpinning for the 
role of n-3 PUFA in colon cancer prevention.   
One should always be conscious of the physiological relevance of the dose of n-3 
PUFA utilized in studies.  Typically, our fish oil-enriched diets contain ~1% energy as 
DHA, and diets using purified DHA contain ~2% energy as DHA.  In contrast, corn oil 
control diets contain only trace amounts of EPA and DHA.  The amount of these lipids 
consumed by human populations varies greatly.  The Japanese typically consume 1–2% 
of energy in the diet from DHA (Nagata et al., 2002), whereas those in most European 
countries and the United States consume 0.1–0.2% of energy as total n-3 PUFA (Gibney, 
1997). Therefore, our experimental diets contain quantities of n-3 PUFA that are within 
the range that can be consumed in the human diet.  In cell culture experiments, we 
typically utilize low, physiologically relevant doses of DHA (50 µM), which replicates 
our in vivo results without inducing apoptosis (Turk et al., 2011).  Duration of treatment 
is another important issue.  Typically, we treat cell cultures with n-3 PUFA for at least 3 
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days, and feed animals diets enriched in n-3 PUFA for a minimum of 2 weeks.  Since 
upon supplementation, DHA is very rapidly incorporated into the phospholipids of the 
plasma membrane of many tissues (Arterburn et al., 2006), relatively little time is 
required in order to observe an effect of n-3 PUFA exposure.  Additionally, removal of 
n-3 PUFA supplementation has been shown to result in a rapid release of n-3 PUFA 
from the plasma membrane and reversal of induced effects (Seo et al., 2006).  This 
demonstrates the need for constant consumption of n-3 PUFA in order to maintain some 
of the effects. 
A significant proportion of the literature describing the effects of n-3 PUFA on 
cellular functions utilizes either fish oil, purified DHA, or a combination of EPA and 
DHA (Chapkin et al., 2008c; Fan et al., 2004; Schley et al., 2007).  This can likely be a 
source of some of the inconsistencies in the literature.  Specifically, although many 
commercially available fish oils contain approximately a 2:1 ratio of EPA to DHA, fish 
oils from different sources contain variable mixtures of EPA and DHA.  This can make 
it difficult or impossible to compare results from different studies.  Furthermore, whether 
the effects of n-3 PUFA supplementation are due to EPA, DHA, or both is often 
undetermined and unappreciated.  EPA is both shorter and less unsaturated than DHA, 
and the structural differences between these two fatty acids are enough to result in 
functional differences (Corsetto et al., 2012).  A recent biophysical study in model 
membranes demonstrated differential efficacies of DHA and EPA to modify lipid raft 
composition and organization (Williams et al., 2012).  The data presented herein indicate 
that DHA and EPA have some distinct biological functions but also share some common 
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effects.  It is important for nutritional researchers to appreciate differences in related 
classes of dietary molecules and to not overlook differential effects. 
  This research is integral because it clearly elucidates a mechanism by which 
DHA inhibits colon carcinogenesis.  This knowledge is required to know how to best 
administer DHA to patients, as well as determining which patients are most likely to 
respond to DHA therapy.  This research indicates that patients with cancer that is 
dependent on overexpression or hyperactivation of EGFR might be more responsive to 
DHA therapy than patients who have mutations in other oncogenic pathways.  
Additionally, the work on both DHA and EPA suggests a role for these fatty acids in 
preventing transactivation of EGFR.  Therefore, it is likely that each of these fatty acids 
could benefit some cancer patients whereas others may not respond.  Many of the human 
clinical trials on the role of n-3 PUFA in colon cancer prevention and treatment have not 
observed beneficial effects.  However, this work suggests that patients who are more 
likely to respond to n-3 PUFA therapy could be targeted based on their genetic 
backgrounds, which might make it possible to clearly demonstrate a beneficial effect.  
Comparable to the therapeutic drugs utilized in cancer treatment, dietary interventions 
should be tailored based on individual diseases. 
It is important to appreciate what these data mean for human health.  It is 
noteworthy that DHA can be either beneficial or detrimental for colon health, depending 
on the disease state and severity.  We detailed the effects of DHA on EGFR signaling in 
the context of two diseases, with contrasting health outcomes.  DHA prevented efficient 
wound healing in an acute wounding model by inhibiting EGFR signaling, but reduced 
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carcinogen and inflammation induced colon cancer in part through the same mechanism.  
Therefore, it is imperative that we further elucidate the complexity of the diet-
environment interaction.  The future for the field of nutrition, and medicine in general, is 
in personalization for optimal health.    
  Overall, this body of work demonstrates a mechanism by which DHA alters the 
regulation and signaling of an important oncogenic protein, EGFR.  We detailed a 
mechanism that contributes to the effect of DHA on EGFR.  We observed this effect in 
different disease states, which helps to clarify some of the conflicting literature on the 
role of n-3 PUFA in these diseases.  This work is important for overall human health, 
and it will likely assist future researchers in understanding the role that dietary n-3 
PUFA play in optimal nutrition.    
 
5.3 Future directions 
The research presented herein set the groundwork for a number of futures studies 
that could further delve into the effects of DHA on receptor signaling and function.   
5.3.1 EGFR localization 
  One question remaining is how DHA is altering the localization of EGFR.  
EGFR has been shown to be localized to lipid rafts due to a cysteine-rich juxtamembrane 
region and N-glycosylation (Cummings et al., 1985; Yamabhai and Anderson, 2002).  
Additionally, targeting of proteins to lipid rafts has been shown to be facilitated by lipid 
shells (Anderson and Jacobson, 2002).  Therefore, future studies should focus on 
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determining how DHA alters EGFR localization to lipid rafts.  This type of study would 
then facilitate determining how other receptors might be similarly affected by DHA. 
5.3.2 EGFR ligand binding 
We have clearly demonstrated that DHA alters EGFR dimerization and 
activation, but we did not assess the effect of DHA on ligand binding to the receptor.  
This is obviously a critical step in receptor activation.  Evidence suggests that EGFR 
within lipid rafts is under restraint that confines some receptors from binding to ligand 
(Matveev and Smart, 2002; Ringerike et al., 2002).  Additionally, EGFR within rafts is 
localized in close proximity of other receptors (Saffarian et al., 2007).  Evidence 
suggests that ligand binding to EGFR dimers follows a model of negative-cooperativity 
(Macdonald and Pike, 2008).  This model indicates that receptor dimerization following 
binding of ligand to one monomer reduces the affinity of the unoccupied monomer in the 
dimer for the ligand.  The reduced clustering of EGFR upon treatment with DHA could 
then directly affect ligand binding.  Future studies on binding affinity of EGFR in the 
presence of DHA could further our understanding of the role of DHA in increasing 
receptor dimerization and phosphorylation.  In addition to ligand binding studies, it 
would be interesting to measure the amount of EGFR ligands upon treatment with EPA 
or DHA, both free and tethered to the membrane.   Our transactivation studies indicate 
that both EPA and DHA prevent transactivation of EGFR, perhaps by reducing the 
amount of EGFR ligands that are being cleaved from the plasma membrane.  Therefore, 
measuring the amount of ligand present upon treatment with DHA or EPA could clarify 
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the mechanism of action of these dietary lipids.  Additional studies should further study 
the mechanism by which n-3 PUFA reduce ectodomain cleavage of EGFR ligands. 
5.3.3 Suppression of signal transduction 
In this study, we found two potential contributing mechanisms whereby DHA 
suppresses EGFR signal transduction.  These included reduced colocalization of 
signaling partners within the plasma membrane and increased receptor endocytosis and 
degradation.  However, the contribution of each of these mechanisms to signal 
perturbation remains undetermined.  Future studies should focus on teasing apart the 
impact of these mechanisms on signaling.  One potential way to study this would be to 
inhibit receptor endocytosis and assess EGFR signaling.  Dynamin plays a fundamental 
role in EGFR endocytosis, and inhibition of dynamin significantly impairs receptor 
endocytosis and degradation (Sousa et al., 2012).  Therefore, future studies could utilize 
dynamin inhibition to analyze the effects of DHA on EGFR signaling under endocytosis-
competent and endocytosis-impaired conditions.  This would provide further 
understanding of the mechanisms of action of DHA.   
5.3.4 Mode of receptor endocytosis  
It is also important to probe more fully into the observed effect of DHA on 
EGFR endocytosis.  Multiple modes of receptor endocytosis, including clathrin-
dependent and lipid-raft dependent endocytosis, have been shown to be involved in 
EGFR internalization, and the mode of internalization often dictates the fate of the 
receptor (Goh et al., 2010; Orth et al., 2006; Puri et al., 2005; Roepstorff et al., 2009; 
Sigismund et al., 2008; Sorkin and Goh, 2009).  Therefore, future studies should focus 
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on elucidating which of these endocytosis mechanism(s) DHA is altering to increase 
EGFR endocytosis.   
5.3.5 EGFR trafficking 
Additionally, following EGFR endocytosis, EGFR is trafficked through multiple 
endosomes, which can ultimately lead to translocation of the receptor to distinct 
destinations.  EGFR can be trafficked to lysosomes for degradation, returned to the 
plasma membrane to signal, or targeted for key organelles including the nucleus and the 
mitochondria (Demory et al., 2009; Sorkin and Goh, 2009; Wang et al., 2010).  The 
evidence provided herein that EGFR localization, internalization, and degradation are 
being affected by DHA strongly indicates that this fatty acid can affect EGFR 
trafficking.  Due to the importance of EGFR localization in cancer (Lo, 2010), it is 
imperative for future studies to analyze intracellular receptor trafficking. 
5.3.6 Ras activation 
Another obvious future direction is to determine the localization of Ras 
activation.  Ras has been shown to be activated largely at the plasma membrane but also 
in endosomes (Prior and Hancock, 2011; Wiley and Burke, 2001).  We hypothesize that 
activation of Ras is inhibited at both sites by treatment with DHA.  Based on current 
evidence, we predict that activation at the plasma membrane would be suppressed due to 
the altered localization of EGFR and Ras, specifically H-Ras.  Additionally, rapid 
ubiquitination and degradation of the receptor would reduce the amount of Ras being 
activated in endosomes.  Additionally, the altered PM localization of EGFR could 
modify the amount of EGFR and Ras that would be localized within an endosome and 
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thereby diminish the capacity of EGFR to activate Ras in endosomes.  We currently have 
probes that bind specifically to activated Ras.  These could be utilized to determine 
where Ras is being activated in order to assess how DHA is altering its activation.  Due 
to the role of Ras activation in colon cancer, further understanding of the role of DHA in 
regulating Ras activation could be beneficial.   
5.3.7 Human study 
We have performed both cell culture and animal studies to observe the effect of 
DHA on EGFR function.  A logical extension of this research is to move into a human 
model.  We predict that long term exposure to DHA could prevent colon carcinogenesis 
by impeding early transformation events that are mediated by EGFR.  Furthermore, we 
hypothesize that humans with overexpression and/or hyperactivation of EGFR are more 
likely to respond to treatment with DHA.  A human study with careful attention to the 
genetics of patients who respond to this therapy could fully elucidate the mechanism of 
action of DHA.  Studies on the efficacy of anti-EGFR therapies have shown that only 
approximately 10% of patients are responsive (Fiske et al., 2009), and patients with 
activating mutations of K-Ras are not responsive to this therapy (De Roock et al., 2008).  
It is likely that DHA will be effective in patients with a similar genetic background.  
Furthermore, it would be interesting to extend our EPA versus DHA comparisons in a 
human model.  We predict that, by reducing transactivation of EGFR, EPA could be 
effective in preventing EGFR-mediated colon cancer.  Due to the complexities of cancer 
and the multiple mechanisms of action of n-3 PUFA, well designed and thorough human 
studies are imperative.   
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5.3.8 Activation of other ErbB family receptors 
EGFR does not function alone.  There are three other members of the ErbB 
family in addition to EGFR, including ErbB2, ErbB3, and ErbB4. Compared to EGFR, 
the other ErbB family members are not as well researched, especially in the context of 
the colon.  ErbB2 is very sparsely expressed in normal colonic tissue, but it is highly 
expressed in colon cancers (Kapitanovic et al., 1997).  Additionally, targeted deletion of 
ErbB3 in the mouse intestine was found to prevent colon tumor formation (Lee et al., 
2009).  Little is known about the role of ErbB4 in colon cancer, but it has been found to 
promote cell survival of colon epithelial cells (Frey et al., 2010).  Each of the ErbB 
family members has been indicated to be important during different stages of colon 
cancer (Lee et al., 2002).   Evidence has been presented for localization of ErbB2 and 
ErbB4 to lipid rafts (Chinni et al., 2008; Ma et al., 2003; Nagy et al., 2002), suggesting 
that DHA could affect activation of these receptors in a similar manner to EGFR.  
Moreover, EGFR can function in a heterodimer with each of the other family members, 
and each of the heterodimers serves to stimulate different cellular functions (Fiske et al., 
2009; Olayioye et al., 2000).  Research focused on the effect of DHA on activation, 
dimerization, heterodimerization, and signaling of the entire family of ErbB receptors 
may reveal additional aspects of the role of DHA in colon cancer prevention. 
5.3.9 Lipid raft receptors 
This research suggests that the effect of DHA on lipid rafts could potentially 
affect other lipid raft localized receptors.  Many receptors have been found to be 
localized to lipid rafts and caveolae, and there is substantial evidence that lipid rafts 
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mediate numerous signal transduction events.  Other receptor tyrosine kinases that have 
been shown to be localized to lipid microdomains or signal from rafts in the plasma 
membrane include platelet-derived growth factor receptor (localized to caveolae), insulin 
receptor (localized to caveolae), and fibroblast growth factor receptor (signals from 
rafts) (Pike, 2005).  Although it is unclear whether DHA equally affects caveolae and 
lipid rafts, it would be interesting to evaluate the effect of DHA on signaling through 
these receptors.   
5.3.10 Lipid rafts 
 Cogent evidence has been presented to show that different classes of lipid rafts 
exist (Asanov et al., 2010; Hofman et al., 2008; Lingwood et al., 2009; Patra, 2008).  
Current work on the effects of DHA on lipid rafts has largely grouped all lipid rafts, 
along with caveolae where applicable, into one category.  With significant strides being 
made in the field of microscopy, future work should focus on differentiating between 
rafts and determining the unique effects of DHA on each class of raft.  This type of work 
could substantially impact the field of membrane research, which directly ties into 
innumerable aspects of human health.  
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APPENDIX A 
YAMC CULTURING PROTOCOLS  
 
 
I.  Preparation of Complete RPMI media for YAMC culture 
Ref: Fan et al. Am J Physiol. 1999 Aug;277(2 Pt 1):C310-9; Ng et al. Carcinogenesis. 
2005 Nov;26(11):1914-21. 
 
Purpose: To prepare complete RPMI media for YAMC cell culture 
 
Materials:  
500 mL RPMI without glutamine (Mediatech # 15- 040 CV) 
26.6 mL Fetal Bovine Serum (Hyclone AK 12434) 
5.3 mL Glutamax (Gibco, 35050-061) 
0.532 mL ITS “-” minus (Insulin, Transferrin, Selenious acid without Linoleic acid) 
(Collaborative Biomed products, # 4351) 
Reconstitution of ITS “-”: add 5 mL of sterile distilled water into lysophylized 
powder. 1 mL of ITS is sufficient for 1 L of media (0.1% dilution) 
 
Procedure : 
1.  Thaw Glutamax and FBS at 4°C overnight  (You can just thaw them the day of assay 
in 37°C for short time) 
2.  Add Glutamax, FBS and ITS “-” into 1 bottle of RPMI 1640 media. 
3.  Gently tilt the bottle to mix 
4.  Label with initials, date, sterile, and complete then store at 4°C. 
 
Final volume: 531.9 mL 
Final concentration: 5% FBS, 1 % Glutamax, 0.1% ITS 
Insulin  5 g/ mL 
Transferin   5 g/ mL 
Selenious acid  5 ng/ mL 
 
The following reagent is to be added fresh into the media before use: 
5 units -IFN (Gibco BRL, #13284-021) per 1 mL complete RPMI 1640 media.  
Add 1mL -IFN per 10 mL of complete RPMI 1640 medium just prior to use. 
 
 
II.  Preparation of YAMC Cell Culture 
Ref: Fan et al. Am J Physiol. 1999 Aug;277(2 Pt 1):C310-9; Ng et al. Carcinogenesis. 
2005 Nov;26(11):1914-21. 
 
Purpose: To start YAMC culture by growing cells in a T-75 flask. 
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Preparation: 
Turn on the UV in the hood for at least 15 min prior to keep it sterile for culture 
 
Procedure: 
1. Warm complete RPMI 1640 media to room temperature 
2. Aliquot 10 mL media in a 15 mL conical tube (to spin down frozen cells) and 
make up 20 mL complete media with 2 L -IFN (to resuspend and grow cells) 
3. Take a vial of YAMC cells from the liquid nitrogen storage system 
4. Thaw it in the water-bath immediately by gently twirling around in the water 
bath for ~ 30sec. to reduce the condensation 
5. Add thawed cells into the media in the conical tube 
6. Centrifuge at 200 x g (1096 rpm: tabletop centrifuge) for 5 min 
7. Using sterile technique, open a T-75 flask and add 12 mL complete media (with 
-IFN) 
8. Following completion of spin, vacuum aspirate the supernatant being careful not 
to disturb pellet 
9. Resuspend the pellet in 5 mL complete RPMI 1640 (with -IFN) 
10. Add resuspended cells into the T-75 flask with media, label the flask - specify the 
cell type,  passage number, date and initials  
11. Gently rotate the flask to distribute the cells evenly 
12. Incubate the flask at 33˚C under 5% CO2 atmospheric pressure 
 
 
III.  Feeding of YAMC Cell Culture 
Ref: Fan et al. Am J Physiol. 1999 Aug;277(2 Pt 1):C310-9; Ng et al. Carcinogenesis. 
2005 Nov;26(11):1914-21. 
 
Purpose: To feed YAMC culture by growing cells in a T-75 flask. 
 
Preparation: 
Turn on the UV in the hood for at least 15 min prior to keep it sterile for culture 
 
Feeding cells: 
Check cell confluence every day 
Feed cells every 24-48 h (maximum 72 h) 
 
Procedure: 
1. Prepare 20 mL RPMI 1640 media with 2.0 µL -IFN.  Warm to 33oC. 
2. Vacuum aspirate old media from the flask of cells using sterile glass pipette.  
3. Add the pre-warmed fresh RPMI 1640 media with -IFN to the flask. 
4. When culture reaches 70-90% confluence, trypsinize the cells and pass them 
(refer to protocol). 
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IV.  YAMC Cell Culture: Seeding, Passing or Freezing 
 
Purpose: To pass and seed or freeze YAMC cell culture. 
 
Preparation: 
Use sterile hood conditions for the procedure 
Warm 50 mL complete RPMI 1640 and trypsin-EDTA (Gibco, #25300-054) to room 
temperature 
 
Procedure:  
For any 70% confluent cell culture in a T-75 flask: 
1. Add 15 mL complete media in a 50 mL conical (to spin cells) – always use at 
least 2X as much media as trypsin to spin down cells after trypsinization.  
2. Add 25 mL media plus 2.5 L -IFN to a 50 mL conical (to grow cells)  
3. Warm both conical of media in water bath (37oC) 
4. Aspirate old media from flask 
5. Rinse monolayer of cells with ~10mL HBSS (Sigma, H-6648) by adding and 
aspirating gently without disturbing the cell monolayer 
6. Add 5 mL Trypsin-EDTA to the flask and incubate cells at 37˚C for 3 minutes or 
until > 90% cells are lifted.  Gently tap the bottom of the flask to assist in cells 
lifting. 
7. Add the 15 mL complete media (step 1) from the conical tube to the flask of 
trypsinized cells (add by rapidly dispensing the media and moving the pipette in a 
back and forth motion across the flask to dislodge any stuck cells).  Then, transfer 
the media and trypsin to the 50 mL conical tube. 
8. Use a glass pipette to transfer approximately 10 μl of the cell suspension onto 
each end of the hemacytometer.  
Count the number of cells:  Cell number (per mL) = Living cells count x 10,000 
 # Squares counted  
 
9. Centrifuge cells at 200 x g (1096 rpm, countertop centrifuge for 5 min) 
10. Vacuum aspirate supernatant (media with trypsin), taking care not to disturb the 
pellet 
 
A.  Procedure to reseed cells  
a) Add 5 mL of complete RPMI 1640 (with -IFN) and resuspend the pellet by 
gently pipetting up and down to make a homogenous suspension. 
(you can also gently tap the “almost dry” pellet before resuspend with medium, 
to help with resuspension) 
b) Seed cell according to desired density in complete RPMI 1640 with γ-IFN.  
 
 
B.  Procedure for cell freezing (to store) cells in liquid nitrogen 
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a) After step 8 in the cell passage protocol, resuspend cells in freezing media 
(EmbryoMax, # S-002-D) Normally, we want to freeze ~ 1-2 million cells/mL  
b) Add 1 – 1.5 mL of cell suspension to cryovials 
c) Label the vials with the cell type, passage number, date, and initials 
d) Keep vials in Mr. Frosty (Nalgene, #5100-0001) at –80˚C for 24-48 h and then 
transfer vials into liquid nitrogen for storage 
e) Enter the rack, box # and vial position into cell culture log book. 
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APPENDIX B 
 
GENERAL EGF STIMULATION OF YAMC  
 
 
Purpose:  To stimulate EGFR activation in YAMC  
 
Materials: 
EGF (Sigma Sigma #E 1257) 
RPMI 1640 (Mediatech # 15040CV) complete and serum starvation: 
Complete: To a 500 mL bottle, add 532 µL ITS Premix (BD Biosciences 
#354351), 26.6 mL fetal bovine serum (FBS, Hyclone SH30070.01), and 5.3 mL 
Glutamax (Gibco 35050).  Immediately prior to use, add 1 µL IFNγ (Gibco 
#13284-021) per 10 mL complete media. 
Serum starvation:  Immediately prior to use, to plain unsupplemented RPMI 
1640 add FBS to a final concentration of 0.5%.  Also add 1 µL IFNγ (Gibco 
#13284-021) per 10 mL complete media. 
 
Procedure: 
1. Culture YAMC cells in complete media (plus any treatment) at 33°C and 5% 
CO2 until they become ~95% confluent. 
2. Aspirate complete media and wash cells 2X with PBS. 
3. Add serum starvation (0.5% FBS) media and incubate overnight (16-18 h) at 
33°C and 5% CO2. 
4. Add EGF to plain unsupplemented RPMI 1640 to a final concentration of 25 
ng/mL (stock EGF is 10 ng/µL). 
5. Remove serum starvation media from the cells and replace with EGF-
supplemented media.  Incubate cells 33°C and 5% CO2 for the amount of time 
required by the experiment (typically 2-30 min). 
6. Aspirate media from the cells and wash with PBS.   
7. Harvest cells according to the experiment. 
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APPENDIX C 
 
TOTAL CELL LYSATE ISOLATION  
 
 
Purpose:  To isolate cell lysate from YAMC cells in 150 mm dishes 
 
Materials: 
Prepare 5 mL of Homegenization buffer (this is the standard HB used in the Chapkin 
lab, but buffer is subject to change based on the experiment): 
500 l of 500 mM Tris-HCl (Sigma #T1503) – Final concentration = 50 mM 
1.25 mL of 1 M sucrose (Sigma #S9278) – Final concentration = 250 nM 
50 L of 200 mM EDTA(Sigma #ED4SS) – Final concentration = 2 mM   
50 L of 100 mM EGTA (Sigma #34596) – Final concentration = 1 mM 
0.625 L of 0.4 M NaF (Sigma #S6521) – Final concentration = 50 µM  
500 L of 10% Triton-X (Sigma #T6878) – Final concentration = 1% 
2395.875 L of double distilled water 
50 L of 10 mM activated sodium orthovanadate (Sigma #S6508) – Final concentration 
= 100 µM 
200 L of protease inhibitor cocktail (Sigma #P8340)   
3.5 L of 14.2 M β-mercaptoethanol (Bio-Rad #161-0710) – Final concentration = 10 
mM 
Items in red are to be added on the day of use 
Cell scrapers 
29-gauge needles 
 
Procedure: 
1. Aspirate media from the dishes and wash with 15 mL ice-cold PBS.  Gently swirl 
the plate and suck off the PBS (to thoroughly remove all traces of media).  
Repeat PBS washes 3X.  Make sure to remove all PBS after the final wash to 
prevent diluting the homogenization buffer. 
2. Keep the plates on ice and add 300 µl of HB per dish and scrape cells using a cell 
scraper.   
3. Transfer the lysate into eppy tubes.  
4. Pass through 29G needle once into the same set of eppy tubes, flush the 
suspension very hard to sheer the cells (perform on ice). 
5. Incubate the total lysate in ice for 30 min.  
6. Centrifuge at 16, 000 x g at 4°C for 20 min. 
7. Transfer the supernatant (lysate) to clean eppy-tube and pipette up and down to 
mix. 
8. Prepare 30 l aliquots and one 10 µL aliquot of each sample, and save aliquots at 
-80°C for further protein estimation using Coomassie Plus and immunoblotting. 
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APPENDIX D 
 
COOMASSIE ASSAY  
 
 
Purpose:  To determine the protein concentration of samples 
 
Materials: 
Homogenization buffer (whichever was used to collect samples) 
EIA/RIA clear polystyrene 96-well plate (Corning #9017) 
Coomassie Plus assay reagent (ThermoFisher #23238) 
Disposable borosilicate glass tubes (VWR #47729-572) 
 
Procedure: 
1. Use this assay with homogenization buffer (HB) used to collect the total cell lysate 
(TCL). 
2. Before beginning, turn on SpectroMax and prepare a template. 
3. Prepare samples and standards in glass tubes by mixing the amounts of 
standard/sample, water, HB, and reagent listed below.  Make triplicates of all 
samples and standards. 
4. After adding everything to each tube, vortex tubes for 3 s and transfer 300 l of 
standard/sample to the designated well on the 96-well plate. 
5. Immediately after adding all standards and samples to the plate, bring to the 
SpectroMax plate reader and read at 595 nm. 
 
Standards: 
Total g Protein 0.25 g/ l BSA  1 g/ l BSA   2 g/ l BSA
   Water     HB Reagent Position  
0 0 l --   --    497.5 l    2.5 l 500 l
 A 1-3 
0.5 2 l --   --    495.5        2.5 500 l B 1-3 
1.0 4 l --   --    493.5        2.5 500 l C 1-3 
2.0 -- 2 l   --    495.5        2.5 500 l D 1-3 
4.0 -- 4 l   --    493.5        2.5 500 l E 1-3 
10.0 -- 10 l   --    487.5        2.5 500 l F 1-3 
20.0 -- --  10 l   487.5        2.5 500 l G 1-3 
 
 
Samples: 
Amt Sample Water Reagent 
2.5 l 497.5 l 500 l 
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APPENDIX E 
 
LIPID RAFT ISOLATION 
 
 
Purpose: To isolate the plasma membrane and use gradient ultracentrifugation to 
harvest lipid raft/caveolae fraction for analysis. 
 
Reference: Kim W, et al. Methods Mol Biol 2009;579:261-70 
 
Materials: 
Sucrose (Sigma #S9378) 
Na4EDTA (Sigma #ED4SS) 
Tricine (Sigma #T-5816) 
Optiprep (Sigma #D1556) 
Percoll (Sigma #P1644) 
Slide-a-lyzer dialysis cassettes (Pierce #66205 and 66203) 
Protease inhibitor cocktail (Sigma #P8340) (1:25 dilution) 
10 mM activated sodium orthovanadate (Na3VO4, Sigma #S6508) 
 
 
Solutions:        
(all solutions make fresh, except PBS and Sucrose) 
1X PBS :  500mL warm (37
o
C), 500mL cold (4
o
C) 
2.5M Sucrose: 
 427.8g Sucrose 
 -Combine with water, heat to 60
o
C to dissolve, final volume to 500mL 
 -Store at 4
o
C 
Buffer A : (stable for 1 week stored at 4
o
C)        Final Conc:   
 20mL 2.5M Sucrose     0.25M 
 0.076g Na4EDTA       1mM 
 0.716g tricine     20mM 
 -Combine with 170mL water, pH to 7.8, bring to final volume of 200mL 
 
To 10 mL of Buffer A, add 400 µL of protease inhibitor cocktail and 100 µL 
Na3VO4 (final concentration 100 µM).  Use this in step #11 
2XA :  (Stable for 1 week stored at 4
o
C)           
 13.32mL 2.5M Sucrose      0.5M 
 0.05g Na4EDTA       2mM 
 0.48g tricine      40mM 
 -Combine with 40mL water, pH to 7.8, bring to final volume of 66.6mL 
OptiPrep Diluent : (stable for 1 week stored at 4
o
C)            
 1mL 2.5M Sucrose    0.25M 
 0.022g Na4EDTA       6mM 
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 0.216g tricine             120mM 
 -Combine with 7mL water, pH to 7.8, bring to final volume of 10mL 
30% Percoll :   Don't make until ready for use! 
 30mL Percoll 
 50mL 2XA 
 20mL water 
50% Opti-Prep (Gibco) : 
 36mL OptiPrep 
 7.2mL OptiPrep diluent 
OptiPrep Solutions: 
5%  -0.4mL 50%OptiPrep+3.6mL Buffer A       10% -2.94mL 
50%OptiPrep+11.74mL Buffer A 
15%-1.5mL 50%OptiPrep+3.5mL Buffer A       20% -5.86mL 
50%OptiPrep+8.8mL Buffer A 
Dialysis buffer: 
1 mM Na4EDTA 
20 mM tricine (pH 7.8) 
 
Procedure: 
1.   Grow YAMC cells in T-175 flasks (need approximately 8 flasks of YAMC cells for 
n=1 per treatment). 
2.   Aspirate media from the flask and wash with 20 mL PBS. 
3.    Aspirate PBS and add 10 mL trypsin. 
4. Place flask in 37
o
C incubator for 3-5 min until all cells are lifted. Tap the bottom of 
the flask to help release cells.  Stop trypsinization with 20 mL of media. 
5.    Place trypsinized cells into a 50 mL conical tube. 
6.    Count cells using hemacytometer. 
7.    Centrifuge cells at 200 x g for 5 min. 
8.    Aspirate trypsin/media from the tube without disturbing the pellet. 
9.    Wash the pellet with PBS and centrifuge at 200 x g for 5 min. 
10.  Aspirate PBS and repeat wash/centrifuge step. 
11.  Aspirate PBS and resuspend pellet in Buffer A with protease inhibitor cocktail and 
phosphatase inhibitor at 1.15-1.2 x 10
7
 cells/mL.  Put into cryovials. 
12.  Lyse cells by performing a rapid freeze (place in liquid nitrogen for 1 min) and thaw 
(place in a 37
o
C water bath for 1 min) twice.   
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13.  Combine cryovials of samples from the same group, save an aliquot (~100 µL) as 
Sample A, and spin at 1000 x g, for 10 min at 4
o
C.     
-During the spin, pre-cool ultracentrifuge and make 30% Percoll. 
14.  Collect supernatant (post-nuclear) and keep on ice. 
15.  Save an aliquot (~100 µL) and label as Sample B. 
16.  Load supernatants on top of 23 mL of 30% Percoll in 38.5 mL Beckman Ultra-clear 
centrifuge tube (Beckman #344059). 
17.  Centrifuge in Beckman SW28 at 84,000 x g (25,000 rpm) for 30 min, 4
o
C. 
 -Meanwhile make remaining OptiPrep Solutions 
18.  Collect 2 mL plasma membrane fraction (visible band ~6 cm from the bottom of 
tube). Place in 15 mL Beckman tube (#343664).  Save aliquot (~100 µL) as Sample 
C. 
19.  For sonication, use the Sonics & Materials sonicator (Model VC50T, Serial 
#344058). 
Set power output 90, J/w/s 50, pulser off.   
       Tune probe in Buffer A before sonicating sample. 
To sonicate sample, place the sample on ice and place the sonicator probe in center 
of solution and sonicate 2X with rapid pulse. 
       Sit on ice 2 min.  
       Repeat rapid pulse 2X, sit on ice 2 min.   
Repeat rapid pulse 2X, put back on ice. 
20.  Prepare 23% Opti (2 mL Sample + 1.84mL 50%Opti + 0.16mL Buffer A) and add 
to 12 mL Beckman Ultra-clear centrifuge tubes (#344059).  On top, layer a linear 
20% to 10% Opti gradient (3 mL each) using a gradient maker connect to a 
peristaltic pump set at a flow rate of 1 mL/min. 
21.  Centrifuge at 52,000 x g (17,000 rpm) 90 min, 4
o
C in SW41 Ti rotor. 
22.  Collect top 5 mL into new tube.  Save aliqot (~100 µL) as Sample D.   
23.  Collect visible cloudy band below and save as Sample E. 
24.  Add 4 mL 50% OptiPrep to sample and mix. 
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25.  Overlay with 1 mL 15% OptiPrep followed by 0.5 mL 5% OptiPrep. 
       Centrifuge at 52,000 x g (17,000 rpm) 90 min, 4
o
C. 
26.  Collect top white band (500-700 µL) within 5% Opti layer, just above interface. 
       Collect additional band below (Sample F). 
27.  After sample collection, dialyze using slide-a-lyzer cassettes using dialysis buffer. 
Dialyze overnight at 4
o
C, change buffer, dialyze 1 h at 4
o
C. 
28.  After dialysis, use Savant Automatic Environmental SpeedVac System (#AES1010) 
and speed-vac samples to between 1/3 and 1/4 original volume to concentrate.  
Follow SpeedVac settings given on the machine. 
29.  Perform Coomassie to determine protein assay. 
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APPENDIX F 
 
COLOCALIZATION ANALYSIS  
 
 
Purpose: To determine the colocalization of EGFR with a lipid raft marker (truncated 
H-Ras) in cells treated with DHA, LA, or control. 
 
Materials: 
Effectene transfection reagents (Qiagen #301425) 
Lab-Tek chambered coverglass #1.0 (Thermo Scientific #155380) 
RPMI 1640 (Cellgro #15-040-CV) 
Gibco Leibovitz L-15 media, no phenol red (Life Technologies #21083-027) 
 
Procedure: 
1. Seed YAMC cells in Lab-Tek 2-well chambered coverglass at a density of 1.0 x 
10
5
 and incubate at 33
o
C with 5% CO2.   
2. After 4 h (allow cells to adhere), change media and add FA to a final 
concentration of 50 µM and incubate O/N. 
3. After 24 h, aspirate old media and replace with fresh (including FA). 
4. Dilute stock of RFP-tH to 0.1 µg/µL with sterile TE. 
5. After 12 h, transfect cells with 0.3 µg RFP-tH using Effectene according to the 
manufacturer’s instructions.  See HFT protocol “Lipofection of YAMC in 2-well 
slides” for detailed instructions.  Use the amount of reagents specified for a 12-
well plate in the manufacturer’s protocol. 
Volume DNA:  3 µL (for 0.3 µg) 
Enhancer volume: 2.4  µL 
Buffer EC:  72 µL 
Effectene Reagent:  6 µL 
Volume of media to add to cells:  800 µL 
Volume of media to add to complexes:  400 µL 
6. After 12 h, transfect cells again with 1.0 µg EGFR-GFP using Effectene 
according to the manufacturer’s instructions 
7. After 8 h, cells were washed once with PBS and placed in serum starvation 
(0.5% FBS) media at 33
o
C with 5% CO2. 
8. After 16 h, bring cells to the Image Analysis Lab and placed in the incubator at 
33
o
C with 5% CO2. 
9.  Immediately prior to imaging, wash cells once with PBS and then replace with 
Leibovitz media with no phenol red. 
10. Collect images on the Zeiss 510 META NLO Multiphoton Microscope System 
consisting of an Axiovert 200 MOT microscope (Carl Zeiss Microimaging).  For 
EGFR-mGFP, use excitation wavelength of 488 nm and emission of 530 nm.  
For RFP-tH, use excitation of 543 nm and emission of 590 nm.  Collect images 
in confocal mode with the pinhole set at 1 AU using a 40x objective (1.3 NA oil 
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immersion lens) at room temperature.  Identical acquisition parameters must be 
used for all images within the experiment. 
11. Quantify colocalization at the plasma membrane using Mander’s colocalization 
coefficient for green (EGFR-mGFP) with red (RFP-tH) using Nikon Elements 
AR 3.2.  Perform analysis on background-subtracted 16-bit images. 
 
Tip for slide layout: Put different treatments on the same slides so that if a slide 
is lost or damaged, you do not lose 2 of the same group. 
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APPENDIX G 
 
WESTERN BLOTTING 
 
 
Purpose:  To measure the amount of total or phosphorylated proteins 
 
Preparation: 
-Thaw samples on ice 
-Label 0.6 mL eppy tubes 
-Turn heating block on and set temperature to 98 C 
-Prepare the western template sheet  
- Cut PVDF membrane and filter papers ready 
  
Procedure: 
Sample preparation 
1.  Thaw the samples on ice while you turn on the heating block and set the temperature 
to 98°C (takes about 15 min).  
2.  Dye used for the sample dilution is 5X Pyronin. Use 1X of the dye based on the total 
volume of sample required (usually 25 mL total).  
3.  With the aid of western template sheet make the necessary dilution (if required) and 
add the calculated amount of dye and water to the samples and standard. 
4.  Quick spin. 
5.  Boil the samples for 5-10 min depending on the volume of the samples (25 mL 
volume boil for 10 min). Do not boil the marker. 
6.  Quick- spin of the samples on the tabletop. 
 
Gel unit set up  
7.  Take the pre-made gel (usually 4-20%) and carefully rip off and discard the white 
tape and the comb.  Mark the lanes on the plate. 
8.  Attach the gel to the gel rack align 3rd with the lower gasket and clamp the unit. 
(Note that the red clip should have the broad end facing you, broad ends face outside on 
all 4 clips).  Either run a gel on each side or attach the white space holder on the empty 
side. 
9.  Pour running buffer to fill the stand and the trough up to the top mark. 
10.  Use gel-loading tips (or 10 mL XL tips) and load the complete sample volume. 
11.  Close the unit with the lid and check the leads and make sure black-to-black and 
red-to-red. 
12.  In the cold room run the gel at 125 V for as long as needed.  Check after 10 minutes 
to make sure it is running. 
13.  After about 1 h check every 15 min. 
14.  Stop the gel when it has run as far as needed. 
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Gel transfer 
15.  Crack open the plate with a scalpel between the markings on the plate all around by 
keeping the large side of the gel down. 
16.  Cut the gel just above the bottom. 
17.  Carefully separate the gel from the plate and cut the gel at lane one to identify the 
side (left end). 
18.  Take the gel transfer unit in a staining tray and pour transfer buffer into it and the 
trough.  Allow gel to equilibrate in transfer buffer for 15-30 min.  Wet membrane with 
methanol then equilibrate in transfer buffer for ~5 min. 
19.  Take the cassette and lay it open. 
20.  Put a sponge on the black side of the cassette and place a filter paper on top of it. 
21.  Pour transfer buffer to keep it wet. 
22.  Take the gel plate out of the running trough and transfer the running buffer into the 
bottle for reuse. 
23.  Place the gel on the filter paper with lane one on the right (protein side facing the 
membrane. 
24.  Cut the right hand top corner of the membrane to identify the side. 
25.  Place the membrane on the gel and place the other filter paper on the membrane. 
Now, use a roller on the filter paper to eliminate any air bubbles in between. 
26.  Place the sponge and close the white side of the cassette and clip it.  
27.  Place the cassette in the transfer unit with the hinges facing the top and black side 
facing back. 
28.  Put a stir bar into the transfer trough. 
29.  Fill the trough with transfer buffer just enough to cover the hinges of the cassette. 
Check the terminals black to black correspond. 
30.  Place it on the cold room stir plate. 
31.  Connect black-to-black and red-to-red and set current to 400 milliamps and let it 
transfer for at least 90 min. 
 
Blocking 
32.  At the end of 90 min- make 4% nonfat dry milk/ PBS/ Tween in a 50 mL tube (to 30 
mL of PBS –Tween and add 1.2 gms of pre-weighted milk powder). Mix gently by 
inverting.  If 5% BSA is required, add 1.5 g IgG free BSA to 30 mL PBS-T. 
33.  Pour the milk into a dish and keep ready to transfer the membrane into it. 
34.  After the transfer is complete- open the gel unit and transfer the transfer buffer into 
the bottle. 
35.  Use a pair of forceps to take the membrane and place the membrane into the milk 
dish (with the side facing gel-protein side now facing top) 
36.  Place it on the shaker for 1 hr at room temperature. 
 
Primary antibody 
37.  Take a dish with 1.2 gm dry milk powder and 30 mL PBS- Tween. Mix and pour 
into a new dish. 
38.  Transfer the membrane from the blocking buffer into the dish with fresh milk.  
 203 
 
39.  Now, add the appropriate volume of the primary antibody (based on the dilution and 
add it into the dish). 
40.  Close the lid of the dish and shake it gently on the cold room shaker overnight. 
 
Washing 
41.  The next day take the membrane and give a quick wash with PBS –Tween. 
42.  Then replace the membrane in fresh PBS- Tween in the dish and keep on the shaker 
at room temp for 10 min. Let it shake vigorously. 
43.  Repeat the wash 2 times at 5-10 min interval. 
 
Secondary antibody 
44.  Make 30 mL milk/ PBS/ Tween and pour into the dish after the second wash. 
45.  Add the required volume of secondary antibody based on the dilution. 
46.  Set on shaker for 1 hr at room temperature. 
47.  Repeat washing with PBS –Tween 3 times. 
48.  While the 1 wash of 2° antibody is going on turn on the imager and set focus. 
 
Developing 
49.  Cut an acetate sheet into 2 halves and remove the black sheet. 
50.  Mix equal parts of chemiluminescent super signal reagent A and reagent B in an 
ependroff tube. Mix gently by inversion. 
51.  Transfer the membrane between the layers of the acetate sheet and evenly disperse 
the developing solution across on the top of the membrane.  
52.  Slowly close the top layer so that the solution gets evenly distributed on the 
membrane. 
53.  Expose for 5 minutes and then transfer the membrane on to the clean acetate sheet . 
54.  Transfer it into the BioRad imager for imaging immediately. 
 
Imaging 
55.  Turn on switch and make sure the lever on the hood is at chemiluminescence. 
56.  Select QuantityOne on program on desktop. 
57.  Select scanner – click on chemidoc.xrs. 
58.  Step 1- option is chemiluminescences.  
59.  Step 2 – live focus. Focus with a printed sheet and set the iris as you need for 
brightness. Zoom and focus, as you need for clarification. 
60.  Freeze. Put the gel in the imager and zoom and freeze again. Close the door. 
61.  Click on live acquire. 
62.  Set the Starting exposure time, Total exposure time, and Number of exposures as 
needed. 
 
Special instructions if western blotting for p-EGFR 
a. Perform blocking steps (#32-36) using Invitrogen Membrane Blocking Solution 
(MBS; 00-0105). 
b.  Following blocking, wash the membrane for 5 min with TBS-T. 
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c.  Incubate membrane with antibody diluted 1:1000 in MBS O/N at 4°C with slow 
rotation. 
d.  Wash membrane according to protocol with TBS-T. 
e.  Incubate the membrane with secondary antibody diluted in 4% milk in TBS-T for 1 h 
at RT with slow rotation. 
f.  Finish protocol (#47-62) according to directions above using TBS-T. 
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APPENDIX H 
 
IMMUNOPRECIPITATION  
 
 
Purpose: To perform immunoprecipitation or co-immunoprecipitation of EGFR 
 
Reference:  Current protocols in protein science 19.4.5 
 
Materials: 
Immunoprecipitation Buffer (for 5 mL): 500 uL of 500 mM Tris-Cl (pH 7.5) (Fisher 
#BP153), 750 µL of 100 mM EGTA (Sigma #E4378), 1 mL of 500 mM NaCl (Sigma 
#S3014), 50 µL of 10% Triton X (Sigma #X-100), 250 µL of 10 mM activated sodium 
orthovanadate (Sigma #S6508), protease inhibitor cocktail (Sigma #P8340), 3.5 µL β-
mercaptoethanol (Sigma #M6250).  Add ingredients in red on the day of use. 
Protein G Dynabeads (Invitrogen #100.04D) 
Magnet (Invitrogen: DynaMag-2 #123.21D; Sample rack #123.22D) 
Anti-EGFR antibody (Millipore #06-847) 
 
Procedure: 
1. Harvest YAMC cells according to the Total Cell Lysate preparation protocol, but 
use the Immunoprecipitation Buffer described above in place of the 
Homogenization Buffer from the protocol.  Perform Coomassie protein assay to 
determine protein concentration. 
2. Prepare samples on ice by combining 250 µg total cell lysate with 25 µL 
antibody.  Add immunoprecipitation buffer to bring to a final volume of 500 µL. 
3. Invert tube gently several (5-7) times followed by incubation on ice for 90 min 
with occasional tube inversion (~every 5 min). 
4. Prepare Protein G Dynabeads by completely resuspending beads by rotating on 
orbital shaker for ~5 min.  Transfer 50 µL Dynabeads to an eppy-tube.  Separate 
on the magnet until the supernatant is clear and remove the supernatant. 
5. Quick-spin the tube from step #3, and add the antibody-antigen (Ab-Ag) mixture 
to the tube with dynabeads. 
6. Rotate tube at 4°C for 1 h. 
7. Place tube on magnet and allow to separate until the supernatant is clear. 
8. Save the supernatant as “flow through”. 
9. Wash the Dynabeads-Ab-Ag complex by adding 200 µL of lysis buffer to the 
tube and resuspending by gentle pipetting.  Separate on the magnet and remove 
supernatant (discard).  Repeat the wash 2 more times. 
10. Resuspend the Dynabeads-Ab-Ag complex in 100 µL lysis buffer and transfer 
the bead suspension to a clean tube.  This is recommended to avoid co-elution of 
proteins bound to the tube wall. 
11. Place the tube on the magnet and remove the supernatant. 
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12. Add 50 µL 2X pyronin and gently pipette to resuspend the dynabeads-Ab-Ag 
complex. 
13. Heat to 98°C for 10 min. 
14. Place the tube on the magnet and remove the supernatant to a new tube. 
15. Repeat elution step and combine the supernatant with that from step #12. 
16. The sample is now ready to be loaded directly onto an SDS-polyacrylamide gel. 
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APPENDIX I 
 
PROLIFERATION 
 
 
Purpose:  To measure proliferation of YAMC cells 
 
Materials: 
RPMI 1640 (Mediatech # 15040CV): 
Complete: To a 500 mL bottle, add 532 µL ITS Premix (BD Biosciences 
#354351), 26.6 mL fetal bovine serum (FBS, Hyclone SH30070.01), and 5.3 mL 
Glutamax (Gibco 35050).  Immediately prior to use, add 1 µL IFNγ (Gibco 
#13284-021) per 10 mL complete media. 
CyQuant Cell Proliferation Assay (Invitrogen #C7026) 
 
Procedure: 
1. Grow YAMC cells in T-75 flasks for 24 h in complete RPMI 1640 at 33°C and 
5% CO2. 
2. Treat YAMC cells for an additional 24 h with complete media supplemented 
with control (no fatty acid), LA, or DHA (50 µM).  Culture at 33°C and 5% CO2. 
3. Wash cells 1X with PBS then trypsinize for 5 minutes at 37°C. 
4. Neutralize the trypsin with complete RPMI 1640 and immediately spin down at 
200 x g for 5 min. 
5. Aspirate the media/trypsin and resuspend cells in 1 mL of complete media 
supplemented with the same fatty acid treatment as previously.   
6. Count cells using a hemocytometer.  Make the final concentration of cells to 
~1x10
5
 cells/200 µL. 
7. Seed 200 µL of cell suspension into a 96-well plate and culture with complete 
media supplemented with fatty acids for an additional 48 h at 33°C and 5% CO2. 
Change the media/fatty acid after 24 h. 
8. After 48 h of growth in the 96-well plate, completely remove all media, wash 1X 
with PBS, and completely remove all PBS. 
9. Wrap parafilm tape around the 96-well plate and the lid. Place the plate in a -
80°C freezer until ready to process (up to 4 weeks). 
10. When you are ready to quantitate the samples, start by preparing the reagent.  
Allow the CyQUANT® GR stock solution (Component A) to warm to room 
temperature. 
11. Dilute the concentrated cell-lysis buffer stock solution (Component B) 20-fold in 
nuclease free distilled water.  
12. Just prior to running the experiment, dilute the CyQUANT® GR stock solution 
(Component A) 400-fold into the 1X cell-lysis buffer. For example, to prepare 20 
mL of CyQUANT® GR working solution (enough for ~100 assays), first make 
the 1X cell-lysis buffer by mixing 1 mL of the 20X stock with 19 mL of 
nuclease-free distilled water; next add 50 μL of the CyQUANT® GR stock 
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solution and mix thoroughly.  It is recommended to prepare the diluted solution 
in a plastic container, rather than in glass because the CyQUANT® GR reagent 
may adsorb to glass surfaces. Protect the working solution from light by keeping 
it in an opaque bottle, covering it with foil, or placing it in the dark to prevent 
photodegradation of the CyQUANT® GR dye. For best results, the solution 
should be used within a few hours of its preparation. 
13. Thaw the plates at room temperature, then add 200 μL of the CyQUANT® GR 
dye/cell-lysis buffer (prepared in Preparing the Reagent) to each sample well.  
14. Incubate the samples for 2–5 minutes at room temperature, protected from light. 
15. Measure the sample fluorescence using a fluorescence microplate reader with 
filters set at ~480 nm excitation and ~520 nm emission maxima. 
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APPENDIX J 
 
ERK1/2 INHIBITION 
 
 
Purpose: To inhibit ERK1/2 activation in YAMC cells 
 
Materials: 
U0126 (Invitrogen #PHZ1283) 
EGF (Sigma #E1257) 
Serum starvation media: RPMI 1640 supplemented with 0.5% FBS and IFN-γ 
Serum free media: Plain, unsupplemented RPMI 1640 media 
Antibodies: 
Anti EGFR antibody Cell Signaling #2646 (1:2000) 
Anti phospho-EGFR antibody Cell Signaling #3777 (1:1000) 
Anti p44/42 MAPK (ERK1/2) antibody Cell Signaling #4695 (1:2000) 
Anti phospho-ERK1/2 antibody Cell Signaling #4370 (1:2000) 
 
Procedure: 
1. Seed YAMC cells into 150 mm dishes in complete RPMI media with IFN-γ. 
2. Incubate O/N at 33°C. 
3. Change media, and incubate for 24 h at 33°C. 
4. Replace complete media with 0.5% FBS serum starvation media.  Incubate at 
33°C O/N. 
5. Prepare a stock of U0126 of 1 mM by adding 0.38 mg U0126 to 1 mL of sterile, 
plain serum free RPMI 1640 media (no supplements). 
6. Add 150 µL of stock 1 mM U0126 to 15 mL of serum free media for each plate 
to be treated.  Final concentration is 10 µM U0126.   
7. Aspirate old media from the plates and add the serum free media with 10 µM 
U0126 and incubate at 33°C for 2 h. 
8. Following treatment with inhibitor, aspirate media, wash 1X with room 
temperature PBS, and stimulate cells for 10 min with serum free media 
supplemented with 25 ng/mL EGF. 
9. Harvest cells in homogenization buffer treated with protease and phosphatase 
inhibitors and isolate total cell lysate (see Total Cell Lysate protocol for details). 
10. Determine concentration of protein using Coomassie assay. 
11. Perform WB for total and phosphorylated ERK1/2 to determine inhibition of 
EGFR-induced activation of ERK1/2. 
12. Perform WB for total and phosphorylated EGFR to determine the effect of 
ERK1/2 inhibition on EGFR activation. 
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APPENDIX K 
 
DIMERIZATION 
 
 
Purpose: To assess EGFR dimerization 
 
Reference:  Sorkin A, Carpenter G. Dimerization of internalized epidermal growth 
factor receptors. JBC 1991;266(34)23453-60. 
 
Materials:  
5 mL Homogenization buffer (for composition, see TCL protocol) 
150 mm dishes 
EGF (Sigma #E 1257) 
BS
3
 (bis sulfosuccinimidyl suberate, Thermo Scientific # 21586; MW=572.4) 
Glycine (Fisher #BP381) 
 
Procedure: 
1. Seed YAMC cells onto 150 mm dishes at a density of 500,000 cells in 15 mL of 
complete RPMI media and incubate O/N at 33
o
C. 
2. The next day, change media and incubate O/N at 33oC. 
3. On the following day, replace media in dishes with low serum (0.5% FBS) and 
place at 33
o
C O/N (16-18 h).  
4. Wash dishes with PBS and incubate for 1 h on ice with 15 mL serum free RPMI 
supplemented with 25 ng/mL EGF.  Incubation on ice allows for ligand binding 
and dimerization but inhibits receptor endocytosis. 
5. Wash dishes 3X with ice-cold PBS. 
6. Crosslink dimers with 5 mL of 3 mM BS3 in ice cold Ca2+, Mg2+ free PBS for 20 
min on ice. To make 3mM BS
3
, add 8.60 mg BS
3
 to 5 mL PBS. 
7. Following crosslinking, quench with 10 mL of 250 mM glycine in PBS for 5 min 
at 4
o
C. 
8. Wash with ice cold PBS 3X. 
9. Add 300 µL of homogenization buffer to each plate and scrape.  Collect scraped 
cells into eppy-tubes and place on ice. 
10. Pass cell homogenates through a 29G needle once into the same set of eppy 
tubes.  Flush the suspension very hard while keeping the tube on ice to sheer the 
cells. 
11. Incubate the total cell suspension on ice for 30 min.  
12. Centrifuge at 16,000 x g at 4°C for 20 min. 
13. Transfer the supernatant (total cell lysate) to clean epi-tube (do not disturb the 
pellet) and mix by pipetting up and down a few times. 
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14. Aliquot the lysates and save the aliquots at -80°C for further protein estimation 
using Coomassie Plus and immunoblotting. Make aliquots of 30 l plus one set 
of 10 μL for protein quantification. 
15. Assess dimerization of EGFR by western blotting for EGFR according to the 
western blotting protocol (with the slight adjustments mentioned below). 
16. Dimers on western blot should be twice the size of EGFR band.  Serum starved, 
unstimulated cells should not have a dimer band and can be used for control. 
17. SDS-PAGE should be run for approximately 4-5 h at 125 V, and transfer should 
be overnight at 400 mAmps.  Make sure to incubate the gel in transfer buffer for 
~15-30 minutes before beginning the transfer. 
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APPENDIX L 
 
TOTAL INTERNAL REFLECTION FLUORESCENCE MICROSCOPY 
 
 
Purpose: To assess recruitment of Grb2 to the plasma membrane following stimulation 
with EGF 
 
Materials: 
SH2-Grb2-YFP (1.5 µg protein/transfection) (Dr. Alexander Sorkin, University of 
Colorado) 
Mouse EGF (Sigma #SRP3196; stock 10 ng/µL) 
Round glass bottom dishes (Glass bottom dishes #P35G-1.5-20-C) 
RPMI 1640 (Complete: supplemented with ITS, glutamine, 5% FBS, and IFN-γ; Serum-
starvation: supplemented with 0.5% FBS) 
Leibovitz media with no supplementation (Sigma #L5520) 
 
Procedure: 
1. Seed YAMC cells into T-75 flasks and culture in 15 mL complete media O/N at 
33°C with 5% CO2. 
2. Aspirate media and replace with complete media (control) or complete media 
supplemented with treatment (50 µM BSA-complexed DHA or LA).  Stock fatty 
acids are 2.5 mM, so add 14.7 mL media and 300 µL stock fatty acid.  Leave 
fatty acid in the fridge and wrapped in foil until ready to add.  Try to add fatty 
acid quickly and without creating bubbles to minimize oxidation.   
3. Culture O/N at 33°C with 5% CO2. 
4. Transfect cells using Nucleofection protocol with 1.5 µg SH2-Grb2-YFP. 
5. Place the round glass bottom dishes into the wells of a 6-well plate.  The dishes 
will sit on top of the wells.  This will prevent the bottom of the dishes from 
touching anything.  Make sure that the bottoms of the dishes do not directly 
touch any surface.  This can interfere with ability to perform TIRF.   
6. Seed 25,000 cells into round glass bottom dishes in 1 mL of complete media 
supplemented with treatment as above.   
7. Culture the cells for 24 h at 33°C with 5% CO2. 
8. Aspirate media and replace with low serum (0.5% FBS) media for 16-18 h at 
33°C with 5% CO2. 
9. Bring cells to the Image Analysis Lab and place in the incubator. 
10. Take 1 dish and wash 2X with plain Leibowitz media (without phenol red) to 
remove all phenol red.  Add a final volume of 1 mL to the dish. 
11. Additionally, in a 1.5 mL epi-tube, add 247 µL of Leibowitz plus 3 µL stock 
EGF for a final concentration of 25 ng/mL EGF. 
12. Take dish and set it on the microscope. 
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13. Focus on a cell.  The light angle works best from the right.  Begin by using a 
critical angle of approximately 72-73.  The best angle will result in even 
illumination of the cell. 
14. Set the software to acquire an image every 5 seconds.  Make sure to turn on the 
perfect focus. 
15. All acquisition of ~5 images and then add the 250 µL Leibowitz + EGF to the 
dish.  BE EXTREMELY CAREFUL while adding.  Do not touch the dish at all 
or it will ruin the acquisition process.   
16. Allow the software to continue capturing images every 5 seconds for up to 10 
minutes. 
 
Analysis: 
1. Using Image J (free NIH software), File – Import – Image Sequence – Choose 
sequence you wish to analyze. 
2. Once the image sequence has been imported, go to Image – Stacks – Plot Z-axis 
profile.  This will give you a graph of the mean intensity for each of the time 
points as well as a table with the area and min, max, and mean intensity. 
3. In Excel, input the initial mean intensity and the mean intensity of the time point 
with the highest mean intensity (peak of Grb2 recruitment to the plasma 
membrane). 
4. Calculate the change in intensity. 
5. Analyze the mean change in intensity per treatment group (Control (untreated), 
DHA, or LA).  Graph in excel using the mean for each treatment and the standard 
error of the mean (SEM). 
6. Perform statistical analysis using SPSS and a one-way ANOVA.  Check for 
normality and equality of variance. 
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APPENDIX M 
 
RAS ACTIVATION ASSAY 
 
 
Purpose:  To assess EGF-stimulated activation of Ras 
 
Materials: 
RPMI 1640 (Mediatech # 15040CV) complete and serum starvation: 
Complete: To a 500 mL bottle, add 532 µL ITS Premix (BD Biosciences 
#354351), 26.6 mL fetal bovine serum (FBS, Hyclone SH30070.01), and 5.3 mL 
Glutamax (Gibco 35050).  Immediately prior to use, add 1 µL IFNγ (Gibco 
#13284-021) per 10 mL complete media. 
Serum starvation:  Immediately prior to use, to plain unsupplemented RPMI 
1640 add FBS to a final concentration of 0.5%.  Also add 1 µL IFNγ (Gibco 
#13284-021) per 10 mL complete media 
Ice cold PBS (Gibco #14190) 
Ras activation assay kit (Pierce #16117) 
EGF (Sigma #E1257) 
Antibodies:  pan-Ras (comes with kit), H-Ras (Santa Cruz #sc-520), K-Ras (Santa Cruz 
# sc-521), N-Ras (Santa Cruz #sc-519) 
 
Procedure: 
 
Cell treatment 
1. Seed YAMC cells into 12 of 150-mm sterile plastic dishes in 17 mL complete 
media.  Incubate cells O/N at 33°C with 5% CO2. 
2. Aspirate media and replace with complete media (control) or complete media 
with 50 µM BSA-complexed fatty acids (LA or DHA).  Stock fatty acid is 2.5 
mm, so add 340 µL stock fatty acid to 16.66 mL media.  Use 4 dishes per 
treatment.  Incubate cells O/N at 33°C with 5% CO2. 
3. Replace media with fresh media containing the same treatments after ~24 h and 
continue incubation. 
4. After ~54-56 h of treatment, aspirate complete media from the dishes, wash 1X 
with PBS, and add serum-starvation media containing the same treatments as 
above.  Incubate cells for 16-18 h at 33°C with 5% CO2. 
 
Harvest 
5. Prepare 5 mL lysis buffer (LB) from kit by adding sodium orthovanadate and 
protease inhibitor cocktail.  Keep on ice. 
6. For each treatment, leave 1 plate unstimulated and stimulate 3 plates with 25 
ng/mL EGF for 2 min at 33°C with 5% CO2. 
7. Wash plates 3X with ice-cold PBS. 
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8. Add 300 µL LB per plate and scrape the plate with a rubber policeman. 
9. Place cells + LB into a 1.5 mL epi-tube on ice and shear cells using a 29 G-
needle. 
10. Incubate on ice for 30 minutes.  Clarify lysates by spinning at 16,000xg for 20 
minutes at 4°C. 
11. Collect the supernatant into a new epi-tube and discard the pellet. 
12. Measure the protein concentration using a Coomassie assay. 
13. Aliquot the lysates and store at -80 C. 
 
Immunoprecipitation 
Perform Ras IP by following the manufacturer’s instructions: 
1. Set up and label a spin cup in a collection tube for each sample. 
2. Thaw 500 µg of lysate from each sample.  Bring all samples to the same final 
volume (must be less than 700 µL) 
3. Swirl the bottle of Glutathione Resin to thoroughly resuspend the agarose beads.  
Add 100 μL of the 50% resin slurry to the spin cup with collection tube.  
Centrifuge the tubes at 6,000xg at 4°C for 30 seconds. 
4. Discard the flow-through. Add 400μL of Lysis/Binding/Wash Buffer to each 
tube with resin. Invert the tubes gently several times. Centrifuge the tubes at 
6,000xg for 30 seconds at 4°C.  Discard the flow-through. 
5. Thaw the GST-Raf1-RBD on ice and immediately make 80 μg aliquots. Store 
aliquots for later use at -70°C. 
6. Add 80 μg of GST-Raf1-RBD to each spin cup containing the glutathione resin.  
7. Immediately transfer up to 700 μL of the cell lysate (containing 500 μg of total 
proteins) to the spin cup. 
8. Seal cap of the collection tube with parafilm to prevent leakage, which may 
result from the presence of detergent in the lysate, and vortex the sample. 
9. Incubate the reaction mixture on a tube rotator at 4°C for 1 hour. 
10. Centrifuge the spin cup with collection tube at 6,000xg for 30 seconds. 
11. Remove the laboratory film and transfer the spin cup to a new collection tube.  
Keep the flow throw and store at -80°C 
12. Wash resin by adding 400 μL of Lysis/Binding/Wash Buffer.  Invert the tube 
three times, and centrifuge at 6,000xg for 30 seconds. Remove the spin cup and 
decant the buffer from the collection tube. Replace the spin cup in the tube and 
repeat this wash step two additional times. 
13. Transfer the spin cup to a new collection tube. 
14. Prepare 50μL of elution buffer by diluting stock 5X pyronin to 2X using ddH2O. 
15. Add 50 μL 2X elution buffer to the resin. Vortex the sample and incubate at 
room temperature for 2 minutes. 
16. Centrifuge the tube at 6,000xg for 2 minutes. Remove and discard the spin cup 
containing the resin. 
17. Heat the eluted samples for 5 minutes at 98°C.  
18. Samples may be electrophoresed on a gel or stored at -80°C until use. 
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19. Apply 25 μL per lane for a 10x10cm mini-gel (4-20% Tris-Glycine gel). 
20. Perform western blotting to determine activation of pan-Ras, H-Ras, N-Ras, and 
K-Ras. 
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APPENDIX N 
 
BIOTINYLATION 
 
 
Purpose: To determine cell surface localization and internalization of EGFR 
 
Hypothesis: EGF stimulation will lead to increased EGFR internalization.  DHA may 
alter EGFR internalization due to its effects on EGFR localization and activation. 
 
Reference: Vassilieva EV, et al. Am J Physiol Gastrointest Liver Physiol. 
2008;295(5)G965-76. 
 
Materials: 
EZ-Link Sulfo-NHS-SS-Biotin (Pierce # 21331) 
NUNC Immobilizer Streptavidin C8 ELISA plates (Thermo Scientific #436022) 
Reducing buffer: 100 mM sodium-2-mercaptoethane sulfonate (MESNA; Sigma 
#M1511-5G), 50 mM Tris (pH 8.6), 100 mM NaCl, 1 mM EDTA, and 0.2% BSA 
RIPA buffer: 20 mM Tris, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 1% sodium 
deoxycholate, 1% SDS, and 1% Triton X-100, protease inhibitor cocktail (Sigma 
#P8340) (1:25 dilution), and 100 µM sodium orthovanadate  
Iodoacetamide (Sigma #I1149) 
PBS 
EGF (Sigma #E 1257) 
Anti-EGFR antibody (Santa Cruz #sc-03) 
Goat anti-rabbit IgG HRP (KPL #074-1506) 
TMB High Sensitivity Substrate Solution (Biolegend #421501) 
 
Procedure: 
1. Seed YAMC cells into 150 mm dishes.  Allow to grow to ~ 80% confluence.  
Culture at 33°C at 5% CO2. 
2. Prepare EZ-Link Sulfo-NHS-SS-Biotin (Pierce # 21331)(0.5 mg/ml) dissolved in 
PBS. 
3. Wash cells 2X with ice cold PBS. 
4. Treat cells with 5 mL biotin for 30 min on ice (leave 1 plate w/o biotin as a 
control).  Make sure that the biotin solution completely covers the surface of the 
plate.  Make sure the plate is flat on the ice and the biotin solution does not 
collect in one side of the plate. 
5. Wash cells 3X with ice cold PBS. 
6. Replace PBS with 15 mL warm, serum-free media supplemented with 25 ng/mL 
EGF for 10 min (leave 2 plates unstimulated). 
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7. Cleave biotin remaining on cell surface by washing 3X for 20 min with 5 mL 
reducing buffer containing reducing agent (100 mM MESNA Sigma #M1511-
5G) at 4°C.  Make sure the entire plate surface is covered with buffer. 
8. Rinse cells 2X with PBS. 
9. Quench excess biotin with 60 mM iodoacetamide (Sigma #I1149) in PBS for 5 
min at 4°C 
10. Wash plates 3X with PBS.  Add 300 µL of RIPA buffer to each plate.  Use a cell 
scraper to scrape the entire plate.  Collect the cells and buffer into an epi-tube.  
Shear cells using a 29 G needle.  Incubate on ice for 30 minutes. 
11. Clarify lysate by centrifugation at 14000xg for 20 min at 4°C.  Place supernatant 
(cell lysate) into a new tube, aliquot, and store at -80°C until ready to process. 
12. Measure protein concentration using Bradford Protein Assay.   
RIPA buffer is not compatible with Coomassie Protein Plus Assay. 
13. Dilute samples to be used to 10 µg/mL using PBS containing 0.5% Tween 20 
(pH 7.3). 
14. Capture biotinylated EGFR using 96-well NUNC Immobilizer Streptavidin C8 
ELISA plates (Thermo Scientific #436022) by incubating 200 µL of diluted cell 
lysates per well. 
15. Place 1 µL RIPA buffer into 200 µL PBS containing 0.5% Tween 20 (pH 7.3) as 
a background well.  Additionally, use cell lysate from unbiotinylated sample as 
an additional control.   
16. A relative standard curve can be generated by incubating 0.5, 0.75, 1, 2, 3, 4, 5 
µg of any sample into 7 wells.  Choose any sample to create the standard curve.  
If multiple plates are being run at the same time, use the same sample to create 
the standard curve on all plates. 
17. Wash plate 3X with PBST (0.5% Tween 20). 
18. Incubate with 100 µL anti-EGFR antibody (1:20 dilution in PBST) at 200 RPM 
on plate shaker for 2 h at RT. 
19. Wash 3X with PBST. 
20. Incubate with 100 µL HRP-conjugated secondary ab (1:250 dilution in PBST) at 
200 RPM on plate shaker for 1 h at RT. 
21. Wash plate 3X with PBST. 
22. Add 100 µL TMB substrate and allow to develop for 10 min. 
23. Stop color development by adding 100 µL of 4 M H2SO4. 
24. Analyze on SpectraMax with wavelength set at 450 nm. 
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APPENDIX O 
 
EXTENSIVE WOUNDING OF YAMC 
 
 
Purpose:  To stimulate signaling in YAMC by injury 
 
Materials: 
RPMI 1640 (Mediatech # 15040CV) complete and serum starvation: 
Complete: To a 500 mL bottle, add 532 µL ITS Premix (BD Biosciences 
#354351), 26.6 mL fetal bovine serum (FBS, Hyclone SH30070.01), and 5.3 mL 
Glutamax (Gibco 35050).  Immediately prior to use, add 1 µL IFNγ (Gibco 
#13284-021) per 10 mL complete media. 
Serum starvation:  Immediately prior to use, to plain unsupplemented RPMI 
1640 add FBS to a final concentration of 0.5%.  Also add 1 µL IFNγ (Gibco 
#13284-021) per 10 mL complete media. 
 
Procedure: 
1. Culture YAMC cells in 150 mm dishes in complete media (plus any treatment) at 
33°C and 5% CO2 until they become ~95% confluent. 
2. Aspirate complete media and wash cells 2X with PBS. 
3. Add serum starvation (0.5% FBS) media and incubate overnight (16-18 h) at 
33°C and 5% CO2. 
4. Using a p-1000 pipette tip, as quickly as possible, scratch the cell monolayer in 
25 vertical lines progressively from left to right.  Turn the dish 45 degrees, and 
repeat scratching in the same way.  Repeat the turn and scratch process 2 more 
times until the dish has been scratched a total of 100 times in 4 directions.  The 
entire process should take less than 1 minute. 
5. Incubate cells 33°C and 5% CO2 for 2 minutes. 
6. Aspirate media from the cells and wash with ice-cold PBS 3 times.   
7. Harvest cell lysates according to the Total Cell Lysate Isolation protocol. 
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APPENDIX P 
 
SCRATCH ASSAY 
 
 
Purpose:  To observe wound healing following a scratch wound of YAMC  
 
Materials: 
35 mm dishes with glass bottom (Glass bottom dishes #P35G-1.5-20-C) 
EGF (Sigma #E 1257) 
RPMI 1640 (Mediatech # 15040CV) complete and serum starvation: 
Complete: To a 500 mL bottle, add 532 µL ITS Premix (BD Biosciences 
#354351), 26.6 mL fetal bovine serum (FBS, Hyclone SH30070.01), and 5.3 mL 
Glutamax (Gibco 35050).  Immediately prior to use, add 1 µL IFNγ (Gibco 
#13284-021) per 10 mL complete media. 
Serum starvation:  Immediately prior to use, to plain unsupplemented RPMI 
1640 add FBS to a final concentration of 0.5%.  Also add 1 µL IFNγ (Gibco 
#13284-021) per 10 mL complete media. 
 
Procedure: 
1. Culture YAMC cells in 4 of T-75 flasks.  Treat for 48 h with 50 μM DHA, LA, 
EPA or control (no fatty acid).  Change media after 24 h.  Incubate at 33°C and 
5% CO2. 
2. After 48 h of treatment, trypsinize cells in each flask, spin down, and resuspend.  
Count cells using a hemocytometer. 
3. Seed cells into 35 mm dishes at a density of ~100K cells/dish.   
4. Incubate in complete media supplemented with the same treatment for ~8 h at 
33°C and 5% CO2. 
5. Replace the media with serum starvation (0.5% FBS) media supplemented with 
the same treatment as above.  Incubate for 16 h at 33°C and 5% CO2. 
6. On the morning of the scratch assay, turn on the microscope.  Set up the 
incubation chamber on the scope with the insert for 35 mm dishes, and set the 
temperature to 33°C and 5% CO2. 
7. Following serum starvation, use a sterile p-200 pipette tip to scratch the 
monolayer of cells in each dish in a straight line down the center.  On the bottom 
of the dish, mark the ends of the scratch with a sharpie so you know where the 
scratch was made.  Make sure to use a new tip for each well.  Try to make the 
scratch as straight as possible.  Also, do not scratch too hard or it will scratch the 
dish. 
8. Wash each dish 1X with PBS, then add 1 mL plain, unsupplemented media (with 
IFN-γ) treated with the same fatty acid treatment as before plus 25 ng/mL EGF 
(stock is 10 ng/µL). 
9. Immediately place on the microscope, and open NIS elements.  Try to orient the 
dish so that the scratch runs either vertically or horizontally (not on an angle). 
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10. Set the time-lapse to take an image every 15 minutes for 48 h. 
11. Use the 10X phase objective, and turn on the PFS (perfect focus system). 
12. Using the “live” image, find the end of the scratch.  Use the PFS to focus on the 
spot, and then on the multipoint analysis, set this to be position #1.  This will 
remember the x-y location as well as the z. 
13. Repeat this for multiple positions within the scratch of the first dish.  Then 
continue to the next dish and repeat the same process.  The insert can hold up to 
4 dishes. 
14. Once you have chosen all of fields of interest, hit “Run”. 
15. The computer will acquire images. 
16. To analyze the image, at time 0 (first time-point), use the polygon tool to 
determine the size of the wounded area.  Then, at the 12 and 24 h time points, 
count the number of cells that have migrated into the wounded area. 
17. Graph the cells/mm wounded area.  Try to choose areas that are approximately 
the same width (i.e. the initial wounded gap is the same distance).  This will 
make comparisons more accurate.  Also, try to use areas that did not have very 
much cell debris following wounding. 
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APPENDIX Q 
 
TRANSWELL MIGRATION ASSAY 
 
 
Purpose: To assess migration of YAMC cells in response to EGF 
 
Materials: 
QCM 24-well colorimetric cell migration assay (Millipore #ECM 508) 
EGF (Sigma # E1257) 
RPMI 1640 (Mediatech # 15040CV) complete and serum starvation: 
Complete: To a 500 mL bottle, add 532 µL ITS Premix (BD Biosciences 
#354351), 26.6 mL fetal bovine serum (FBS, Hyclone SH30070.01), and 5.3 mL 
Glutamax (Gibco 35050).  Immediately prior to use, add 1 µL IFNγ (Gibco 
#13284-021) per 10 mL complete media. 
Serum starvation:  Immediately prior to use, to plain unsupplemented RPMI 
1640 add FBS to a final concentration of 0.5%.  Also add 1 µL IFNγ (Gibco 
#13284-021) per 10 mL complete media 
 
Procedure: 
1. Grow cells until ~80% confluent in a T-75 flask. 
2. Starve cells by incubating 16-18 hours prior to assay in serum starvation (0.5% 
FBS) media with IFN-γ. 
3. For optimal results, bring plates and reagents to room temperature (23-25°C) 
prior to initiating assay.  Sterilize forceps (provided with kit) with 70% ethanol 
and handle inserts with forceps. 
4. Following starvation, wash cells with PBS then trypsinize for 5 minutes. 
5. Neutralize the trypsin with complete RPMI 1640 and immediately spin down at 
200 x g for 5 min. 
6. Aspirate the media/trypsin and resuspend cells in 1 mL of serum free media with 
IFN-γ.   
7. Count cells using a hemocytometer.  Make the final concentration of cells to ~1 x 
10
6
 cells/mL. 
8. Add 300 mL of prepared cell suspension to each insert supplied in the kit. 
9. Add 500 mL of serum free media with 25 ng/mL EGF to the lower chamber. 
10. Ensure the bottom of the insert membrane contacts the media. Air may get 
trapped at the interface. 
11. Cover plate and incubate for 12-24 hours at 33°C and 5% CO2. 
12. Carefully remove the cells/media from the top side of the insert by pipetting out 
the remaining cell suspension, and place the migration insert into a clean well 
containing 400 μL of Cell Stain. Incubate for 20 minutes at room temperature. 
13. Dip insert into a beaker of water several times to rinse. 
14. While the insert is still moist, use a cotton-tipped swab (provided with kit) to 
gently remove non-migratory cells layer from the interior of the insert. Take care 
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not to puncture the polycarbonate membrane. Be sure to remove all cells on the 
inside perimeter, as any remaining cells inside the insert will contribute to 
background staining. Repeat procedure with a second, clean cotton-tipped swab. 
15. Allow insert to air dry. 
16. Transfer the stained insert to a clean well containing 200 μL of Extraction Buffer 
for 15 minutes at room temperature. Extract the stain from the underside by 
gently tilting the insert back and forth several times during incubation. Remove 
the insert from the well. 
Note: Alternatively, cells can be counted manually through a microscope. 
17. Transfer 100 μL of the dye mixture to a 96-well microtiter plate suitable for 
colorimetric measurement. 
18. Measure the Optical Density at 560 nm. 
 
 
 
 
